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Cardiovascular disease remains the number one killer globally. However, adherence to 
medication is a major health problem. It has been reported that 50% of cardiovascular 
patients do not adhere to treatment. This level of nonadherence results in poor health 
outcomes for the patient, hospital readmissions and avoidable deaths. Wasted and 
unused medicines cost the National Health Service up to £4 billion annually. Commonly 
used methods of assessing adherence to therapy in clinical practice such as self-report, 
pill counting, pharmacy refill and claims data log and electronic monitors are 
subjective, based on proxy evidence, hence not effective. Blood drug concentrations 
are associated with effectiveness of the treatment and is therefore a good marker for 
cases of nonadherence. However, plasma and serum analysis require blood sampling 
by venepuncture which is highly invasive and large volumes of blood (1 – 5ml) to 
produce enough sample for analysis. Microsampling methods offer a cost-effective 
alternative to self-collect finger prick blood samples for the determination of drug 
levels to indicate adherence to medication. 
 The work undertaken in this thesis describes the development, validation and 
application of a microsampling based liquid chromatography – high resolution mass 
spectrometry (LC-HRMS) assay for simultaneous determination of eleven candidate 
cardiovascular drugs to indicate adherence to medication. The target drugs include 
amlodipine, atenolol, atorvastatin, bisoprolol, diltiazem, doxazosin, lisinopril, losartan, 
ramipril, simvastatin, and valsartan. The LC-HRMS method was validated, with results 
for accuracy and precision within acceptable limits; analytes were stable at room 
temperature in dried blood format for at least 8 weeks and hematocrit values had no 
significant effect. The LC-HRMS assay was used to analyse 850 dried blood samples 
from 141 volunteers, some of whom were prescribed one or more of the target drugs. 
The assay successfully identified volunteers who were known to be either adherent or 
nonadherent; confirmed the correct drug/drugs for multiple prescriptions; and 
revealed several examples of unsuspected nonadherence. These results demonstrate 
the possible application of microsampling based LC-HRMS assays for therapeutic drug 
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Chapter 1 Cardiovascular disease and the global problem 
with medication adherence  
 
Cardiovascular disease is the number one global killer, responsible for 17.7 million 
deaths globally every year (World Health Organisation, 2016). About a third of these 
deaths are needless and preventable if patients adhered to their prescription 
medication. The primary aim of the work presented in this thesis was to develop an 
evidence based method for assessing cardiovascular patient adherence to medication 
in routine clinical practice using microsampling methods followed by liquid 
chromatography high resolution mass spectrometry (LC-HRMS) analyses. An overview 
of the problem of nonadherence to prescribed medication, the prevalence of 
medication nonadherence, the consequences of nonadherence to medication and the 
various factors that affect medication adherence are presented in this chapter. The 
currently available methods of assessing patient medication adherence and their 
limitations are also presented and discussed. 
1.1 Introduction 
Cardiovascular disease (CVD) involves disorders of the heart and blood vessels, namely 
angina, hypertension, stroke, heart attack and heart failure (World Health 
Organisation, 2016). It affects an estimated 7 million people in the UK and is 
responsible for about 155,000 deaths each year. The economic burden of CVD is large 
with healthcare costs alone estimated at £11 billion every year in the UK (British Heart 
Foundation, 2013). An essential component of managing cardiovascular diseases 
properly and ensuring treatment success is to ensure patients take the prescribed 
medication (Keenan, 2017). Studies have demonstrated a link between medication 
nonadherence and adverse clinical outcomes among patients with heart disease (Ho et 
al., 2008; Bitton et al., 2013; Zullig et al., 2017). The drug selected and the dose 
prescribed should produce therapeutic drug levels in the patient’s blood stream. 
Patient adherence to the prescription helps ensure that the blood concentration of the 
drug is within the therapeutic limits in order to improve treatment outcomes (Tanna 
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and Lawson, 2016). However, irrespective of the importance and the benefits of the 
treatment, appropriate use of prescribed medicine remains a big challenge for both 
patients and health care providers (Bosworth et al., 2011). Statistics indicate that 20% 
to 30% of patients do not adhere to medication regimens that are curative or relieve 
symptoms, 30% to 40% fail to follow regimens designed to prevent health problems 
and 50% of patients fail to adhere to the prescribed regimen for the treatment of 
chronic conditions (Pharmaceutical group of the European Union, policy statement on 
adherence, 2017).  
A World Health Organisation (WHO) report (Sabate, 2003) states that about 50% of all 
patients do not adhere to their treatment regimen. Further evidence suggests that 
˃50% of heart disease patients do not adhere to their prescription treatment (Kronish 
and Ye, 2013). In the UK, for example, about 370 million prescriptions were dispensed 
for heart diseases in 2014 and half of these were believed to be wasted because 
patients did not take their medicines as prescribed (British Heart Foundation, 2015). 
The problem of nonadherence to medication is now a global issue of striking 
magnitude. According to a National Institute of Clinical Excellence (NICE) guideline on 
medication adherence, wasted (unused) medicines cost the UK National Health Service 
(NHS) up to £4 billion annually (NICE, 2014; Iuga and McGuire, 2014). These statistics 
are shocking and the level of nonadherence to medication are startling. This level of 
nonadherence results in poor clinical outcomes, increased cost of care, hospital 
readmission, and sometimes death (La Caze et al., 2014; Yang et al., 2017).  
A recent report by the British Broadcasting Corporation (BBC) health watch 
programme found that hospital readmissions of patients within 30 days of discharge 
has risen by a third (BBC, October 2017) and is estimated to cost the NHS about £1.6 
billion. The cause of the rise in hospital readmissions is linked to patient nonadherence 
to prescription medication particularly in cardiovascular disease patients. When 
patients are on admission at the hospital, there are no problems with adhering to the 
treatment, since hospital staff (directly observed therapy) normally administer the 
medication. However, adherence to medication become a problem when patients are 
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discharged and must self-medicate at home.  Nonadherence to medication is therefore 
a global problem affecting patients in all disease states. For example, cancer (Gupta 
and Bhatia, 2017; Mislang et al., 2017), diabetes (Schwartz et al., 2017), HIV/AIDS 
(Monroe et al., 2017), schizophrenia (Phan, 2016; Tessier et al., 2017), depression 
(Goldstein et al., 2017), epilepsy (Montouris and Hohler, 2016; Malek et al., 2017), 
asthma (Harris et al., 2016; Brandstetter et al., 2017) and malaria (Bruxvoort et at., 
2014). 
Hence, it is not difficult to conclude that prompt action is needed to address the 
problem of nonadherence to medication (Stirratt et al., 2018). Improving adherence to 
medication in patients taking prescription medication is pivotal to improving patient 
safety and the quality of healthcare tailored to the patient’s needs (Du et al., 2017). It 
is also key to reducing unused and improperly used medications. As well as optimising 
the cost effectiveness of therapies and the effectiveness of managing chronic diseases.  
As a matter of fact, the World Health Organization has reiterated that “increasing 
effectiveness of adherence interventions may have a far greater impact on the health 
of the population than any improvement in specific medical treatments” (Sabate, 
2003). This is because increased adherence to medication will lead to better health 
outcomes and help optimise the use of scarce health resources.  
Hence as the pharmaceutical industry and clinical research develops new treatments 
for patients, it is equally important that measures are also put in place to identify and 
optimise patients’ adherence to medication. Efforts are therefore required to generate 
innovative, objective and patient friendly means of proper assessment of medication 
adherence. This should be a top priority for all stakeholders’ particularly health care 
providers and the pharmaceutical industry. Such approaches will not only improve 
treatment outcomes for patients and decrease health care spending, but will also 
increase revenue for the pharma companies. For example, Forrisier and Firlick (2014) 
found that an increase in medication adherence by 10 percentage points will turn into 
a $134 billion global pharmaceutical revenue opportunity. This represent a clear win–
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win situation for all stakeholders.  Hence evidence based method of assessment are 
required to enable proper assessment and help improve medication adherence.  
1.2 What is medication adherence? 
Adherence as defined by the WHO is the extent to which a person’s behaviour, 
comprising of taking medication, following a diet or executing lifestyle changes, 
corresponds with agreed recommendations from a health care provider (Osterberg et 
al., 2005; Ferdinand et al., 2017). Most patients with chronic conditions are normally 
prescribed with medication that are administered orally. Thus, medication adherence 
is a problem for drugs administered mainly by the oral route. In this context, 
medication adherence refers to whether patients take their medications exactly to 
agreed doctor’s recommendations, for example one capsule at night or two tablets a 
day. Tanna and Lawson (2014) argue that proper medication adherence involves six 
key factors. These include taking the right drug; at the right dose; at the right time; on 
the right schedule; under the right conditions; and with the right precautions.  
1.2.1 Medication adherence - why it is important 
 
 
Figure 1.1 A plot of a drug concentration versus time profile in (a) nonadherence and (b) adherence  
Failure to adhere to any of the identified factors affecting medication adherence could 
possibly lead to complications for the patient which could result in sub optimal or 
adverse outcomes (Otto, 2017). For example, from Figure 1.1(a), if a dose is missed, 
the drug concentration in the blood subsequently drops below the effective 
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therapeutic window with time. This leads to sub optimal levels, which has catastrophic 
consequence for the patient, because the treatment will have no positive effect on the 
clinical condition and will lead to deterioration. Whereas when the patient is adhering 
to the treatment, as shown in Figure 1.1(b), the blood concentration of the drug stays 
within the effective therapeutic window and ensures that the patient gets the full 
benefits of the treatment leading to an improvement in health (Roehr, 2013). More 
importantly, Figure 1.1(b) depicts the development of the steady-state concentration 
of the drug over several days, which should be maintained for any patient following a 
fixed dose drug regimen. This therefore shows that adherence to medication is the 
cornerstone for ensuring optimal clinical outcomes (Keenan, 2017). Researchers and 
clinicians are therefore interested in assessing adherence to medication to maximise 
safety and optimise treatment for patients. 
There are barriers to medication adherence, health practitioners find it difficult to 
identify patients who do not adhere to their treatment (Wheeler et al., 2014). Policy 
makers, healthcare professionals and managers underestimate the chance to improve 
health outcomes and rationalise health expenditure by monitoring what happens after 
a medicine has been prescribed to a patient (Zullig et al., 2017). As demonstrated in 
Figure 1.1, the adherence to the prescription regimen is what ensures safe and high-
quality pharmacotherapy.  
Proper assessment of adherence to medication is another challenge. There is currently 
no gold standard measurement tool for assessing adherence to prescription 
medication in routine clinical practice (Lehmann et al., 2014). Current methods to 
assess medication adherence involves patient self-report, pill counts, pharmacy refill or 
claims data logs and electronic monitors (Neiheisel et al., 2014).  None of these can 
confirm the patient ingested the medication and therefore only capture a part of the 
information needed for accurate assessment of medication adherence and may 
consequently lead to optimistic results (Tanna and Lawson, 2014). Sensors are now 
available that can document ingestion, but patient security and cost are of major 
concern (Kvedar et al., 2011; Hafezi et al., 2015).  
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Adherence rate is the percentage score of a patient’s level of adherence to the 
treatment. It is normally used to express the patient’s degree of adherence. However, 
cut-off levels, which authors use to categorise adherence to medication, is inconsistent 
(Nieulaat et al., 2014).  It is generally accepted that rates 80% and above are adherent 
and rates less than 80% usually considered problematic with patients termed 
nonadherent (Clifford and Coyne, 2014). However, such an assumption is not always 
correct. The reason being that in certain disease states an adherence rate of 100% may 
be paramount. For example, in patients with human immuno-deficiency virus (HIV) 
where any reduction in adherence rate could result in the formation of drug resistant 
strains of the virus leading to poor clinical outcomes or at worse death (Monroe et al., 
2017). Such difficulties in categorising patients’ degree of adherence presents 
challenges for policy makers because it prevents results comparison between 
medication adherence studies.  
Coupled with this research shows that interventions designed to increase adherence to 
medication have shown little improvement in adherence (Van Dalem et al., 2012; 
Ruppar et al., 2017). Nieuwlaat et al (2014) assessed the effects of interventions 
intended to improve patient adherence to prescribed medication in 182 studies and 
concluded that, effects were inconsistent from study to study. Sapkota et al (2014) also 
argues that currently available methods of improving adherence to medication for 
patients with chronic conditions are complex and ineffective. This may be because 
factors driving adherence to medication are different in different parts of the world.  
More importantly, interventions designed to improve adherence cannot confirm a 
therapeutic level of the drug in the patients’ blood, hence the full benefit of the 
treatment cannot be realised. For example, mHealth, which involves the use of mobile 
phone technology to support the delivery of medical care, has been hailed as a 
promising intervention. mHealth has been used by health care providers to deliver 
messages to increase medication adherence to CVD medication (Palmer et al., 2017). 
Yet there is still limited evidence for its effectiveness. Alder et al (2017) reviewed the 
use of mobile phone text messaging to improve medication adherence in secondary 
prevention of cardiovascular disease. They concluded that, there was not sufficient 
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evidence to support the effectiveness of text message-based interventions to increase 
medication adherence.  
Aslani and Schneider (2014) also report a lack of consistency in terminology used to 
describe adherence. For example, the use of terms such as adherence and compliance. 
Compliance until recently was the concept used to describe patients’ medication 
taking behaviour and was widely used in pharmaceutical and medical publications. 
However, it is now criticised due to the negative effect it portrays on the prescriber-
patient relationship. It appears to suggest a relationship where the prescriber just 
decides on the best treatment option and give instructions, whilst the patient’s role is 
to passively follow the clinician’s orders. Such a connotation side-lines the patient in 
the treatment decision making and more importantly puts the blame of 
noncompliance on the patient because they were unable to follow the prescriber’s 
instructions (Ahmed and Aslani, 2014).  
Adherence on the other hand describes the extent to which a patient follows agreed 
recommendations by the prescriber. Adherence has been accepted mainly in the 
sociological and psychological literatures as a substitute to compliance with the view of 
emphasising that the patient has the freedom to decide whether to follow the 
clinician’s recommendations (Barnett, 2014). Hence not following the regimen should 
not be reason to blame the patient.  Adherence therefore develops the concept of 
compliance with special emphasis on the need for agreement (Ahmed and Aslani, 
2014). This shift reflects the modern-day patient centred ideal of healthcare where 
clinicians and patients agree on the plan of treatment, rather than patients just 
following the prescriber’s instructions. 
Another terminology which has recently being introduced in the UK is concordance. It 
refers to the bigger concept of patient support in medicine taking and focuses more on 
the patient-prescriber relationship. It stresses on the need for the prescription to 
represent a shared decision. Concordance, takes into full consideration the beliefs and 
preferences of both the prescriber and the patient with the recognition that the 
patient’s views are supreme. The foundation of concordance includes the level of 
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information given to patients, explanation of side effects, the cost of medication and 
the effect on lifestyle. It is worth mentioning that the idea of concordance is related to 
but not the same as adherence (Horne et al., 2014; Khair, 2014). 
1.3 Medication nonadherence 
Nonadherence to medication refers to when patients fail to follow agreed 
recommendations by their doctor with regards to their prescription treatment. It 
remains a major problem, especially for people with chronic diseases (Bitton et al., 
2013; Palmer et al., 2017). For example, medication nonadherence is known to raise 
the risk of revascularization, heart disease related hospitalization and death in 
cardiovascular patients (Ho et al., 2008). Medication nonadherence as explained by the 
WHO can take any of the following forms, failing to initially fill a prescription, failing to 
refill a prescription as advised, skipping a dose or doses, administering more of a 
medicine than prescribed, taking a dose at the wrong time, and prematurely stopping 
medication.  
The National Institute for Health and Care Excellence (NICE) classifies medication 
nonadherence into two overlapping categories, these are intentional and unintentional 
(NICE guidelines, 2009).  Intentional medication nonadherence refers to when the 
patient decides not to follow the treatment recommendations due to beliefs and 
perceptions about the treatment, example deliberately skipping a dose to avoid side 
effects or due to cost of the medication. It’s been reported that about half of 
medication nonadherence cases are intentional (Pound et al., 2005; Mukhtar et al., 
2014). 
With unintentional, the patient wants to follow the treatment recommendations but 
has practical problems. Examples include poor recall, difficulty in understanding the 
instructions or inability to pay for the prescription. It is normally characterised by 
several behavioural patterns. These include failure to collect prescriptions, not 
following instructions with regards to doses. In both situations, the outcome may be 
dangerous. NICE however are of the view that the patient should not be blamed and 
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advocate a non-judgmental approach in which the patient's perceptions and 
preferences can be explored (NICE guidelines, 2009). 
1.3.1 Consequence of nonadherence to medication 
The consequences of non-adherence to prescribed medication include poor health 
outcomes for patients, missed opportunities for therapeutic gain, and increased cost of 
health care mainly linked with deterioration of the medical condition being treated, 
increased referrals, additional laboratory investigations and death. (Sabate, 2003; 
Mahoney et al., 2008; Boswell et al., 2012; Chisholm-Burns et al., 2012; Clifford and 
Coyne, 2014). The effects of nonadherence to medication affects not only the patient, 
but the health care provider and the pharmaceutical industry as well. Hence the 
impact of nonadherence can be grouped into consequences for the patient, 
pharmaceutical industry and health care provider. This confirms why the problem of 
nonadherence to medication should be a top priority for all stakeholders. Below is a 














Table 1.1 Consequences of non-adherence to medication 
Group Consequences 
Patient  Suboptimal clinical outcome for patients (Piepoli et 
al., 2016). 
 Missed opportunities for therapeutic gain (McCarthy, 
1998). 
 Adverse effects on the health and wellbeing of 
patient. Nonadherence to immunosuppressive drugs 
has been linked to heart, kidney, and liver transplant 
failures (Rapoff, 2010). 
 Reduce cost effectiveness of the treatment. 
 Disease related complications resulting in mortality. 
 Negatively impact medical decisions by health 
professionals. 
 Request for unneeded laboratory test, dose 
adjustment or unnecessary change in prescription.  
Pharmaceutical 
industry 
 Loss of revenue due to medication wastage, 
classified as either as therapeutic loss or material 
waste (IMS Health, 2013; Hazel and Robson, 2015).  
 Cost to global pharmaceutical market is estimated at 
$637 billion (Forrisier and Firlick, 2014).  
Healthcare provider  Increased cost of care, unnecessary clinical 
appointments and emergency room visits (Barnett et 
al., 2014).  
 Hospital re-admissions, hundreds of billions of dollars 
spent on re-admissions annually (Boswell et al., 
2012). 
 Significant human cost estimated at 195,000 deaths 
in Europe (Pharmaceutical Group of the European 
Union, 2008) and 125,000 deaths in the US (Boehme 
et al., 2017; Ferdinand et al., 2017). 
 Wasted resources due to non-use of medicines 
funded by healthcare systems (Bitton et al., 2013). 
 Drug resistance, e.g.  Resurgence of infectious 
diseases such as tuberculosis, development of drug 
resistant forms of the HIV-AIDS virus resulting in high 
viral loads (Chisholm-Burns et al., 2011).  
 Reduction in life expectancy of the aging population 




1.3.2 Prevalence of medication nonadherence 
High rates of nonadherence exist in several disease states. Examples include 
cardiovascular diseases, cancer, diabetes, asthma, mental health (neurological 
disorders) (Oung et al., 2017). Medication adherence assessment suggest an average 
nonadherence rate of 50% with huge variation in patient populations based on disease 
condition (DiMatteo, 2004). For example, higher rates of nonadherence have been 
reported in psychiatric disorder patients’ example elderly patients with depression or 
cognitive disorder (Velligan et al., 2009). As well as in patients undergoing treatment 
for multiple conditions e.g. hypertensive patients with diabetes (Ho et al., 2009, Brown 
et al., 2011, Monroe et al., 2017). Even when experiencing symptoms, more than 50% 
of asthmatic patients could not achieve the desired level of inhaled corticosteroid use 
(Adherium, 2017). Medication nonadherence is also prevalent in the treatment of 
malaria and HIV - AIDS, which is common in sub Saharan Africa and Asia (Taneja at al., 
2013). 
Taking Europe for example the rate of nonadherence to medication varies between 
43% and 60%, whilst in the US it is estimated to be around 50%. However, such 
information does not take into consideration the extent of variation that may occur in 
certain disease states or patient groups (Larsen et al., 2009). For example, in cancer 
patients, published figures reveal wide variations in nonadherence rates. From as high 
as 73 – 86% for haematological cancers compared to 12 – 47% in breast cancer 
patients and about 3% for patients with ovarian cancer. (Partridge et al., 2002; 
D’Amoto, 2008; Ruddy et al., 2009; Mathes et al., 2014 and Mitchell et al., 2014). 
In the USA, more than 25% of patients released from hospital following acute 
myocardial infarction do not collect their medicines within 7 days of discharge. In 
addition, about 34% of patients stop taking at least one of their medications, with 12% 
stopping all medications within a month of being discharged from hospital. In a study 
by Jackevicius et al (2008) looking at medication usage consistency over a period of 6 
to 12 months, 56% of heart patients were found to be nonadherent to statins and 54% 
were nonadherent to beta blockers (Ho et al., 2009). In a study by Kronish et al (2011), 
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nonadherence rates were as high as 72% for β-blockers and 35% for angiotensin 2 
receptor blockers. In a study conducted in China, nonadherence rates to 
antihypertensive medication was found to be 35% among patients. (Lee et al., 2013). 
In HIV patients, antiretroviral therapy is required to reduce viral load in the blood. 
Hence living a healthy life depends on adherence to these medications and to prevent 
drug resistance. However, treatment regimen complexity makes it difficult for patients 
to adhere to therapy. Nonadherence rates of 5 – 30% have been reported in HIV 
patients in the US, meanwhile rates below 5% is required to achieve consistent viral 
suppression. Naderi et al (2012) also reported variation in nonadherence based on 
whether medications are prescribed for primary or secondary prevention, with high 
rates of nonadherence seen in primary prevention. There has also been documented 
evidence of poor adherence in clinical trials participants, where patients have been 
carefully chosen. Despite the differences in the methods used to measure 
nonadherence in these cited studies, it is obvious that prevalence of nonadherence to 
medication is common among patients with chronic conditions.  
1.3.3 Factors affecting medication adherence 
Factors driving adherence to medication are different in different parts of the world. 
Taking Europe and Africa for example, the system of healthcare in these continents are 
totally different. A patient in Europe may book an appointment to see the doctor and 
afterwards pick the prescription medication from the pharmacy at a subsidized cost 
paid through insurance contributions by the patient. Whilst in Africa, no insurance 
contributions are made by patients towards healthcare, hence patients may pay to see 
a clinician and fully pay for the prescription. Hence cost of treatment (Figure 1.2) may 
be a driving factor in Africa, but not in Europe. In a study by Awad et al (2017), 
assessing medication adherence among cardiac patients in Sudan, high cost of 
medication, polypharmacy and poor clinician/patient communication about the 
treatment were identified as the main barriers to adherence. Abdulazeez et al (2014) 
also identified a direct link between patient financial status and adherence among 
patients taking prescribed diabetic medication in Nigeria. In view of this, interventions 
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designed to increase adherence in Europe may not necessarily apply in Africa since the 
underlying factors may be different and the awareness of this by stakeholders is very 
important. 
Nobre and Domingues (2017) reported many factors affecting patient medication 
adherence. To increase patient adherence to medication, there is the need to 
understand the reasons why nonadherence occurs. These reasons are seen to be 
multifactorial (Monroe et al., 2017) and can generally be grouped into patient related, 
clinician related and health system related factors; the WHO further classifies these 
factors into five subclasses (Figure 1.2): socioeconomic, healthcare system, disease 
related, therapy related and patient related factors (Iuga and McGuire, 2014; 
Ferdinand et al., 2017). 
1.3.3.1 Patient-related factors 
These factors are further classified into demographic (gender, age, marital status and 
level of education), social and psychological factors (patient’s beliefs, attitude and 
motivation towards the treatment). They are mainly due to a lack of understanding of 
the disease condition, lack of patient involvement in the treatment decision making 
and medical illiteracy (Halladay et al., 2016; Khalesi et al., 2017). In the US for example, 
over 80 million adults are reported to have inadequate health literacy increasing their 
risk of hospital readmissions and suboptimal clinical outcomes (Mayo-Gamble and 
Mouton, 2017). Other causes include the health beliefs of the patient and attitudes 
with regards to the treatment effectiveness, past treatment experiences, religious and 
cultural beliefs about the condition, mental health problems and an utter lack of 
motivation (Figure 1.2).  In countries where patients pay for treatment, high 
prescription cost and longer pharmacy waiting times has been identified as barriers to 
medication adherence (Otto, 2017). In patients with mental illness a lack of social or 
family support also serves as a predictor of nonadherence (Baroletti and Dell’orfano, 
2010; Brown and Bussell, 2011). In a study by Chen et al (2014), gender was found to 
be specifically associated with adherence to antihypertensive medication and 
awareness of the factor was key to delivering best interventions. 
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1.3.3.2 Clinician-related factors 
Clinicians normally fail to identify patients who are nonadherent and sometimes 
worsen the situation by the prescribing of complex medication regimen especially in 
patients with co-morbid conditions (Monroe et al., 2017). Kronish et al (2013) reported 
that the most common approach to assessing medication adherence by clinicians in 
clinical practice is clinical judgement. However, there is evidence that prescribers are 
poor at judging the extent to which their patients take their medication (Zeller et al., 
2008). Hence prescribers underestimate the problem of nonadherence to medication 
which were attributable to many factors including the lack of awareness of the high 
prevalence of nonadherence, not believing that their own patients will not adhere to 
their regimen, lastly relying heavily on patient self-report whilst patients over estimate 
their level of adherence (Singh, 2017). 
Some healthcare providers also fail to give full explanation about the benefits and side 
effects of the treatment (Figure 1.2). Improving patient adherence, Martinez and 
Finken, (2006) showed that patients who are satisfied with their relationship with their 
clinicians were adherent to their diabetes treatment, whilst patients who rated the 
relationship with clinician as poor were nonadherent to oral medication. In countries 
where patients pay for the service, proper considerations are normally not given to the 
financial constraint to the patient, taking into consideration the duration of the 
treatment. A poor clinician communication skill also complicates the patient’s 
understanding of his or her condition, any likely complications and the essence of 
adhering to the treatment (Schoenthaler et al., 2017). Finally, lack of proper 
communication between healthcare personnel involved in the patient care could 
sometimes lead to medication errors and hence avoidable readmissions (Ferdinand et 
al., 2017).  
1.3.3.3 Health system factors 
Fragile healthcare systems facilitate nonadherence to medication by limiting the 
coordination of care for the patient. Longer waiting times at the clinic or pharmacy 
have been identified as a barrier to patients’ medication adherence (Ferdinand et al., 
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2017). Lack of support from healthcare team members and poor clinician-patient 
relationship have been identified as determinants of medication nonadherence. In 
addition, health systems that lacks the ability to provide education on treatment or 
follow up promote nonadherence to treatment. E.g. having patient information 
leaflets written at a high level of literacy may make it difficult for patients to 
understand (Schoenthaler et al., 2017).  
It is worth noting that several interconnections exist between all these factors and 
demonstrate clearly that medication nonadherence is indeed a complex problem 
(Kardas et al., 2013). Mathes et al (2014a) concluded in a review that just a small 
number of factors regularly influenced adherence. In addition to these factors 
unemployment, belonging to an ethnic minority and cost to the patient (Figure 1.2) 
demonstrated a negative influence on medication adherence (Dhaliwal et al., 2017). 
Hence indicating the involvement of social factors. It is therefore not surprising that 
guidelines to improve adherence have been issued worldwide given the magnitude of 
complexity (Mathes et al., 2014b). In a review by Ruppar et al (2015) they identified 23 
international and national clinical practice guidelines intended to assist healthcare 
providers. These guidelines were from the USA, UK, Canada, Spain and Australia. 
 
Figure 1.2 A subdivision of factors affecting medication adherence 
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1.4 Methods of assessing adherence to medication 
Assessing the problem of nonadherence to medication is further challenged by the 
range of tools that are available for assessment. Ahmed and Aslani (2014) call for an 
implementation of robust systems within primary healthcare which will enable routine 
assessment as well as monitor patients’ adherence to medication. They believe this 
will aid in identifying nonadherence to medication and allow health providers to 
address the problem to allow optimisation of treatment. Several methods have been 
studied to measure adherence to medication, but there is currently no universally 
accepted gold standard measurement tool for assessing adherence to therapy in 
clinical practice (Lehmann et al., 2014). A range of methods have reportedly been used 
to assess adherence to medication, each having its own advantages and disadvantages. 
The mode of assessment can be grouped into indirect and direct methods.  
1.4.1 Indirect methods of assessing medication adherence 
Indirect methods are subjective and assume ingestion based on proxy evidence and 
normally do not prove the presence of the medication in the body. Examples include 
self-report by patients, electronic monitors, pharmacy refills and claims data, and pill 
counting (Lawrence et al., 2017). Recent developments include computerized logbooks 
and the use of downloadable apps on smart phones for real time assessment and 
alerts (Marawski et al., 2017). Indirect methods therefore capture just a part of the 
information needed for proper assessment. For example, pill counting provides no 
information on dose timing which may be crucial to determine outcomes clinically.  
1.4.1.1 Self-report 
Self-reporting by the patient or their carer is the simplest method of assessing 
adherence. It is a way of asking the patient for their subjective rating of medication 
adherence. It is done through interview, questionnaire or using a diary. It is cheap and 
easy for the patient to perform but often inaccurate because it does not provide a 
precise measure of adherence (Pérez-Escamilla et al., 2015). Whether a patient tells 
the truth may depend on the clinician/patient relationship and the way the questions 
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are asked (Neiheisel et al., 2014).  Also, patients may be tempted to exaggerate their 
adherence if they believe that reports of nonadherence will disappoint their clinician 
(Gupta et al., 2016). They may also overestimate adherence through forgetfulness 
(Zullig et al., 2017).  Thus, doctors may prescribe alternative medication, request 
additional laboratory tests, or arrange specialist consultations to evaluate the cause of 
unexplained or persistent symptoms which may have been avoidable (Wagner and 
Rabkin, 2010). 
1.4.1.2 Pill counts 
Pill counts basically involve counting the dosage units that the patient has not taken by 
the scheduled appointment or clinic visit (Haynes et al., 2016). The returned dosage 
units are counted and compared with the number of units received by the patient in 
the most recent prescription and the length of time since the medication was 
dispensed. Adherence is then calculated by subtracting the number of unit returned 
from the number of units issued. This gives an indication of the number of medication 
used by the patient within a specific period (Neiheisel et al., 2014). However, the 
accuracy of pill counts in estimating medication adherence is questionable because 
some patients may intentionally not return their medications (Lawrence et al., 2017).  
1.4.1.3 Electronic monitors 
Electronic monitors such as medication event monitoring systems (MEMS) record 
when a prescription bottle is opened, pills are removed from a dosage pack, or when 
an inhaler is activated. They generate data which provides detailed profile of 
medication usage over time (Park et al., 2015). However, Zullig et al (2017) argues that 
the opening of the container does not guarantee ingestion of the medication. The dose 
could be discarded by the patient. Furthermore, electronic monitors are costly and 
each device can monitor only one medication. Another disadvantage is that they 
cannot be fitted to many of the dosage forms and packaging used in routine care. 
Hence the focus should be centred on developing and improving methods of assessing 
if the medication was consumed (Seabury et al., 2014). 
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1.4.1.4 Pharmacy refill and claims data 
Pharmacy databases can be used to check when prescriptions are initially filled, refilled 
or prematurely discontinued. This involves electronic review of prescription claims in 
databases containing patient’s records (Gupta et al., 2016). Some patients may use 
more than one pharmacy, hence access to all pharmacies patronised by the patient is 
necessary for accurate assessment (Lawrence et al., 2017). However, such reviews 
provide no confirmation that the medication was ingested by the patient and have a 
high tendency of yielding optimistic results. 
1.4.2 Direct methods of assessing medication adherence 
Direct methods are objective, examples include directly observed therapy (DOT) and 
biochemical measurements that detect the presence of medication in the body. For 
example, analysis of bio fluids for the presence of the drug or its metabolite or 
detection of a biomarker that is given with the drug. Such test can be done at specified 
intervals or randomly when it is appropriate. It provides evidence that the patient has 
taken the medicine (Morrison et al., 2015). Hence direct methods of assessment are 
the most accurate means to measure adherence (Gupta et al., 2016; Aonuma et al., 
2017). The down side to these approaches are cost in relation to patient and clinician 
time. Sampling may also require a visit to the clinic. Recent developments include the 
testing of ingestible sensors which are incorporated into pills as a means of 
documenting ingestion (digital pills) (Gupta et al., 2016). However patient security and 
cost may be of concern when sensors are used (Kvedar et al., 2011; Chai et al., 2015; 
Hooman et al., 2015). The effect of cost linked with direct approaches can be 
significantly reduced with no disadvantage to the information generated by using a 
finger prick blood sample collected as a dried microsample for the quantification of 





1.4.2.1 Directly observed therapy  
Directly observed therapy (DOT) involves invitation of patients to the hospital to take 
part in ingestion of their mediations under the direct supervision of a nurse. Hameed 
et al (2015) reported in a study involving the use of DOT for assessing antihypertensive 
medication adherence, that 25% of nonadherent patients developed symptomatic 
hypotension. Gupta et al (2016) also states that there are reports of nonadherent 
patients being admitted in hospital due to sudden drop in blood pressure triggered by 
the sudden ingestion of previously avoided prescribed medication. The main 
limitations of DOT include costs and labour. Patients may have to travel long distances 
to get to the hospital and may spend half of the day at the clinic. In addition, 
supervision of patients may have to done by trained personnel. 
1.4.2.2 Drug assay in biofluids (Biochemical measurements) 
This mode of assessment involves the assay of biological fluids example blood, urine, 
saliva and sweat for the presence of the drug or its metabolite. It may also involve the 
addition of non-toxic biological markers to medications and assessing their presence in 
biofluids such as blood, plasma, serum or urine (Singh, 2017). It provides confirmation 
that the patient has received the dose. However, the technique required for sample 
collection of biofluid such as blood may be invasive. In addition, variation in 
individuals’ metabolism and volume of distribution may affect drug levels. In the case 
of urine, the presence of a metabolite may not give a true indication of the 
concentration of the drug in blood. In addition, the effect of collection times for urine 
sample on results have been shown to produce a white coat adherence effect. Where 
there is marked improvement in adherence to medication in just a few days to a 
scheduled clinical appointment (MacLaughlin et al., 2005). Urine analysis has been 
used to investigate the presence of prescribed CVD drugs for patients exhibiting 
‘resistant hypertension’ (Tomaszewski et al., 2014; Hamdidouche et al., 2015; Lawson 
et al., 2016; De Nicole et al., 2017, Hamdidouche et al., 2017) but this approach 
provides no information of the drug levels in the patient’s blood. Other studies (Olds et 
al., 2015; Moore, 2015; Ferrari et al., 2017) have investigated the use of saliva and hair 
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in adherence to medication research due to the benefits they offer over blood and 
urine such as a non-invasive, painless and stress-free sampling, wide detection window 
and ability to provide a measure of long term drug use for hair samples, low cost and 
no requirement to visit a clinic or hospital for the sample to be taken. 
1.4.2.3 Dried blood spot (DBS) microsampling  
A significant limitation in assessing adherence to medication using a direct method 
involving analysis of biological fluid such as blood is the need for blood sampling. 
Conventional plasma or serum based drug quantification methods often require large 
volumes of blood (1 – 5ml) at each sampling time to produce enough plasma/serum 
for analysis (De Nicolo et al., 2016). There is the need for patients to visit a 
phlebotomist (specialist collection). The process of blood sampling is also highly 
invasive and makes patients uncomfortable (De Nicolo et al., 2017). This poses 
practical challenges in performing medication adherence studies to allow treatment to 
be optimised for patients. Dried blood spot represents an alternative matrix for 
measuring blood drug concentrations. Requiring only a micro blood volume (<30µl) it 
has great potential in overcoming the barriers associated with blood collection using 
venepuncture. 
The use of DBS obtained from heel or finger prick, and spotted onto filter paper for 
collection and analysis of human blood dates back to the early 1960’s when Dr. Robert 
Guthrie used the technique to measure phenylalanine in newborns for the detection of 
phenylketonuria (Shah et al., 2013).  By using DBS sampling, public health laboratories 
screened more than 95% of all newborns in the USA for inborn metabolic disorders 
(Deep et al., 2012). Over the past several years dried blood spot (DBS) sampling has 
emerged as a pertinent method in both qualitative and quantitative bioanalysis.  
Advantages of DBS such as low blood volume requirement, transportation and storage 
without special treatment, better analyte stability, enhanced clinical cooperation in 
clinical trials and reduced unforeseeable exposure of biohazard to analysts make it 
feasible for blood sampling (Sharma et al., 2014). Hence, the ease of use and low cost 
(<£2.00) of the DBS sampling platform compared to blood sampling by venepuncture 
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makes it ideal for assessing adherence to medication. In addition, DBS sampling 
enables samples to be collected by patients themselves or parents/guardians at home. 
Samples can then be posted by regular mail to the laboratory. This allows for 
convenient monitoring at any desired sampling time and for the results to be readily 
available at the clinic during a routine check-up (Spooner, 2013).  
For example, Martial et al (2016) performed a rigorous cost analysis on the potential 
savings achieved by using DBS sampling compared to conventional blood sampling at 
the clinic for TDM in renal transplant and hemato-oncology pediatric patients. Their 
findings revealed that, using DBS samples collected at home could lead to a cost 
reduction of 61% for renal transplant patients and 43% for hemato-oncology patients. 
The key factors contributing to the huge difference between DBS “at home” sampling 
and conventional sampling at the clinic were additional costs of travel, lost productivity 
for the caregiver and the nurse’s time spent collecting samples. 
Dried blood spot sampling has been used in the quantification of antiepileptic drugs 
(Shah et al., 2013a; Shah et al., 2013b; Linder et al., 2016; Das et al., 2017), 
immunosuppressants (Koop et al., 2013; Li et al., 2010; Koster et al., 2017; Martial et 
al., 2017; Veenhof et al., 2017), antiretroviral drugs for HIV - AIDS (Castillo-Mancilla et 
al., 2013; Hoffman et al., 2013; Zheng et al., 2014; Alcaide et al., 2017), cardiovascular 
therapy drugs (Lawson et al., 2012; Lawson et al., 2013; Tanna et al., 2014; Bernieh et 
al., 2017), antibiotics (Al-Ghazawi et al., 2010; La Marca et al., 2012; Hawwa et al., 
2014; Vu et al., 2014; Barco et al., 2017; Weber et al., 2017), antidiabetics (Aburuz et 
al., 2006) and antimalarial (Blessborn et al., 2010). This demonstrates that DBS 
microsampling is a viable option compared to tradition plasma or serum sampling 
technique. 
1.4.3 Strength and limitations of the various methods of assessing 
medication adherence 
Each of the available direct and indirect methods used for assessing adherence 
discussed in Section 1.3 has certain flaws which limit their accuracy, reliability or 
practical application. Most of the available methods function as indicators of 
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adherence rather than exact, quantitative measure of adherence (Singh, 2017). There 
are also wide variations in the rates of adherence stated in most of the studies and this 
is because each method captures different information about patient’s medication 
taking behaviour. Table 1.2 summarises the strength and limitations of various 






Table 1.2 Strengths and limitations of the various methods of assessing adherence to medication 
















Strength                  
Easy to administer √ √   √ √       √ 
Cheap/ global √     √        √ 
Non- Invasive √ √ √ √ √ √     √ 
Data on dates and time of use   √     √   √ √ √ 
Confirms medication usage         √ √ √ √ √ 
Provides quantitative information            √ √ √ 
Provides PK data          √ √ √ √ 
Limitations                  
Invasive            √ √   
Expensive equipment    √      √ √ √ √ 
No confirmation of adherence √ √ √ √  √       
Limited to certain dosage forms   √              
References                  
  Wagner & 
Rabkin, 
2000 























1.5 Gaps in the literature 
Irrespective of the volume of work done on assessing patients’ adherence to 
medication, there are gaps in knowledge concerning how patient adherence to 
medication can be objectively assessed (Gupta et al., 2016) and how developed 
adherence interventions can be tailored to suit patients (Seabury et al., 2014). 
Interventions offered and tested to increase adherence to medication though many, 
are complex and mostly ineffective hence the full benefits of treatment are not 
achieved (Nieuwlaat et al., 2014). Examples of such interventions are: behavioural 
counselling (Roberts et al., 2014), interventions utilizing pictorial aids of medication 
(Monroe et al., 2017), interventions utilising smartphone apps (mHealth) that provide 
reminders to take medication, education, and enable social interactions between 
individuals with similar health concerns (Morawski et al., 2017), interventions 
facilitating patient provider communication, providing patient education and 
psychosocial support (Zullig et al., 2017). Yet despite these interventions the rate of 
nonadherence to CVD medication is still high and carries a significant human cost 
(Granger et al., 2015). 
There is also no universally accepted assessment tool for inferring adherence in clinical 
practice. Hence the wide variety of adherence measures limits comparison between 
studies (Nieuwlaat et al., 2014). Most of the assessment tools available are indirect 
methods which are not effective because they are based on proxy evidence and 
therefore yield optimistic results. Most importantly, these adherence measures are not 
able to establish any direct link between improved medication adherence and clinical 
outcomes which is essential if the patient is to gain the full benefit of the treatment. 
This is because they provide no information on the therapeutic levels of the 
medication.  
Cardiovascular disease affects mainly the elderly, thus as the global population of the 
elderly increases and patients are prescribed more medicines (polypharmacy – not less 
than five medicines) factors such as individual variation in drug metabolism and 
possible drug-drug interactions become more important (Gonzalez et al., 2015). Hence 
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monitoring therapeutic drug levels by direct analyses of patient blood samples can 
offer clinicians very valuable information about possible drug-drug interactions, side 
effects occurring from the co-administration of several cardiovascular drugs and a 
patient’s adherence to a complex prescribed medication regimen by looking at the 
data from a patient’s blood drug concentrations for all prescribed medicines. Blood 
drug concentrations are associated with effectiveness of the treatment and can 
therefore be a good marker for cases of nonadherence. For example, in patients 
exhibiting resistant hypertension, application of therapeutic drug monitoring (TDM) of 
CVD drugs in plasma and serum samples to recognize poor adherence is known to 
prevent some unnecessary invasive techniques employed in its management example 
(renal denervation or baroreceptor stimulation) (Brinker et al., 2014; De Nicole et al 
2016).  
Thus, simple and objective adherence measures are therefore required to effectively 
assess patient adherence to medication. Such approaches will provide concrete 
scientific evidence upon which medical professionals can make sound clinical 
decisions. Direct method of assessment is seen as the best way to measure medication 
adherence to cardiovascular medication since it confirms the presence of the 
medication in the body. Direct measurement of therapeutic drug levels post-dose is 
known to be of significant value as a means of dose optimisation for individual 
patients, particularly with cardiovascular disease since most CVD drugs have high inter-
patient variability (Aonuma et al., 2017). This is because it makes the treatment 
effective and safe for the patient by ensuring the patient blood drug concentration is 
within the safe and effective therapeutic window. 
However, assessment by direct methods has its own challenges. Therapeutic drug 
levels are conventionally monitored using either whole blood or plasma samples. The 
reason is to ensure that the sample accurately represents the analyte in circulating 
blood (Verhaeghe et al., 2017). Hence data obtained from the routine analysis of 
plasma or serum can confirm satisfactory adherence to medication by confirming a 
therapeutic level of the drug in the patient’s blood (De Nicolo et al., 2016; Tanna and 
Lawson, 2016). However, to generate the required plasma, about 5ml liquid blood 
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sample will be needed from the patient at each sampling time which will require an 
invasive blood sampling procedure (venepuncture) and the service of a phlebotomist. 
This makes such an approach not feasible for routine clinical testing. 
Urine samples has been used in adherence studies, but can only confirm that drugs 
were ingested based on the detection of either the drug or its metabolite 
(Tomaszewski et al., 2014; Hamdidouche et al., 2015; Lawson et al., 2016; De Nicolo et 
al., 2017; Hamdidouche et al., 2017). However, this approach provides no information 
on the drug levels in the patient’s blood, which is key to relate adherence to positive 
clinical outcomes (Morrison et al., 2015; Tanna and Lawson, 2016, Bernieh et al., 
2017).  
The study aims to address these limitations by developing an evidence based 
bioanalytical method for inferring patient’s adherence to commonly prescribed 
cardiovascular medication using dried blood microsampling methods coupled with 
liquid chromatography – high resolution mass spectrometry (LC-HRMS) analyses. Blood 
microsampling is a simple sampling method which is minimally invasive and offers 
better patient comfort compared to venepuncture.  
Blood microsampling based CVD drug concentration measure will allow the inference 
of medication adherence by confirming a therapeutic level of the drug in the patients’ 
blood. Which is important to relate adherence to positive clinical outcome. The 
information derived from such an approach will help clinicians in the clinical decision 
making. It will enable the implementation of routine TDM of cardiovascular 
medications in everyday clinical practice. Data from microsampling based CVD drug 
concentration measurements could be used to adjust doses for individual patients. 
Hence enabling the patient to achieve blood drug concentration within the therapeutic 
range at which patients are expected to exhibit an optimal clinical response 
(Milosheska et al., 2015). Thus, allowing the full benefit of the treatment to be 
realised. 
To date, only a few bioanalytical assays are reported in literature for the quantification 
of CVD drugs using microsampling methods (Lawson et al., 2012; Lawson et al., 2013; 
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Tanna et al., 2015) and none of them can quantify a wide panel (≥10) CVD drugs in the 
same run. Most importantly, the limit of quantification for the target analyte reported 
in these papers are poor, hence quantification of CVD drugs in volunteer samples at 
very low concentrations may yield negative results. Since heart disease patients are 
normally treated with combined therapies (Gonzalez et al., 2015), the adoption of 
multi panel drug assays is practically mandatory.  
The novelty of this research resides in the ability to simultaneously quantify a wide 
panel of commonly used cardiovascular drugs: amlodipine, atenolol, atorvastatin, 
bisoprolol, diltiazem, doxazosin, lisinopril, losartan, ramipril, simvastatin and valsartan 
in microvolume blood samples collected using microsampling methods coupled with 
LC-HRMS analyses for the inference of cardiovascular medication adherence. LC-
MS/MS remains the gold standard in regulated bioanalysis, but the advantage of high-
resolution full scan mass spectrometry analyses for TDM of cardiovascular drugs is that 
all the mass spectral data from the sample is collected. This allows the data to be 
revisited at a later time if it becomes clinically important to the management of the 
patient’s condition. For example, in situations where a patient may be taking other 
medications in addition to the prescribed drug which the clinician is not aware of. 
Possibly causing drug interactions, which could lead to potentiation or inhibition of 
one drug response over the other.  
Moreover, this assay stands out for its sampling simplicity using microsampling 
methods, which offer the possibility for self or “at home sampling” eliminating the 
requirement for clinic visits and the services of a phlebotomist. The assay is also 
unique because of its potentially wide applicability to other conditions with known 
prevalence of medication nonadherence such as diabetes, depression and cancer. In 
addition, the use of microsampling methods enables the wide applicability of the assay 
in resource-limited areas of the world where there are no logistics for transportation 





The objectives of this thesis are: 
 To develop and validate microsampling based LC - HRMS assay for the 
simultaneous determination of eleven (11) candidate cardiovascular drugs. 
 To apply the developed microsampling based LC - HRMS assay for multi 
compound drug determination in volunteer/patient microvolume dried blood 
samples to indicate adherence to prescription cardiovascular medication. 
Volunteers who are prescribed one or more of the target cardiovascular drugs 
will be recruited from De Montfort University staff in Leicester - UK and from 
cardiovascular disease patients attending a routine clinical follow-up at the Al 
Sader Teaching Hospital and the Misan Cardiac Centre in Iraq. Dried blood 
spots and blood microvolume samples from a novel DBS self-collection device 
will be obtained as finger-prick samples from the recruited volunteers. The 
collected volunteer samples will be tested using the bioanalytical method 
developed and validated. For each dried blood sample, the presence of each of 
the target drug(s) prescribed to the volunteer will be ascertained. The 
combination of the measured drug concentration, the time at which the last 
drug(s) dose was taken and average pharmacokinetic data for the target drug(s) 
would allow medication adherence or nonadherence to be inferred. 
 To assess the usability of current microsampling methods for patient self-use. 
Home sampled or self-sampled DBS approach which provides the patient with 
the capability to collect their own dried blood samples is the way forward for 
therapeutic drug monitoring of CVD drugs, since it eliminates the need for 
phlebotomy appointments or clinic visits which complicates the objective 
assessment of adherence to medication. Thus, a novel device called volumetric 
absorptive microsampling (VAMS) developed to overcome the barriers with 
using the traditional DBS card, for example, for self-sample collection will be 
used for volunteer sample collection in this research. Hence volunteers will be 
asked to provide feedback on the ease of use of the VAMS sampler and the DBS 
card for self-sample collection. 
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Chapter 2 Drug selection for the medication adherence 
study 
 
This chapter focuses on the selection of cardiovascular drugs for investigation. The 
types of cardiovascular drugs commonly prescribed in the UK and the county of 
Leicestershire are discussed. A compilation of the relevant pharmacokinetic, 
bioavailability and dosage information for the selected drugs which will influence the 
detection capabilities required for the investigation is presented. As well as the 
analytical techniques that have previously been used for the quantification of the 
cardiovascular drugs in biological matrix such as plasma and serum. 
2.1 Introduction 
Success in drug discovery research means there are several medicines that can be used 
to manage cardiovascular disease. Most of these medicines are taken orally as tablets 
or capsules. Cardiovascular medications are grouped into different therapeutic classes 
depending on their mode of action in the body. In the UK, several factors are 
considered by clinicians when selecting a medication for the treatment of a patient’s 
condition. The main ones include safety, efficacy and cost. Prescriptions are therefore 
normally issued in line with prescribing guidelines provided by the NHS (Collier et al., 
2017). The frequency of taking the prescribed medication depends on the patient’s 
condition thus whether acute or chronic. Since cardiovascular disease is a chronic 
condition, medications must be taking regularly by the patient. Despite the wide 
variety of cardiovascular medications available for treatment, the goal of proper 
management of cardiovascular disease with pharmacotherapy is still not achieved in 
many patients due to nonadherence to treatment (Baroletti and Dell'Orfano, 2010).  
The cause of CVD’s is multifactorial and involves several risk factors, the most common 
include: hyperlipidaemia, diabetes and obesity (Gonzalez et al., 2015). The prevalence 
of any of the risk factors is known to increase with age and lifestyle. The result is an 
increase in the prevalence of multimorbidity and the total number of medications 
taken (Stegmann et al., 2010). Hence the need for combination of drugs to properly 
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manage cardiovascular disease. Cardiovascular disease patients are therefore normally 
prescribed with cardiovascular medications from different therapeutic classes 
(complex regimen) (Anderson and Nawarskas, 2001). Combined therapy, ageing and 
the high rates of multimorbidity leads to polypharmacy prescribing where patients are 
prescribed with no less than five different medications at the same time (Volpe et al., 
2010; Di Bari and Balzi, 2017). Polypharmacy increases the risk of adverse drug effects 
and drug interactions for patients with cardiovascular disease mainly the elderly 
(Abolbashari et al., 2017). Drug interactions are further complicated by the regional 
and pharmacogenetic differences in response to cardiovascular medication (Joseph et 
al., 2014). All this points to the fact that a one size fits all approach to treatment is not 
the best. There is therefore the need to look carefully at the levels of cardiovascular 
drugs in the patient’s blood. As demonstrated by (Lawson et al., 2013, Tanna et al., 
2015; Bernieh et al., 2017), with the use of DBS based LC-HRMS analyses for the 
determination of CVD drug. Such data could provide the basis for clinical decision 
making and help tailor the treatment to each patient. 
2.2 Types of cardiovascular drugs prescribed in the UK 
There are several classes of cardiovascular drugs prescribed in the UK. The most 
commonly used are angiotensin converting enzyme (ACE) inhibitors, beta blockers, 
cardiac glycosides, diuretics, angiotensin 2 receptor antagonists, nitrates, calcium 
channel blockers, anticoagulants, antiplatelets and statins. Table 2.1 presents 
examples of the commonly prescribed oral CVD medication in the UK with their 








Table 2.1 Table 2.1 Types of commonly prescribed oral cardiovascular drugs in the UK and their classes 
(BNF, 2016) 
DRUG CLASS 
Digoxin Cardiac glycosides 
Indapamide, chlorothiazide, benzthiazide,  
metolazone, chlortalidone, clopamide, 
furosemide, bumetanide, torasemide, butanide 
spironolactone, eplerenone 
amiloride, triamterene 




Potassium sparing diuretics 
Acebutolol, atenolol, betaxolol, bisoprolol, carteolol, 
carvedilol, celiprolol, esmolol, labetalol, levobunolol, 
metoprolol, nadolol, nebivolol, oxprenolol, pindolol, 
propranolol, sotalol, timolol 
Beta blockers 
Doxazosin, terazosin, prazosin Adrenergic neurone blockers 
Lisinopril, fosinopril, imidapril, moexipril, ramipril, 
perindopril, trandolapril, captopril, enalapril, quinapril 
ACE Inhibitors 
Azilsartan, losartan potassium, candesartan, eprosartan, 
irbesartan, olmesartan, valsartan, telmisartan 
Angiotensin II receptor 
antagonist 
Glyceryl trinitrate, isosobide mononitrate, isosobide 
dinitrate 
Nitrates 
Amlodipine, felodipine, nimodipine, lacidipine, 
nifedipine, isradipine,  
diltiazem HCL, verapamil, 
Calcium channel blockers 
Nicorandil Other anti – angina drugs 
Edoxaban, fondaparinux, danaparoid, bivalirudin, 
argatroban, apixaban, rivaroxaban, dabigatran, Warfarin, 
acenocoumarol, rivaroxaban,  
Anticoagulants 
Aspirin, clopidogrel Antiplatelet drugs 
Tranexamic acid Antifibrinolytic drugs 




2.3 Top 10 cardiovascular drugs prescribed in the UK 
One of the objectives of this research as outlined in (section 1.5 of Chapter 1) was to 
develop a microsampling based bioanalytical assay to identify and quantify selected 
commonly prescribed cardiovascular medications that a patient may be taking orally. 
Hence the top most prescribed cardiovascular drugs in the UK were considered.  
Cardiovascular drugs for the study were therefore selected based on information 
acquired on the top ten cardiovascular drugs by the volume of prescriptions issued in 
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the UK (Table 2.2). As well as data compiled on the commonly prescribed 
cardiovascular drugs by general practitioners (GPs) and health personnel in the county 
of Leicestershire (Table 2.3). The idea was to ensure that volunteers undergoing 
prescribed cardiovascular treatment could be easily recruited within the university 
community for the planned study. 
Table 2.2 Top 10 cardiovascular drugs prescribed in the UK by prescription volume for the year 2013 
(Health & Social Care Information Centre, prescription cost analysis 2014) 
Number Cardiovascular drug Prescription volume 
(thousands) 
1 Simvastatin 39,856.0 
2 Aspirin 30,611.0 
3 Ramipril 24.939.6 
4 Amlodipine 23,074.8 
5 Atorvastatin 18,249.9 
6 Bendroflumethiazide 16,007.5 
7 Bisoprolol 15,957.1 
8 Atenolol 10,675.0 
9 Lisinopril 10,006.9 

















Table 2.3 List of CVD drugs prescribed locally by hospital specialist and GP’s in Leicestershire 
(Leicestershire health community NHS, medicines formulary). 
DRUG CLASS ORDER OF 
PREFERENCE 





Thiazide & related diuretics 
Loop diuretics 
 







Beta blockers 1st 
2nd 
Doxazosin Adrenergic neurone blockers 1st 
Lisinopril 
Ramipril 












Calcium channel blockers 1st 
1st 







Antiplatelet drugs 1st 
2nd 






The data from the Table 2.2 was compared with Table 2.3 and the following 
cardiovascular drugs were selected for the study mainly because they are among the 
most recommended for first line therapy both in the UK and in the county of 
Leicestershire where the study will be undertaken. They are amlodipine, atenolol, 
atorvastatin, bisoprolol, diltiazem, doxazosin, lisinopril, losartan, ramipril, simvastatin 
and valsartan. The decision was taken to operate the mass spectrometer in the 
positive ionisation mode, hence from Tables 2.2 and 2.3, aspirin and 
bendroflumethiazide were not included in the list of selected drugs for investigation 
because they ionise negatively. Valsartan which does not appear in the list in Tables 
2.2 and 2.3 was included for investigation because there was a permanent volunteer 
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taking valsartan in combination with amlodipine and bisoprolol to provide 
microvolume blood samples for investigation. 
It is envisaged that the drugs belonging to different groups or classes will present a 
challenge for the development of the dried blood microsampling based LC-HRMS 
assay. This is because different classes of drugs will have different physicochemical 
characteristics (molecular weight, logP, logD, pKa, polarity, stability, dissolution, 
protein binding and thermodynamic properties). For example, atenolol is a beta 
blocker and lisinopril is an ACE inhibitor but both drugs are hydrophilic, whilst 
atorvastatin and simvastatin belong to statins and are extremely hydrophobic. Hence 
the wide difference in solubility could impact on extraction, separation and 
subsequent quantitation.  
2.4 Pharmacokinetic, bioavailability and dose information for the 
CVD drugs 
An objective of this research was to investigate if the presence of the specified target 
analytes can be quantified in microvolume blood samples from individual volunteers 
undergoing treatment with oral cardiovascular medication. Therefore, the range in 
blood drug concentrations from individual volunteers is considered more significant 
than just an average value for the population because of the regional and 
pharmacogenetic differences which is known to affect the concentration of drugs in 
individual patients (Joseph et al., 2014).  
For a bioanalytical method to be used to infer adherence to medication, the 
requirement will be to detect residual levels of drug or its metabolite up to 24 h after 
the initial dose was taken. From this time point the patient will be taking a repeat 
dose. In view of this, the minimum likely drug concentration in the dried blood 
microvolume sample must be taken into consideration. The blood drug levels of the 
patient will depend on the dosage of medication given, the drug pharmacokinetic (PK) 
parameters for that patient, bioavailability and the time delay post dosing. No 
comparison studies have been performed between plasma and DBS concentration 
levels for any of the selected target drugs and such comparison work could not be 
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investigated as part of this research. Hence the PK, bioavailability and dosage 
information derived from plasma sample for the selected target drugs is essential in 
defining the detection parameters required for this study.  
It should however be noted that drug solubility is another important factor that can 
impact on the desired plasma levels of drug for pharmacological activity. Murtaza 
(2012) reported that about 40% of oral drugs are not soluble in water and are 
therefore poorly absorbed from the gastrointestinal tract (GIT) resulting in low 
bioavailability. Available literature PK data, for the selected target drugs, was gathered 
to help define the detection parameters required of the analytical instrumentation 
(Tanna and Lawson, 2014). Table 2.4 shows documented PK information as well as 
dosage and bioavailability for the eleven target drugs investigated. 
To define the calibration ranges for investigation, the lowest possible concentration of 
each drug in DBS must be taken into consideration. This will be the case for either a 
drug with a very low bioavailability or a low dosage, rapid elimination (short t1/2) with a 
low Cmax attained in a short time (tmax). In view of this drugs like losartan and 
simvastatin (Table 2.4) should present the greatest challenge. 
Hence Table 2.4 was used as the basis to determine the proposed calibration range for 
each of the selected drugs considering the Cmax data reported for the available dosages 
of each drug, the time it takes to reach the highest concentration (tmax) and the 
duration for the blood drug concentration to reduce by half (t1/2). The WHO states that 
drugs are not effective after about 4.5 half-lives, which is equivalent to a blood drug 
concentration of <5% of the Cmax (Moffat et al., 2011). Thus, the calibration ranges for 
each of the selected drugs were therefore chosen to cover (<2% the Cmax value of the 
lowest dose to the respective Cmax value of the highest dose of that drug (Table 2.4)).  
For example, from Table 2.4 the smallest and biggest doses for doxazosin are 1mg and 
16mg with a reported Cmax range of 8 – 14ng/ml and 49 – 84ng/ml respectively. The 
Cmax of doxazosin is reached in about 3 hours (tmax) and it has a t1/2 of about 22 hours. 
Thus 2% of 8ng/ml which is the low Cmax value of 1mg is 0.16ng/ml. Hence a 
calibration range of 0.1 – 100ng/ml was chosen to ensure that the target drug could be 
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adequately quantified in volunteer samples well below and above the therapeutic 
concentration range of 8 – 84ng/ml for all the available doses of doxazosin. Hence, 

























Cmax (ng/ml) T max (h) T half (h) Bioavailability (%) References 







11.7 – 14.1 
 
 
5 - 8 
6 – 8 
7.5 – 8.3 
 
35 – 50 
40 – 60 
40 – 60  
 
60 – 80 
60 – 65 
60 – 80  
Abernethy, 2012 
Bhatt et al., 2007; Meredith, 1992 
Ramani et al., 2009; Lv et al., 2013 
Nirogi et al., 2006; Qi et al., 2013 





159 – 377 
590 –1370 
 
1.5 – 4 
2 – 4  
 
6 – 7, 4 – 11 




De Abreu et al., 2003; Irshaid et al., 
1996; Najib et al., 2005; Vergin and 
Nitsche, 1989; Wu et al., 2003; 






2.1 - 17.1 
3.2 – 10.6 
5.0 – 20.5 
27 – 66  
45.9 – 71.5 
0.7 – 3.0  
0.8 – 2.8 
0.5 – 3.0 
2.0 – 3.0 
11 – 14 
7.4 – 20.2 
4.2 – 11.4 
15 - 30 




Garcia et al., 2003; Koytchev et al., 
2004; Yacoub et al., 2013; 
Lennernas, 2003; Ghosh et al. 2011; 
Mendoza et al., 2006; Shen et al., 
2012; Tippabhotla et al., 2013; 








17.3 – 26.9 
37–87, 29-43  
 
 
1.5–4, 2 – 4 
1.2 – 2.6  
 
 
5 – 16, 8 – 14 
7.1 – 9.1  




90, 82 - 94 
90 
 
Lancaster and Sorkin 1988; Leopold 
1986; Bhatt et al., 2007; Leopold et 
al., 1986; Ding et al., 2007a; Ding et 





21.9 – 86.7 
41.7 – 109.3 
98 - 304 
90.3– 113.1 
1.8 – 3.86 
1.9 – 3.6 
1.5 – 4.5 
12.1 – 14.2 
1.9 – 4.5 
3.2 – 4.3 
5.1 - 7.9    
10.3 – 13.0 
40 
27 - 49 
34 - 54 
50 
Hermann et al., 1983 
Echizen et al., 1986 
Boyd et al., 1989 






8 – 14  
13.2 – 23.6 
20.9 – 37.7 
49.2 – 84.4 
2 - 3 
2 – 3  
2.2 – 5.2  
2.7 – 5.1 
 
22 
24.7 – 33.7  
10 - 12 




65 – 69 
50.3 – 75.3  
Kwon et al., 2007; Ma et al., 2007; 
Sripalakit et al., 2005; Sripalakit et 
al., 2006; Elliot et al., 1987; Chun et 
al., 2006; Chung et al., 1999; 




20 - 40 
50 - 88 
80 – 140 
52.7 – 121.3 
6 – 8 
5.8 – 7.8 




21 - 29 
16 - 36 
25 -  50 
Gomez et al., 1987; Lancaster & 
Todd, 1988; Huang et al., 2006; 
Beermann 1988; Padua et al., 2004; 










43.6 – 125.4 
79 - 433 
89.1 – 306.1 
263.6 -783.4 
274 – 1036.4 
0.5 – 1.1 
0.54 – 2.52 
0.5 – 2.2 
0.54 – 1.88 
0.4 – 1.0 
0.94 – 4.02 
1.77 – 2.97 
0.94 – 2.44 
1.51 – 2.31 
1.1 – 1.92 
 
 33 
20.3 – 51.3 
25 – 35 
33 
Ohtawa et al., 1993,  
Yang et al., 2012; Sica et al 2005 
Ohtawa et al., 1993;  
Salvadori et al., 2006,  






4.7 – 7.7 
9.3 – 20.8 
11 – 31 
 
2 – 4 
0.5 – 1 
1 - 2 
 
4 – 6 
3 – 7  
4 – 7  
 
44 - 66 
54 - 65 
Hosie & Meredith 1991; Kelly & 
O’Malley 1990; Meisel et el., 1994; 











4.9 – 5.86 
2.4 – 3.5 
4.9 - 5.9   
5 - 40 
1.1 – 4.4 
7.4 – 12.2 
10 – 34  
5 - 38.1 
15 – 58.1 
10.34 – 57.4 
1.98 – 2.52 
1 - 3 
2.0 - 2.52 
1.7 - 3 
0.6 – 2.9 
1.1 – 1.8 
1.3 – 2.4  
1.2 
2.1 – 2.4  
1.50 - 3 
1.78 – 3.06 
2.5 – 6.6 
1.8 – 3.06 
2.0 – 5.9  
2.5 – 4.0 
3.6 – 6.1 
2 – 3  
1.8 – 3.8 












Selvan et al., 2009 
Kosoglou et al., 2002 
Jang et al., 2010; Patel et al., 2008 
Reinoso et al., 2002 
Najib et al., 2003 
Zhi et al.,2003  
Bellosta et al., 2004 
Yan et al., 2003 
Ahmad et al., 2011 








1010 - 2270 
1200 - 2540 
1786 – 3460 
1930 - 3940 
 
2 - 4 
1.5 - 2 
0.83 – 4.97  
1.5 – 3.0 
 
6 – 9, 6 - 10 
5.5 – 8.6 
3.3 – 5.3 




10 - 35 
 
Iqbal et al., 2010; Kim et al., 2014; 
Li et al., 2007; Flesch et al., 1997;  
Zakeri-Milani et al., 2010; 




2.5 Quantification of the selected cardiovascular drugs reported 
in DBS, plasma and serum 
A variety of analytical techniques have been documented for the detection and 
quantification of the selected cardiovascular drugs in DBS, plasma, serum and urine. 
These include LC with UV, fluorescence, or MS detection. LC coupled with MS 
techniques involves LC-MS, LC-MS/MS and LC-HRMS. A comparison of analytical 
techniques reported in the literature for the determination of the selected 
cardiovascular drugs showing the calibration ranges investigated and the sample 
volume used for analysis in DBS, plasma and serum is presented in Table 2.5. Data on 
published work in urine was not included in Table 2.5, since drug/metabolite levels in 
urine do not reflect a true measure of the analyte in circulating blood. This is because 
the urine matrix is linked with the elimination stage of the pharmacokinetic disposition 
of the target drug in the body under the process of absorption, distribution, 
metabolism and elimination (ADME).  
Despite all the data in Table 2.5, there are only four (4) references reported for the 
quantification of some of the selected cardiovascular drugs, which include amlodipine, 
atenolol, bisoprolol, ramipril and simvastatin in dried blood spots (DBS). Thus, 
affirming the need for the development of a microsampling based LC - HRMS assay for 






















 Matrix LOQ 
(ng/ml) 
Internal Standard Ion, Precursor to 
Product (m/z) 
References 
Amlodipine HPLC 10 - 1000 ACN:Acetic acid 0.2% Dihydrogen 
phosphate 
500 Plasma 10 Amytryptyline None Alsarra et al., 2009 
 LC-MS/MS 0.1 - 50 ACN:Water 0.1% Formic acid 200 Plasma 0.1 Amlodipine d4 409 - 238 Qi et al., 2013 




1000 Plasma 0.1 Imipramine  409 - 238 Bhatt et al., 2007 
 LC-MS/MS 0.2 – 12.8 MeOH: Water 78:22,v/v 0.15% Ammonium 
acetate 
200 Serum  0.2 Omeprazole 409 - 238 Li et al., 2011 




200 Plasma 0.2 Pravastatin 
Sodium 
408.68 – 238.00 Yacoub et al., 2013 
 LC-MS/MS 0.1 - 10 ACN:Water Ammonium acetate 200 Plasma 0.1 None 409.1 – 237.9 Danafar and Hamidi, 2016 
 LC-MS/MS 0.05 - 12 MeOH:NH4 acetate Ammonium acetate 500 Plasma 0.05 Gliclazide 409.2 – 238.1 Chan-Mei et al., 2013 
 LC-MS/MS 0.2 - 20 MeOH:NH4 acetate 0.1% Formic acid 1000 Plasma 0.2 Ondansetron 409 - 238 Bathula and Devani, 2011 
 LC-MS/MS 0.3 – 20.73 ACN:NH4 formate 0.2% NH4 formate 300 Plasma 0.3 Amlodipine d4 409.2 – 238.1 Jangala et al., 2014 
 LC-MS/MS 0.1 – 5.0 ACN:Formic acid 0.1% Formic acid 500 Plasma 0.1 Eplerenone 409.1 – 238.14 Rezk and Badr, 2014 
 LC-MS/MS 0.02 - 20 ACN:NH4 formate 0.1% Formic acid 100 Plasma 0.02 Amlodipine d4 409.4 – 238.2 Shah et al., 2017 
 LC-MS/MS 0.1 – 10.22 Water: MeOH 0.2% Formic acid 200 Plasma 0.1 Fluoxetine HCL 409.1 – 238.1 Shentu et al., 2012 
 LC-MS/MS 0.46 - 1000 ACN:Water 0.1% Formic acid 50 Plasma 0.46 Nitrendipine 409.1 – 237.9 Yu et al., 2011 
Atenolol LC-MS 200 - 12000 ACN:Water 0.5% Formic acid 500 Plasma 5 Pantoprazole 267.0 Sridharan et al., 2010 
 LC-MS/MS 5.05 - 503 Ammonium acetate: 
ACN, 15:85 v/v 
0.2% Ammonium 
acetate 
250 Plasma  5.10 Carbamazepine  267.3 – 145.1 Kallem et al., 2012 
  LC-MS/MS 10-800  MeOH:ACN 0.1% Formic acid 200 Plasma  10 Atenolol- d7 267.0 – 190.1 Kallem et al., 2013 
 LC-MS/MS 1 - 800 MeOH:Water 0.1% Formic acid 500 Plasma 5 Phenazone 267.2 – 190.1 Phyo Lwin et al., 2017 
 
LC-HRMS 25 -1500 ACN:Water 0.1% Formic acid 30 DBS 25 Atenolol- d7 267.1903 Lawson et al., 2012 
















 Matrix LOQ 
(ng/ml) 
Internal Standard Ion, Precursor to 
Product (m/z) 
References 
Atorvastatin LC-MS/MS 0.035 - 25 ACN: Ammonium 
acetate, 50:50v/v 
0.3% Formic acid 500 Plasma 0.035 Lansoprazole 559.09  - 440.21 Ravi et al., 2012 
  LC-MS/MS 0.10 – 30.0 0.1% Formic acid: ACN, 
20:80,v/v 
0.1% Formic acid 250 Plasma  0.1 Nevirapine 559.2 - 440.2 Ghosh et al., 2011 
 
 LC-MS/MS 1.5 - 150 Water:MeOH, 14:86, v/v 0.2% Trichloroacetic 
acid 
200 Plasma 1.5 Pravastatin 
Sodium 
559.09 – 440.21 Yacoub et al., 2013 
 LC-MS/MS 0.2 - 151 MeOH:ACN  0.2% Acetic acid  250 Plasma 0.2  Proguanil 559.2 – 440.0 Gagula et al., 2012 
 LC-MS/MS 0.05 - 100 Water:ACN:MeOH, 
35:25:40, v/v/v 
0.005% Formic acid 200 Plasma 0.05 Atorvastatin-d5 557.4 -278.1 Partini et al., 2013 
 LC-MS/MS 0.1 - 100 ACN : Ammonium 
acetate, 30:70 v/v 
0.1 Ammonium 
acetate 
900 Serum 0.1 Atorvastatin-d5 559.0 – 440.1 Novakova et al., 2009 
Bisoprolol LC-MS/MS 0.5 -70 ACN:Ammonium 
formate 5mM, 80:20 v/v 
5mM Ammonium 
formate 
500 Plasma 0.5 Metoprolol 326.2 - 116.1 Bhatt et al., 2007 




1000 Plasma 0.05 Metoprolol 326.4 Ding et al., 2007 
  LC-MS/MS 0.1-30 1mM Ammonium 
acetate:MeOH: ACN, 
65:17.5:17.5v/v/v 
0.1% Formic acid 250 Plasma 0.1 Moxifloxacin 326 - 116 Tutunji et al., 2009 
  LC-MS/MS 
 
0.5 -100 MeOH: Ammonium 
acetate: Formic acid,  
70:30:0.1, v/v/v 
0.2% Formic acid 100 Plasma 0.5 Diphenhydramine 326 - 116 Liu et al., 2007 
 LC-HRMS 1.0 - 500 ACN:Water 0.1% Formic acid 1000 Serum 3.3 Metoprolol D7 326.2331 Tomkov et al., 2017 
 LC-HRMS 1 -100 ACN:Water 0.1% Formic acid 30 DBS 25 Atenolol- d7 326.2326 Lawson et al., 2013 




1000 Plasma 2.5  None  N/A Baviskar et al., 2009 
 LC-MS 1 - 225 MeOH:Ammonium 
acetate 
10mM Ammonia 1000 Plasma 1.0 Codeine 415.5 Molden et al., 2003 




300 Plasma  0.48 Ziprasidone 415.37 - 177.93 Dasandi et al., 2009 















 Matrix LOQ 
(ng/ml) 
Internal Standard Ion, Precursor to 
Product (m/z) 
References 





250 Plasma 0.1 Terazosin 388 Ma et al., 2006 
 LC-MS/MS 0.1 -50 MeoH:Ammonium 
actetate 
0.2% Formic acid 200 Plasma 0.1 Prazosin 452 - 344 Liu et al., 2010 
 HILIC-
MS/MS 
0.2 - 50 ACN:Ammonium 
formate 
0.1M NaOH 100 Plasma 0.2 Cisapiride 452.2 – 344.0 Ji et al., 2008 
 LC-MS/MS 0.078-10 ACN:Water 0.05% formic acid 200 Plasma 0.078 Quinoxaline 452.2 - 343.9  De Nicolo et al., 2016 
Lisinopril LC-MS 6 - 150 ACN:MeOH, 72:7:21 Ammonium formate 1000 Serum 6 Hyoscyamine 406.5 Tsakalof et al., 2002 
 LC-MS 2.5 - 320 MeOH:ACN, 58:25:17, 
v/v 
0.1% Formic acid 250 Plasma 2.5 Enalaprilat 406 Zhou et al., 2008 
  LC-MS/MS 2 - 200 ACN:Water, 60:40,v/v  0.2 % Acetic acid 500 Plasma 2 Enalaprilat 406.3 - 84.3 Padua et al., 2004 
 LC-MS/MS 1.29 - 129 ACN:Water, 11:89, v/v 0.1% TFA 250 Plasma 1.29 None 406 - 246, 291, 309 Vlase et al., 2010 
 LC-MS/MS 0.5 - 250 ACN 5mM Ammonium 
formate 
100 Plasma 0.5 Lisinopril-d5 404.3 – 114.1 Shah et al., 2016 
 LC-MS/MS 0.78 -100 MeOH:Water, 50:50, v/v 0.1% Formic acid 400 Plasma  0.78 Pseudoephedrine 
HCL 
406.1 – 246.0 Huang et al., 2005 
 LC-MS/MS 2 - 200 Ammonium 
Acetate:MeOH, 70:30v/v 
0.2% Acetic acid 500 Plasma 2 Enalaprilat 406 - 246 Qin et al., 2007 
  LC-MS/MS 1.03 - 206 MeOH:Water, 55:45,v/v 0.2% Formic acid 100 Plasma 1.03 Enalaprilat 406  -246, 84  Qin et al., 2011 
Losartan LC-MS 1.0 - 1000 ACN:0.2% Formic acid, 
68:32, v/v 
0.2% Formic acid 200 Plasma  1.0  Butylparaben 422.79 Choi et al., 2008 
  LC-MS/MS 4.0 - 800 ACN:0.05% Acetic acid, 
70:30,v/v 
0.05% Acetic acid  200 Plasma 4 Valsartan 421 - 179 Salvadori et al., 2009 
 LC-MS/MS 1 - 1000 Triethylamine:Acetic 
acid:ACN 
0.1% Acetic acid 400 Plasma 1 DuP-167 421.2 – 126.7 Iwasa et al., 1999 
 LC-MS/MS 5 - 500 ACN:Water 0.2% Formic acid 50 Plasma 5 Losartan-d3 
carboxylic acid 















 Matrix LOQ 
(ng/ml) 
Internal Standard Ion, Precursor to 
Product (m/z) 
References 
 LC-MS/MS 2 - 400 ACN:Water 0.1% Formic acid 250 Plasma 2 Irbesartan 420.73 – 126.70 Prasaja et al., 2009 
 LC-MS/MS 1 - 500 ACN 0.1% Formic acid 100 Plasma 1 Losartan-d5 
carboxylic acid 
423 - 207 Polinko et al., 2003 




500 Plasma 0.1 Trandolaprilat 
HCTZ 
415.43 – 154.97 Gupta et al., 2011 
 LC-MS/MS 0.078 - 100  ACN:Water 0.05% formic acid 200 Plasma 0.078 Quinoxaline 417.1 -234.2 De Nicolo et al., 2016 
 LC-MS/MS 0.1 - 100 Methanol 0.1% Formic acid 300 Serum 0.1 Enalapril 417.3 – 234.3 Lu et al., 2006 
 LC-MS/MS 2 - 170 MeOH:Water 0.1% Formic acid 200 Plasma 2 Carbamazepine 417.2 – 234.1 Patel et al., 2014 
 LC-MS/MS 0.25 - 208 Formic acid:ACN, 15:85 0.2% Formic acid 500 Plasma 0.25 Nevirapine 417.2 – 234.3 Pilli et al., 2010 
 LC-MS/MS 0.2 - 80 MeOH:Water, 70:30, v/v 5mM Ammonium 
formate 
300 Plasma 0.2 Ramipril-d3 415.3 – 154.1 Tan et al., 2009 
 LC-MS/MS 0.107 - 107 Formic acid:ACN, 25:75 0.1% Formic acid 500 Plasma 0.107 Enalapril 417.4 – 234.2 Yuan et al., 2008 




500 Plasma 0.5 Enalapril 417.2 – 234.1 Zhu el al., 2002 
 LC-HRMS  0.5 - 100 ACN: Water 0.1% Formic acid  30  DBS  1  Atenolol d7 417.2384 Lawson et al., 2013 
 Simvastatin HPLC-FD 0.1 - 10 MeOH:Water 80:20, v/v  None 1000 Plasma 0.1 Lovastatin  N/A Ochiai et al., 1997 
  LC-UV 20 - 1000 ACN:Sodium Dihydrogen 
Phosphate 
 None  1000 Plasma  20 None  N/A Carlucci et al., 1992 
  LC-MSMS 0.1 - 101 ACN:Ammonium acetate 
(5mM), 80:20 v/v 
5mM Ammonium 
acetate 
 500 Plasma 0.1 Nevirapine  419.3 – 285.3 Pilli et al., 2012 




900 Serum 0.05 Simvastatin d6 419.0 - 199.2 Novakova et al., 2009 




500 Plasma 0.2 Simvastatin d6  437.3 – 303.2 Ramani et al., 2009 
  LC-MS/MS 0.1 - 20 ACN:0.5% Formic acid, 
(90:10, v/v) 
0.5% Formic acid  200 Plasma 0.1 Propranolol HCL M+Na+, 441.3 – 
325.1 
Selvan and Pal., 2009 
  LC-MS/MS 0.05 – 20.4 ACN:Water, 85:15, v/v 10mM Ammonium 
acetate 
















 Matrix LOQ 
(ng/ml) 
Internal Standard Ion, Precursor to 
Product (m/z) 
References 
Simvastatin LC-MS/MS 2.5 - 500 ACN:Ammonium acetate 0.5% Acetic acid 475 Plasma 2.5 Lovastatin 419.3 – 199.3 Ahmed et al., 2012 
 LC-MS/MS 10 - 10000 ACN: Water, 20:80, v/v 10mM Phosphate 250 Serum 10 Simvastatin d6 419.2 – 199.1 
441.3 – 325.1 
Bews et al., 2014 
 LC-MS/MS 0.25 - 50 ACN:Water, 75:25, v/v 0.1% Formic acid 200 Plasma 0.25 Lovastatin M+Na+, 441.3 – 325 Alakhali., 2013 
  LC-MS/MS   ACN: 3.0mM formic acid Sodium acetate   100 Plasma 0.5 Lorvastatin 419 - 285 Jemal et al., 2000 
  LC-MS/MS 0.05 - 105.0 ACN:Ammonium acetate  Ammonium acetate  950 Plasma 0.1 Carbamazepine  419.2 – 285.3 Burugula et al., 2013 
 LC-MS/MS 0.5 - 500 ACN: Water Ammonium acetate 250 Plasma 0.5 Simvastatin d3 419.1 – 199.1 Zhang et al., 2004 
 LC-MS/MS 0.2 - 100 MeOH:Water  0.1mM Ammonium 
Trifluoroacetate 
500 Plasma 0.1 6-demethyl 
mevinolin 
 419.4 – 285.3 Silva et al., 2014 
 LC-MS/MS 0.1 - 100 MeOH:Water,  0.1% Formic acid, 
Ammonium formate 
200 Plasma 0.1 Hesperetin 419.23 – 199.13, 
285.17, 303.19 
Wang et al., 2015 
 LC-MS/MS 0.1 -40.0 ACN:5mM Ammonium  
acetate (82:18, v/v) 
0.2% Acetic acid 300 Plasma 0.1 Lorvastatin 419.1 - 199.3 Apostolou et al., 2008 
  LC-MS/MS 0.1 - 16.0 ACN:MeOH Ammonium acetate 1000 Plasma 0.1 Lovastatin  [M + CH3CN + 
Na]+,481.2 
Barrett et al., 2005 
  LC-HRMS  1 - 100 ACN: Water 0.1% Formic acid  30  DBS  5 Atenolol d7 441.2611  Lawson et al., 2013 
Valsartan LC-MS/MS 10,000 - 
5,000,000 
ACN:Water with 0.01% 
formic  acid 
10mM Ammonium 
formate 
500 Plasma 2000 Pravastatin 436.0 - 234.9  Gonzalez et al., 2010 
  LC-MS/MS 5.0 - 4000 ACN:MeOH 1% Ammonia  500 Plasma  5 Clonazepam  434.22 – 179.22 Shah et al., 2009 
  LC-MS/MS 1.0 - 2000 ACN:Formic acid 0.1% Formic acid  200 Plasma  1 Tamsulosin  434.2 – 179.0 Selvan et al., 2007 
 LC-MS/MS 11.7 - 3000 Water: MeOH None 100 Plasma 11.7 Irbesartan 434.2 – 178.9 Liu et al., 2008 
  LC-MS/MS 4.0 - 3600 ACN: Ammonium 
acetate 
0.1% Formic acid 500 Plasma 2 Probenecid 434.2 - 350.2 Li et al., 2007 
 LC-MS/MS 2.0 - 2000 MeOH:ACN 0.1% TFA 500 Plasma 5 CGP48791 436.2 – 291.2 Koseki et al., 2007 
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2.6 Proposed calibration ranges to be investigated for the selected 
cardiovascular drugs 
Except for amlodipine, atenolol, bisoprolol, ramipril and simvastatin (Lawson et al., 
2012; Lawson et al., 2013; Tanna et al., 2015), no prior investigations had been carried 
out on atorvastatin, diltiazem, doxazosin, lisinopril, losartan and valsartan in dried 
blood matrix. Hence the information from Tables 2.4 and 2.5 for the selected target 
drugs investigated using plasma and serum was used as the basis to determine the 
proposed calibration range to be investigated using dried matrix microsampling. The 
calibration ranges (Table 2.6) were chosen to cover the anticipated levels of each drug 
in blood from all the recommended prescription doses, given the bioavailability of the 
drug. For example, bisoprolol has a bioavailability of 90% (Table 2.4) and is giving at a 
dose of 2.5 – 10mg whilst valsartan has a bioavailability of 23% and is prescribed at a 
dose of 20 – 160mg, hence the huge difference in calibration ranges of 0.1 – 100ng/ml 
and 50 – 4000ng/ml for bisoprolol and valsartan respectively. Table 2.6 shows the 
doses and the proposed calibration ranges selected for the eleven cardiovascular drugs 
in human whole blood. 
Table 2.6 Proposed calibration ranges of the 11 target cardiovascular drugs in human whole blood 
Drug Dose (mg) Calibration ranges (ng/ml) 
Amlodipine 2.5 - 20 0.5 – 100  
Atenolol 25 -100 10 – 1500  
Atorvastatin 10 - 80 0.5 – 100  
Bisoprolol 2.5 - 10 0.1 – 100  
Diltiazem   60 - 360 0.5 – 600  
Doxazosin   1 - 16 0.1 – 100  
Lisinopril 10 - 80 0.1 – 100  
Losartan 25 - 100 5 – 1000  
Ramipril 1.25 -10 0.1 – 100  
Simvastatin 10 - 80 0.1 – 100  





2.7 Choice of internal standard 
The use of internal standard (IS) in chromatography based bioanalytical assays 
employing HPLC or LC with (MS, MS/MS and HRMS) has been well accepted and is 
often considered critical for the performance of the assay in terms of accuracy and 
precision of analytical results (Piorkowska et a., 2017). The IS will compensate for the 
associated variability that may occur because of sample preparation, the subsequent 
extraction of targets from DBS and the possible variability of ionisation.  
The application of MS brings along the challenge of matrix effects which may affect 
ionisation of the analyte at the ion source of the MS leading to variability in analytical 
results. Hence suitable internal standards may be required that behave similarly to the 
analyte of interest not only during the extraction and separation but also at the 
ionisation and detection stages of analysis. The internal standards therefore provide 
characteristics to compensate for the experimental variability. For the development of 
DBS based bioanalytical assays, the ideal choice of internal standard is a stable analyte 
that is readily available and matches the chromatographic properties, recovery and 
ionisation properties of the target analyte being investigated (Wagner et al., 2014). 
On this basis, several types of IS have reportedly been used, examples are close 
analogue of the target analyte or a stable isotopic label of the analyte.  However, for 
assays developed for clinical applications, the choice of using a close analogue of the 
target analyte may not be ideal (Srinivas, 2016). This is because, the IS may be a 
commonly prescribed drug and hence may restrict the wider applicability of the newly 
developed assay especially in the patient population. It is therefore recommended that 
a stable isotopic label of the analyte is used when available. The use of stable isotopic 
label IS efficiently addresses the various issues during extraction, separation and 
detection allowing for the unambiguous quantification of the analyte of interest. On 
this basis, atenolol D7 an isotopically labelled compound was selected as the IS for this 
study. However, due to the solid nature of DBS samples, it is important to note that 
unambiguous quantification of the analyte depends on the point of application of the 
IS. For example, onto the blank sampling paper to dry before blood spotting, in the 
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extraction solvent, onto the DBS sample prior to punching or spotting separately the 
blood sample and IS unto the card and punching both into a tube for extraction. 
Wagner et al (2014) reports that there are arguments on the stage at which the IS 



















Chapter 3 Blood microsampling methods and the various 
analytical techniques used for the analyses of collected 
samples 
 
This chapter gives an overview of microsampling methods currently used for blood 
sample collection. The challenges of using blood microsampling, the process of sample 
collection and target analyte extraction are discussed. The advantages of using blood 
microsampling for the assessment of cardiovascular medication adherence and the 
analytical techniques that are used for analysing dried blood matrix microvolume 
samples are also presented. 
3.1 Introduction 
Microsampling involves the collection of small amounts (microlitre – picolitre) volume 
of samples for analysis of the concentration of an analyte or endogenous substance 
(Zane and Emmons, 2013). Blood microsampling therefore involves the collection of 
microvolume blood samples by means of a finger or heel prick. The application of 
microsampling has evolved innovatively with great emphasis on using the platform to 
aid clinicians and researchers conduct research in patient populations such as 
paediatrics, geriatrics and in resource limited areas of the world where traditional 
liquid blood sampling and storage may be difficult. Microsampling offers enormous 
advantages in comparison with traditional liquid blood sampling. 
3.2 Advantages in using blood microsampling 
The benefits of microsampling are numerous and include low blood volume 
requirement, storage and transportation without special treatment, better analyte 
stability, enhanced clinical cooperation in clinical trials and reduced unexpected 
exposure of analysts to biohazard (Zane and Eamons, 2013; Sharma et al., 2014; Nys et 
al., 2017). These benefits make blood microsampling attractive in areas such as 
Newborn Screening (NBS), Therapeutic Drug Monitoring (TDM), Pharmacokinetic (PK) 
and Toxicokinetic (TK) studies, Paediatric studies, Metabolism and pharmaceutical drug 
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development. This is because of the small volume of blood required for analyses at 
each sampling time. 
For the measurement of cardiovascular drugs from dried blood matrix, the advantages 
of using microsampling methods are the ease of sampling and minimal invasiveness of 
the technique (Wilhelm et al., 2014). Microsampling is therefore seen as “patient 
friendly” due to its high patient acceptability (Zane and Emmons, 2013; Sharma et al., 
2014; Verhaeghe et al., 2017). Microsampling overcomes the limitations of traditional 
blood sampling technique (venepuncture) which is highly invasive and requires 
relatively large blood volume (1 - 5 ml) at each sampling time to generate sufficient 
plasma/serum required for analysis (De Nicole et al., 2016). This poses practical 
challenges in conducting TDM, medication adherence and pharmacokinetic (PK) 
studies.  
For the purposes of drug concentration measurements in TDM and medication 
adherence, the possibility of self-sampling or “at home” sampling by a patient is 
unique to microsampling (Spielberg et al., 2000). Samples can be collected at any 
desired sampling time (Tanna and Lawson, 2014) by the patient and posted by regular 
mail to the laboratory for analysis (Spooner, 2013). This eliminates the need for 
appointments, clinic visits and the services of a phlebotomist with huge cost savings 
(Martial et al., 2016). For example, by means of microsampling, the City Hospital in 
Birmingham-UK, offers a testing service for Vitamin D for a small fee to clients around 
the world. A test kit is mailed to the client and samples are taking at home and mailed 
back to the laboratory for analysis. Results are sent to the client within 5 days by email 
(City Hospital, Birmingham, 2015). Similar services are provided using DBS 
microsampling in the USA for the screening of patients at high risk of HIV – AIDS and 
antiretroviral drug adherence. (Stekler et al., 2017). 
Microsampling also allows researchers the possibility to ship dried matrix without the 
need for dry ice or special equipment at clinical sites compared to liquid blood or 
plasma (Shah et al., 2013). This presents huge savings in terms of cost of shipment 
because analytes are more stable in dried matrix compared with liquid matrix 
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(Waterman et al., 2005; Manicke et al., 2016). For example, for unstable glucuronides, 
prodrugs and other compounds likely to suffer from interconversion due to enzymatic 
activity, dried matrix offers a stabilising effect on the compound during sample 
collection and subsequent shipping to the laboratory for analysis (Sharma et al., 2014). 
This eliminates the need for adding stabilising agents which may be required for liquid 
samples such as plasma, serum or whole blood.  
Microsampling also enables TDM and medication adherence studies to be performed 
in resource limited areas of the world where special storage and transportation of 
blood and frozen plasma samples may not be readily available. For example, in Africa 
DBS microsampling has enabled the collection of blood samples in remote villages with 
no access to clinical facilities. Samples are then sent to hospital laboratories in the city 
for the screening of Human Immunodeficiency Virus (HIV) and assessment of 
adherence to antiretroviral medication (Boillot et al., 2016).  
The ease of usage of microsampling coupled with the capability of modern analytical 
instruments to quantify ultra-low levels of drugs and/or metabolites has increased its 
adoption for TDM and for medication adherence studies. This provides a user-friendly 
means of monitoring medication levels in the body which would otherwise be difficult 
to do using venepuncture. However, for TDM the gold standard matrix is either whole 
blood or plasma sample. The reason is to ensure that the sample accurately represents 
the analyte in circulating blood (Verhaeghe et al., 2017).  
3.3 Current microsampling techniques 
Even though DBS card microsampling has not been able to meet all primary 
expectations such as patient self-sampling, collection of fixed volume blood samples or 
adoption in regulated bioanalysis, it has prompted research into alternative 
microsampling platforms (Verhaeghe et al., 2017). This has led to the development of 
other techniques, for example capillary microsampling (CM) (Jonsson et al., 2012), and 
volumetric absorptive microsampling (VAMs) (Deniff and Spooner, 2014). Each of 
these developments have been introduced to overcome the limitations observed with 
traditional DBS card microsampling such as the volumetric hematocrit effect. Though 
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significant progress has been made in this area, research is still ongoing to develop 
user friendly self-use devices for both clinical and non-clinical applications. The reason 
is that microsamplers provide a cheap and easy alternative to collect and store 
biological specimens from humans (infants, children and adults). Currently, 
microsampling techniques used include card or paper microsampling (DBS), volumetric 
absorptive microsampling (VAMs), and capillary microsampling (Stove, 2015). 
3.3.1 Card microsampling 
Card microsampling refers to the collection of drops of blood on filter paper, popularly 
known as DBS. Dried blood spot dates back to the 1960’s when Dr. Robert Guthrie 
used the technique to measure phenylalanine in newborns for the detection of 
phenylketonuria (Shah et al., 2013).  Dried blood spot became popular and was utilised 
mainly in NBS because of the small sample volume. In addition, the filter paper was 
cheap, readily manufactured, easily printed and have good adsorption properties 
(Pelton, 2009). Since then cards used for blood sample collection have been 
commercially available and can be grouped into two types (untreated and chemically 
treated cards) (Wagner et al., 2014). The card material may either be made of cellulose 
(Whatman 903, Ahlstrom 226) or non-cellulose based material (Agilent bond elut dried 
matrix card, (Tomtec PDMS 7 polyester cards, refer to Figure 7.3b)). 
 
Figure 3.1 A Whatman 903 card containing three spots of dried blood and two punches in the marked 
sections. 
The card thickness, pore size and particle retention power are the main factors that 
determine the loading capacity and spreadability of blood on the filter paper (Quraishi 
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et al., 2013). The Clinical and Laboratory Standards Institute (CLSI) recommend the use 
of three specific sampling cards (Hannon et al., 2007; Wolff, 2017). These are the 
Perkin-Elmer 226, Ahlstrom 226 and Whatman 903 sampling cards, which serve as the 
conventional devices for blood sample collection. These types of cards have been used 
since the inception of the DBS platform in the 1960’s. These cards consist of untreated 
DBS paper mainly cellulose and made from pure cotton linters. They are registered by 
the U.S. Food and Drug Administration (FDA) as invitro Class II medical devices and 
approved by the Newborn screening Quality Assurance Program (NSQAP) and the 
Centres for Disease Control and Prevention (CDC) (Wayne, 2013; Wolff, 2017). 
The choice of sampling card is important to attain good quality data, because of the 
small sample volumes. Conventionally DBS samples collected on a card are analysed by 
punching a fixed size disk from the spot and extracting with solvent. Hence the size of 
the disk punched will be directly proportional to the volumetric measure obtained 
from quantitative analysis (Lawson et al., 2013). The exact blood volume on the 
punched disk will be a function of thickness of the spot and the area of the disk. It is 
reported that due to the difference in hematocrit range for individuals, blood from 
different people will have different viscosities which will affect the spread on cellulose 
based paper leading to spots of different sizes (Fan and Lee, 2012). This could present 
variability in analyte quantification due to possible blood spot inhomogeneity, 
variability in blood spot volume and hematocrit values. These challenges have been 
overcome with the development of novel devices like VAMS which utilise precise 
volume sampling or whole spot sampling from capillary collection. Other 
developments include the HemaSpot – HF blood collection device, Noviplex cards, 
Hemaxis – DB blood collection device, Ahlstrom 167L cards and Tomtec dry media spot 
slides which are discussed in Chapter 7.  
3.3.2 Volumetric absorptive microsampling (VAMS) 
Volumetric absorptive microsampling, an example of which is known as MitraTM is a 
microsampling device made of a polymeric tip attached to a moulded plastic handle. 
The process of sample collection involves the absorption of a liquid sample onto the 
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porous substrate by wicking. VAMS is a novel development for acquiring a dried blood 
sample for quantitative analysis. It enables accurate and precise collection of a 10µl or 
20µl fixed volume of blood directly from the finger eliminating the volumetric 
hematocrit effect associated with the conventional DBS sampling when a punched disk 
is used. Since a precise volume is taken, the whole sample is used for extraction. VAMS 
come in a clamshell containing two or four sampling devices, which can be closed to 
securely protect the sample after collection and allowed to dry. There is a label on the 
clamshell for collecting sample information. Figure 3.2 shows an unused (white tip) 
and used (red tip) novel VAMS device. 
 
Figure 3.2 VAMS consisting of a hydrophilic polymeric tip attached to a moulded plastic handle. The 
white-tipped sampler is unused while the red-tipped sampler contains a sample of dried blood 
(Denniff and Sponner, 2014).  
3.3.3 Capillary microsampling 
Capillary microsampling (CMS) provides an alternative to collecting a predefined low 
volume of blood in commercially available glass capillaries (Coleman et al., 2017). 
These capillaries come in different sizes with volumes in the range of 1–75μl (Nilsson 
et al., 2013). Example, the Aqua-Cap sample collection tube (Drummond Scientific, 
USA) designed to be a single-use disposable glass EDTA-coated capillary, which collects 
precise 75µl of blood (Bowen et al., 2013). Capillary microsampling offers handling of 
microvolume blood samples in the liquid state from which plasma can be generated 
through centrifugation of the capillary. This makes CMS compatible with existing work 
flows for sample handling and clean-up prior to instrumental analysis. Alternatively, 
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the blood in the capillary can be washed out generating a diluted sample that is then 
subjected to extraction and analysis or frozen as liquid, or can be applied to absorbent 
paper to prepare dried blood spots depending on the application required (Parker et 
al., 2016). Verougstraete et al (2016) reported the use of capillary microsampling as an 
alternative to traditional venous sampling for the assessment of HbA1c in diabetic 
patients. It is progressively replacing traditional, larger volume sampling in the 
assessment of HbA1c in diabetic patients. 
It has been demonstrated that, fixed volume blood sample collection using a capillary 
onto a DBS card eliminates the Hct effect. (Youhnovski et al., 2011; Li et al., 2011; 
Meesters et al., 2012; Rincon and Meesters, 2014). However, the main benefit of a 
procedure for a punch DBS analysis is the ease of self-sampling by the patient, which 
becomes complex and prone to sampling errors when precise blood volumes must be 
collected by the patient and applied on the DBS card by means of a capillary. This 
problem has been addressed by the introduction of a novel microsampling device like 
the Hemapen (Trajan Scientific and Medical, 2015). Designed in the form of a pen to 
sample precise volumes of blood with ease using capillary collection onto a precut DBS 
card housed in a secured cartridge within the device. Thus, eliminating the Hct effects 
and more importantly offering the possibility of self-sampling by the patient. A 
description of the Hemapen is shown in Chapter 7, Section 7.1.6. 
3.3.4 Blood sample collection, spotting and storage on DBS and VAMS 
The popularity of microsampling stems from the fact that, collection of sample is taken 
from a finger (adults) or heel prick (children) rather than a venepuncture. This makes it 
minimally stressful for the patient. Microsample blood collection involves a sampling 
kit, containing a sampling device (DBS card, VAMS, small vacutainers), a disposable 
sterile lancet, gauze, capillary tubes or pipetting device, envelopes, desiccant, and 
zipper storage bags for shipping. 
For clinical applications, capillary blood collection is the conventional approach to 
microsampling. Microsamples are obtained from each volunteer by gently massaging 
the fingertip to encourage blood flow. The finger is pricked with a retractable lancet 
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and the first drop of blood wiped with a sterile gauze. Subsequent drops are either 
deposited onto marked sections on a sampling card or wicked onto the tip of a VAMS 
device and labelled appropriately. In the case of DBS, spot sizes should be sufficient to 
allow the use of a punch device without compromising the DBS sample. Samples of 
smaller spot sizes should be rejected. The collected samples are air dried at room 
temperature for about 3 hours and placed in zipper bags for storage.  
The United Nations International Children’s Emergency Fund (UNICEF) and the World 
Health Organization (WHO) certify the quality of card microvolume samples through 
the provision of standard operating procedures (SOP) and guidance manuals for 
sample collection (WHO, 2005; UNICEF, 2009). Several sampling protocols have also 
been published by Public Health Authorities like the NHS in the UK, and the Centre for 
Disease control and Prevention in the US which describes the process of bleeding, 
spotting, drying and packaging of samples in newborn screening programmes (CDC, 
1993; NHS, 2016). 
3.4 Analytical challenges in using dried matrix microsampling 
Microsampling since its inception was initially used for qualitative analysis, for example 
in newborn screening (NBS) programmes for inborn errors of metabolism. Its 
application outside NBS was limited due to the small sample size, matrix complexity 
and the lack of sensitive and selective detection techniques. This presented analytical 
challenges, which hampered the attractiveness of the technique. However, in recent 
years microsampling has become popular due to the advancement in analytical 
instrumentation such as LC and MS (Wilhelm et al., 2014). This has allowed the 
quantification of analytes in biological specimen such as blood collected as 
microvolume samples. 
Irrespective of the numerous advantages, collection of microvolumes of blood on DBS 
card present challenges for implementation in everyday use. This is to do with the 
ability to recover the analyte from microsamples. Interferants from the card material 
and blood matrix, sometimes interfere with MS analysis. Studies have also shown that 
paper/sample combination may also age and prevent the recovery of analyte with 
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long-term storage (Wagner et al., 2014). Hence, the gain in analyte stability for some 
target compounds are sometimes offset by the difficulty encountered in recovering 
other compounds from the card (Linder et al., 2016). 
The volumetric hematocrit effect has also been shown to be a significant parameter 
that impacts quantitative analyses with card microsampling method (Deniff and 
Spooner, 2010; De Vries et al, 2013). It has been shown to affect DBS drying time, 
homogeneity, diffusion and assay reproducibility (Timmerman et al., 2011). The 
hematocrit (Hct) level represents the relative volume of red blood cells (RBC) in blood. 
It affects the blood viscosity and that in turn influences the spread of a blood spot 
(Koster et al., 2015). Blood with high Hct (due to the high cellular composition) is more 
viscous and leads to the formation of small spots on DBS cards. Hence, the Hct effect is 
profound when a punch is used (0’Mara et al., 2011). The Hct range varies according to 
age for healthy adult males and females over the age of 18. It is 40 – 54% and 36 – 48% 
respectively (Walker et al., 1990). Hct values may however, deviate from these ranges 
in certain disease states where the relative volume of RBC in blood is affected e.g. 
anaemia and polycythaemia, which is a rare condition in which the bone marrow cells 
produce too many red blood cells. 
It has been demonstrated that, the approach of whole spot analysis or pre-cut disks 
eliminates the Hct effect. (Youhnovski et al., 2011; Li et al., 2011; Meesters et al., 2012; 
Rincon and Meesters, 2014). The problems about the Hct effect have been addressed 
by the development of novel microsampling devices like VAMs, the Hemapen device 
and the Tomtec dry media spot slides which have been designed to sample precise 
volumes enabling the use of whole sample or pre-cut disks for analysis hence 
eliminating the Hct effects (Deniff and Spooner, 2014; Trajan Scientific and Medical, 
2015; Tomtec Limited, 2015). A discussion of the innovations in microsampling 
methods is presented in Chapter 7. Unfortunately, official guidelines for validation of 
assays developed using microsampling have not yet been provided by regulatory 
authorities. Hence for microsampling to be adopted in a regulated environment, it is 
imperative that these factors are investigated to provide assurance that the analytical 
results are acceptable (Fan and Lee, 2012). 
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Influence of the matrix on DBS analyte recovery is important. Some analytes may be 
difficult to extract from the card matrix due to the formation of complexes with 
endogenous compounds present in the DBS matrix (Koster et al., 2009; Koster et al., 
2013; Vu et al., 2014). Hence the extraction efficiency may be influenced by factors like 
nature of the DBS material, analyte stability, extraction conditions, analyte solubility, 
Hct and analyte concentration. The bioanalyst should be aware of these possible 
interactions to acknowledge them in an early stage of the assay development. For 
example, in the determination of clarithromycin and rifampicin from DBS, iron from 
the blood was found to interact with rifampicin to form a complex (Vu et al., 2014). 
Deferoxamine and ethylenediaminetetraacetic acid (EDTA) were added to the 
extraction solution to form a complex with the iron and recovery of rifampicin in the 
DBS extraction increased to approximately 100%. Lawson et al (2012) also 
demonstrated that in the extraction of captopril from calibration and volunteer DBS 
samples, captopril was found to undergo rapid oxidation to inactive disulphide dimers. 
This conversion is known to occur “in vivo” and was found to occur “in vitro” as well 
during sample preparation and analysis. Hence 1,4-dithiothreitol was used both to pre-
treat the DBS cards and as part of the extraction process to ensure stability of the 
captopril extract from DBS. 
3.4.1 Extraction of target analytes from dried blood matrix 
The process of DBS extraction can be performed on-line by direct extraction or off-line 
by punching DBS spots into tubes or well plates before extraction with solvents (Heinig 
et al., 2011; Oliveira et al., 2014a). On-line approaches involve automated handling of 
dried matrix samples without any treatment or manual disk punching (Manicke et al., 
2016; Damon et al., 2016). Examples of on-line extraction includes flow-through 
elution of DBS and direct extraction from the surface of the card (Fingerhut et al., 
2014; Oliveira et al., 2014b; Griffiths et al., 2015; Verplaetse and Henion, 2016).  
For off-line extraction, punching can be done manually or by automation which is now 
integrated into current workflows (Wong et al., 2010). Biosamples are complex 
mixture of constituents, with the analyte of interest normally at a lower concentration 
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compared to other constituents (Gjelstad and Pedersen-Bjergaard, 2014). Hence a 
clean-up step to remove unwanted material from the sample or a process of selective 
extraction of the analyte(s) from the blood and/or card matrix prior to concentration 
and analyses is necessary (Liu et al., 2014; Bylda et al., 2014; Tanna and Lawson, 2016). 
In addition, the sample volume required is very small, hence the extraction protocol 
should be robust to guarantee analyte detection and increase recovery. Dried blood 
spots are solid samples hence they must be extracted with a suitable solvent to enable 
analysis with commonly used analytical techniques such as LC-MS. The dominant 
extraction technique for the extraction of analytes from dried blood matrix (DBS and 
VAM’s) is solid liquid extraction (SLE) (Cape et al., 2017).  
In solid-liquid extraction, there is a solid phase (the sample) and a liquid phase (the 
extraction solvent). Three factors; solubility of the target analyte, matrix effects and 
mass transfer (Alkhateeb, 2015) affect the efficiency of SLE. Solubility of the analyte of 
interest depends on the type of extraction solvent, which is in turn affected by 
temperature and pressure.  Mass transfer deals with the extraction of the analyte from 
the core of the card matrix into the solvent. Mass transfer is difficult in SLE because it 
requires solvent penetration of the solid matrix followed by displacement of the 
analyte from the adsorbed sites. It is dependent on the particle size, matrix structure 
and the diffusion of the analyte of interest into the extraction solvent (Singleton, 
2012). Hence smaller particle size, high diffusion and solvents with low viscosity 
facilitate mass transfer. Matrix effects involve the influence of the sample matrix on 
the recovery of the analyte of interest. For dried matrix samples, components of the 
blood and the card material may impact negatively on the extraction efficiency of the 
target analyte (Takyi-Williams et al., 2015).  
Some target analytes are also highly bound to proteins which are normally retained on 
the card, hence co-precipitation can arise during extraction from dried matrix. In such 
situations, a volatile acid or base such as formic acid (FA) or ammonium hydroxide 
(NH4OH) may be used to hydrolyse the drug-protein bond, to increase the extraction 
and recovery of the target analyte (Cape et al., 2017). Following extraction, the 
resulting supernatant or extract is subjected to analysis.  
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3.5 Analytical techniques used in conjunction with dried matrix 
microsampling 
Since the introduction of microsampling various analytical techniques have been used 
for the identification and quantification of the target analyte. These include 
immunoassay methods, polymerase chain reaction (PCR) amplified DNA analyses, high 
performance liquid chromatography (HPLC), and hyphenated techniques such as gas 
chromatography mass spectrometry (GC-MS), liquid chromatography coupled with 
mass spectrometry methods (LC-MS, LC-MS/MS, LC-HRMS) (Tanna and Lawson, 2011). 
However, some of these methods suffer in terms of sensitivity and selectivity. For 
example, a major drawback for immunoassays is the lack of selectivity due to cross-
reactivity of interferents (Tanna and Lawson, 2016; Cape et al., 2017).  
In recent years, improvements in bioanalytical detection have allowed for 
measurement of analytes from blood samples collected using microsampling methods. 
Such advancement in instrumentation has provided broader options for analysis and 
improved throughput. This has enabled the extension of microsampling to non-
newborn screening applications such as TDM (Kneepkens et al., 2017; Weber et al., 
2017), PK and TK studies (Kole et al., 2017), forensic applications (Chepyala et al., 2017; 
Simoes et al., 2017), sports doping screening (Verplaetse and Henion, 2016; Tretzel et 
al., 2016), environmental analysis (Provatas et al, 2017), food safety (Xue et al., 2016), 
endocrinology and metabolism (Heussner et al., 2017).  
In a review by Zakaria et al (2016), considering the advantages and challenges of DBS 
microsampling analysis by MS, they identified 121 biological markers that have been 
screened using DBS microsampling platform beyond its application in NBS. Out of the 
121 biomarkers, 77 were pharmaceutical agents, 6 on illicit drugs, 4 on banned 
substances in sports and 2 were on chemical exposure agents. This highlights the wide 
applicability of the dried matrix microsampling platform which has been made possible 
with advancement in detection technologies notably MS. Many instrumental and 
methodological solutions specifically dedicated to dried blood microsampling, have 
now been developed with their common denominator being the use of MS (Wagner et 
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al., 2014). Making MS the key technique reported in the literature for analysis using 
microsampling (Zakaria et al., 2016). The reason is because MS provides data which is 
characteristic of the analyte. The first application of MS to DBS analysis was reported 
in 1976 for fatty acid determination using direct chemical ionisation (Wagner et al., 
2014). Since 1976, MS based bioanalytical assays using microsampling platforms have 
evolved. Sample collection, preparation, chromatography methods, ionisation sources 
and mass analysers continue to advance to overcome the challenges associated with 
using microsampling, as well as meet the needs of the bioanalytical industry (Rago and 
Negahban, 2016).  
3.5.1 Immunoassay 
Immunoassays can quantify a wide group of compounds from small molecule 
therapeutic drugs to biological markers of diseases (Flores et al., 2017). Immunoassay 
methods have been widely used for the quantification of therapeutic drugs since the 
80’s, developed in parallel to chromatography methods. Before the adoption of MS 
detectors in bioanalytical work flows, immunoassay-based methods occupied, the 
sensitivity gap seen with chromatographic assays (Cape et al., 2017). Hence many new 
drug applications (NDAs) at the time used bioanalytical methods that were 
immunoassay based. For example, NDA for lisinopril, a commonly prescribed 
antihypertensive drug was supported with immunoassays (Breidinger and Woolf, 
2017). DBS based immunoassay methods were reportedly used to quantify 
concentrations of therapeutic drugs irrespective of the small sample volumes (Li et al., 
1986). They are easy to perform, require minimal sample preparation with fast analysis 
time. However, the assay protocol may demand handling radioactive materials, the 
need for prolonged incubation, selection of the correct antibody, addition of precise 
volumes of liquids followed by washing (Shipkova et al., 2017). Specificity is based 
upon the interaction between the analyte and an antibody to the analyte. The 
disadvantage of such methods is the susceptibility to cross-reactivity by endogenous 
components and nonspecific binding which leads to a lack of specificity and inability to 
simultaneously measure different analytes. Hence an immunoassay requires 
appropriate reagent; that is, a specific antibody for the analyte of interest. Otherwise 
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there will be inconsistencies between patient results as well as reference ranges 
caused by susceptibility of the antibodies to interferences or cross-reactions by the 
structurally related compounds (Leung and Fong, 2014). Currently, LC-MS/MS methods 
have largely eradicated the need to develop immunoassays to support small molecule 
bioanalysis using dried matrix microsampling. In contrast, immunoassay methods are 
still widely used for the measurement of proteins and peptides in biological fluids. 
3.5.2 High performance liquid chromatography (HPLC) 
High Performance Liquid Chromatography (HPLC) is a form of column chromatography 
that pumps a sample mixture in a solvent (mobile phase) at high pressure through a 
column with packing material (stationary phase). As the mobile phase passes through 
the column, the analytes interact with the two phases at different rate due to their 
polarities (Snyder et al., 2012). Analytes that have less interaction with the stationary 
phase or the most interaction with the mobile phase exit the column quicker. The 
components of a typical HPLC system is shown in Figure 3.3. 
 
Figure 3.3 A schematic representation of an HPLC system 
Chromatographic assays improved specificity by means of separation before detection. 
Early chromatography based assays used gas chromatography (GC) for separation, but 
GC was limited because of the requirement for the analyte to be volatile (Stevenson, 
2011). This limitation triggered the adoption of HPLC for small molecule bioanalysis, 
since it eliminated the need for the analyte to be volatile. However, early HPLC assays 
had a huge limitation in terms of sensitivity. Commonly used HPLC detection method 
was ultraviolet (UV) spectrometry, which limited sensitivity to the extinction 
coefficient of the analyte based on the detection wavelength (Suyagh et al., 2010; 
Stevenson, 2011). Sensitivity problems were partly addressed by the development of 
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derivatisation procedures to attach chromophores to the analyte which could then be 
detected by fluorescence (Synder, 2012). DBS based HPLC-UV and fluorescence 
methods have been used to quantify therapeutic drugs, however these assays suffered 
in terms of sensitivity. Rao et al (2011) reported DBS based HPLC fluorescence 
detection for the determination of antihypertensive drugs valsartan and losartan with 
LOQ’s of 120ng/ml and 60ng/ml respectively. AbuRuz et al (2006) reported a DBS 
based HPLC-UV assay for the TDM of metformin with an LOQ of 150ng/ml. Green et al 
(2002) also reported a DBS based HPLC assay for the determination of sulfadoxine and 
pyrimethamine with sensitivities at 10,000ngml and 1,000ng/ml respectively. Allanson 
et al (2007) also reported a DBS based HPLC-UV method for the quantification of 
rifampicin with an LOQ of 1,500ng/ml. HPLC sensitivity issues were overcome by the 
introduction of LC coupled with MS detectors (LC-MS). The MS detector provides the 
most definitive identification of all HPLC detectors since it provides data characteristic 
of the analyte (Breidinger and Woolf, 2017). 
3.5.3 Liquid chromatography – mass spectrometry (LC-MS) 
Over the last two decades, LC-MS has been the main tool for quantitative and 
qualitative bioanalysis (Xie et al., 2012). LC-MS central position in bioanalysis stems 
from the fact that there is the need for rapid, effective and sensitive qualitative and 
quantitative determination of biomarkers to aid drug discovery, TDM, PK and TK 
studies, neonatal screening and metabolism. LC-MS operating in the single ion 
monitoring (SIM) mode, assay specificity is partly achieved by chromatographic 
methods through the separation of analytes prior to detection (Figure 3.2).  
 
Figure 3.4 A schematic representation of a typical LC-MS system 
LC-MS utilises a single mass analyser (the quadrupole mass filter) which has a mass 
range of around 3,000 with a resolution up to 3000. The quadrupole consists of four 
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rods with the opposite pairs connected electrically. When a voltage is applied, ions of a 
particular mass to charge (m/z) follow a stable trajectory through the rods and reach 
the detector. The quadrupole mass filter is a low resolution device, because it is only 
capable of measuring the m/z ratio of an ion to the nearest integer value and therefore 
unable to provide the elemental composition of an ion (Breidinger and Woolf, 2017). 
LC-MS also utilises soft ionisation which primarily produces molecular species with no 
fragmentation of the molecule. It is therefore unlikely that the molecular weight alone 
will make structural assignment possible. Hence the wealth of data resulting from 
fragmentation pattern from which the molecule can be independently identified is not 
available. This presents a challenge since there may be several compounds with the 
same mass to charge ratio (m/z) as the analyte of interest (Lawson et al., 2012). 
Therefore, in the absence of any data on fragmentation pattern, dependence on 
retention time will not be enough to provide the needed selectivity. The problem has 
been overcome with the introduction of tandem mass spectrometry (MS/MS) 
instruments (Tanna and Lawson, 2016). 
3.5.4 Liquid chromatography – tandem mass spectrometry (LC-MS/MS) 
Challenges in performing analysis with microvolume dried blood samples forces the 
bioanalytical scientist to look for better technology that offers advantages in 
selectivity, sensitivity and robustness. One such technique is LC coupled with MS/MS. 
The benefits of this technique which include ease of use, lower limits of detection and 
high throughput are well documented (Li et al., 2014). As a result, LC-MS/MS has 
rapidly moved from research sites to routine laboratories, gaining reputation in 
laboratory medicine due to its application in many domains like therapeutic drug 
monitoring (TDM), newborn screening (NBS), toxicology and drug discovery. The 
expanding role of LC-MS/MS in DBS analysis is based on improvements in analytical 
instrumentation which offers unique specificity, faster method development, 
simultaneous analysis of multiple drugs and their metabolites in microsamples and 




Figure 3.5 A schematic representation of an MS/MS architecture  
Tandem MS architecture simply comprises two mass analysers (MS1) and (MS2) with a 
collision cell in between (Figure 3.5). It initiates the process of fragmentation by 
allowing only the ions pre-selected by (MS1) into a collision cell, where collision 
induced dissociation occurs, and the product ions are monitored by (MS2). Tandem MS 
can be performed by four different configurations of a mass spectrometer (MS). These 
are triple quadrupole (QqQ), Quadrupole – Time of Flight (Q-ToF), Ion Trap - Time of 
Flight (IT-ToF) and the Ion Trap. The QqQ, Q-ToF and IT-ToF are examples of tandem in 
space instruments whilst the ion trap is a tandem in time system (Tanna and Lawson, 
2011). The Q-ToF instrument utilises a linear quadruple as MS1 and a Time of Flight 
(ToF) mass analyser as MS2. The third variant of the linear systems (IT-ToF) has an Ion 
Trap as MS1 and utilises a ToF as MS2. In an alternative mode of operation an ion trap 
can reproduce similar fragmentation processes by first isolating ions of a single mass, 
then relaxing the storage conditions to allow fragmentation to occur and finally 
analysing the masses of the resultant ions (Johnson et al., 1990). The most frequently 
cited MS platform in bioanalytical applications is the triple quadrupole (QqQ) mass 
analyser. This establishes, LC coupled with a QqQ-MS as the gold standard in regulated 
quantitative bioanalysis (Wagner et al., 2014; Schultz and Henion, 2017). 
For DBS analyses, the review by Zakaria et al (2016), shows that out of the 87 drugs 
analysed by LC-MS methods from the literature, 67 were performed by LC-MS/MS, 
with drug monitoring for both therapeutic and toxicological studies being the most 
extensively reported. However, it should be noted that, this does not guarantee LC-
MS/MS provides superior advantage and reliable results over other MS techniques 
(Shipkova and Svinarov, 2016). In contrast with other techniques such as LC-HRMS, LC-
MS/MS requires that optimised MS/MS parameters such as (selection of the 
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appropriate precursor – product ions, declustering potential (DP) and optimised 
collision energy (CE) needed for collision induced dissociation (CID)) are determined 
for each compound of interest to be analysed (Zhang et al., 2009; Li et al., 2011). In 
addition, since only pre-selected ions from a sample by (MS1) enter the collision cell, 
data on other ions in the sample will be lost hence there is no possibility to revisit the 
collected data to mine for information on other ions when it becomes relevant. 
Current LC-HRMS instruments (Bowen et al., 2016) resolve most of these challenges. 
3.5.5 Liquid chromatography – high resolution mass spectrometry (LC-
HRMS) 
Though LC-MS/MS has been established as the standard technique for the 
development of bioanalytical assays, there has been huge interest within the 
bioanalytical community in other MS approaches to handle bioanalytical challenges 
over the past few years (Zhang et al., 2009; Kaufmann et al., 2011; Korfmacher, 2011; 
Tanna and Lawson, 2011). One such alternative to the traditional LC-MS/MS has been 
the use of LC coupled with high resolution MS (LC-HRMS). HRMS simply refers to a 
mass analyser with a resolving power (R) > 10,000 (Xian et al., 2012). For decades, 
HRMS was mainly used qualitatively in drug metabolism and metabolite identification 
studies (Ramanathan and Korfmacher, 2012), the reason was due to the poor 
sensitivity on older variants of HRMS instruments. However, HRMS capabilities for 
quantitative analysis has recently been established through advancement in 
instrumentation. Advantages such as accurate mass determination (superior mass 
accuracy) where the mass of the molecular ion can be measured to better than 1.0 
ppm of the relative molecular mass (RMM). Hence, this precise value can be used to 
determine the atomic composition based on for example, C = 12.0000, H = 1.0078, N = 
14.0031, O = 15.9949 and therefore the likely molecular structure (Tanna and Lawson, 
2011). For example, considering three compounds of mass 266.3 where atenolol a beta 
blocker (C14H22N2O3) = 266.3361, dienestrol (C18H18O2) = 266.3340 and leptospermone 
(C15H22O4) = 266.3330, nominal mass measurements cannot differentiate these but 
measurement to the 4th decimal place will distinguish between these compounds. 
Enhanced compound selectivity (an example of which is demonstrated with atenolol in 
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Chapter 5, section 5.2.1), full scan acquisition that allows quantification, profiling and 
data mining post acquisition has given HRMS the competitive edge (An example of 
which is shown in Chapter 4, Figure 4.1 and 4.2). Rochat et al (2012) argues that a 
paradigm shift was taking place and HRMS will soon be the first choice in MS 
detectors.  
There are several HRMS platforms available to bioanalysts, these are (Q-TOF (Figure 
3.6), TOF, Fourier transform ion cyclotron resonance and orbitrap-based mass 
analyzers), (Sturm et al., 2016). HRMS has been investigated at research laboratories 
for the data rich information it can provide in a single run and is now utilised to resolve 
most of the challenging bioanalytical demands in various fields (Zhang et al., 2009). For 
example, its ability to conduct multiple drug and metabolite profiling (Ma et al., 2013; 
Ramakrishnan et al., 2016) by rapid and simultaneous measurements from a single 
run. This significantly augments the value of data acquired leading to patient care 
improvement. Simultaneous analyses of multi compounds reduces the sample volume 
required in comparison to other techniques (Shipkova and Svinarov, 2016). Its 
capability to reduce method development time with a single MS scan that offers both 
qualitative and quantitative data is of great advantage (Xie et al., 2012). This has been 
demonstrated with the analysis of biofluid collected as DBS samples in early drug 
discovery (Korfmacher, 2011; Ramanathan et al., 2011; King et al., 2014; Korfmacher 
and Ramanathan, 2016), therapeutic drug monitoring (Li et al., 2011; Oliveira et al., 
2014) and medication adherence studies (Lawson et al., 2012a; Lawson et al., 2012b; 
Lawson et al., 2013; Tanna et al., 2015; Bernieh et al., 2017), environmental science 
(Krauss et al., 2010). Figure 3.6 shows a schematic of the LC-QTOF-HRMS used for 




Figure 3.6 A schematic of an LC-QTOF-HRMS used for analyses (Agilent, 2010). 
Improvement in scan speed and superior selectivity offered by HRMS, has enabled 
most laboratories to see HRMS sensitivity comparable or superior to the conventional 
MS/MS approaches (Korfmacher and Ramanathan, 2016). Zhang et al (2009) 
investigated the quantitation of small molecules using a linear ion trap HRMS (LTQ-
Orbitrap) in comparison with a triple quadrupole (API 4000) operated using selected 
reaction monitoring and reported comparable validation results and quantitative 
performance for all drug candidates using the two approaches. 
The competitive edge of current HRMS instruments is attributed to the selectivity gains 
that HRMS allows for due to the accurate mass, which can eliminate interference in 
samples due to matrix effects leading to a huge increase in signal to noise and overall 
increase of sensitivity. This is further confirmed by (Bateman et al., 2009; Kaufmann et 
al., 2011; Ramanathan et al., 2011; Dillen et al., 2012; Henry et al., 2012) 
demonstrating that quantification capabilities of state-of-the-art HRMS instruments 
were comparable to the dominant QqQ mass analysers regarding sensitivity and 
analytical throughput in clinical laboratories. In these projects, various matrices and 
extraction protocols were adopted and HRMS appeared as specific (owing to high 
resolution (HR) measurement), robust (due to stable mass accuracy (MA)) and quan-
titative (owing to good dynamic range and level accuracy) as QqQ-MS.  
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In comparison with HRMS, LC-MS/MS assays may struggle with interference at lower 
detection limits from matrix effects and may require the use of complex sample 
preparation and chromatography to isolate these interferences (Li and Tse, 2010). 
Whereas HRMS has an in-built selectivity advantage due to its precise mass scanning 
technology. Also, due to the high resolution employed in mass analysers for HRMS, 
limits of quantification can be increased in cases where there are interfering peaks in 
the chromatogram. This means an LC run can be employed for the separation and the 
MS relied upon for isolation of interference detected in clinical samples due to various 
factors, example diet, disease state and polypharmacy.  
Full scan MS also allows all mass spectral information from a sample to be collected 
offering the potential for the data to be re-interrogated if it is deemed clinically 
relevant. In addition, since data is collected simultaneously over the selected mass 
range it is also possible to directly monitor interfering ions in the sample matrix that 
could produce ion suppression. 
Whilst there is much excitement for the use of HRMS to develop bioanalytical assays, 
there are still limitations to the wider acceptance across the bioanalytical community. 
HRMS systems are not as robust compared to QqQ instruments (Huang and Weng, 
2013). Rago and Negahban (2016), argue that more guidance is need from regulators 
on the acceptance of bioanalytical assays developed with HRMS. Currently, data from 
laboratories employing HRMS is limited. Hence more submissions with the HRMS 
platform are required to provide industry with the confidence that regulators are on 
board. 
Another challenge with the extension of HRMS to clinical studies is the informed 
consent process. Taking into consideration targeted LC-MS/MS or targeted HRMS 
experiments where the analytes are predefined, full scan HRMS analysis preserve all 
the information about the sample. Hence without proper informed consent from the 
patient or volunteer, the full benefits of full scan HRMS data cannot be realised. In 
addition, the wealth of data generated from large full scan data file acquisition 
presents challenges with software processing and data storage. Table 3.1 compares 
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the various analytical techniques that have reportedly been used for DBS analysis in 
terms of cost, sensitivity, specificity and throughput. 
Table 3.1 Compares the strengths and limitations of the analytical techniques for the analysis of dried 
blood samples collected using microsampling methods. 
  Cost  Availability Sensitivity Specificity Throughput 
Immunoassay     √√√     √√√     
HPLC   √√   √√ √    
LC-MS √ √   √√ √  √ 
LC-MS/MS √ √     √√√     √√√      √√√ 
LC-HRMS  √  √     √√√     √√√      √√√ 
 
3.5.5.1 Advantages of HRMS in comparison with MS/MS 
 HRMS does not require molecular fragmentation for selective detection 
 HRMS platforms can record various acquisitions at high resolution with 
accurate mass determination (measure the mass of the molecular ion to better 
than 1ppm of the RMM) which enables discrimination of compounds with 
similar masses. 
 HRMS is capable of full scan acquisitions 
 HRMS full scan acquisition allows a better overview of the analysed extract, 
because coeluting compounds, contaminants, adducts and charge state can be 
monitored which are useful during method development and troubleshooting. 
 HRMS full scan acquisition does not need experimental determination of 
collision energies as is required in selected reaction monitoring (SRM) 
acquisition. 
 HRMS allows target and untargeted analysis to be done in parallel. 
3.5.5.2 Disadvantages of HRMS in comparison with MS/MS 
 Slow progress in embracing the HRMS technology may be due, in part, to 
difficulties in replacing an entire fleet of triple quadrupole MS in clinical 
laboratories 
 Cost of HRMS instruments compared to QqQ-MS 
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 Lack of official guidelines by regulatory authorities 
 Problems with system robustness 
3.5.5.3 Conclusion 
Though evidence suggest that LC-MS/MS is the primary technique used for routine 
determination of therapeutic drug from DBS where the target analytes are readily 
predetermined, there is evidence that the selective data-acquisition modes of triple 
quadrupole mass spectrometers (e.g., precursor ion scan or multiple reaction 
monitoring) are increasingly being replaced by full-scan or MS/MS experiments on 
HRMS instruments for quantitative applications. This is because the information gained 
from high-resolution, accurate mass data often outweighs the benefits of highly 
selective measurements on low-resolution mass spectrometers. The greatest 
advantage of high-resolution full scan mass spectrometry for TDM of CVD drugs is that 
all the mass spectral data from the sample is collected. This allows the data to be 
revisited at a later date if it becomes clinically essential to the management of the 
patient’s condition. For example, in situations where a patient may be taking other 
medications in addition to the prescribed drug which the clinician is not aware of. 
Thus, LC-HRMS was selected as the technique of choice for identification and 
quantification of the selected cardiovascular drugs in dried blood matrix for the 











Chapter 4 Bioanalytical method development 
 
This chapter discusses the development of the bioanalytical assay (identified as one of 
the objectives of the study in Chapter 1, section 1.5) using DBS based LC-HRMS assay 
for the identification and quantification of candidate cardiovascular drugs selected in 
Chapter 2, section 2.3 (amlodipine, atenolol, atorvastatin, bisoprolol, diltiazem, 
doxazosin, lisinopril, losartan, ramipril, simvastatin and valsartan). The extraction 
procedure and optimisation of LC and MS method parameters are presented since 
they are of critical importance because the blood spot presents only about 30 µl of 
sample in total. The resolution of specific analytical challenges discussed in Chapter 3, 
section 3.4 encountered in identification and quantification for some target analytes 
from dried blood matrix are also presented. 
4.1 Introduction 
An objective of the study was to investigate if the presence of specified target drugs 
could be quantified from small volume dried blood samples collected using DBS cards 
and volumetric absorptive microsampling (VAMS). Due to the small sample volume, 
analyses require a very sensitive detection technique.  Hence the advantages of the 
HRMS platform as discussed in Chapter 3, subsection 3.5.5, made it the technique of 
choice for the determination of the selected candidate cardiovascular drugs in DBS and 
VAMS sample. 
4.1.1 Investigation of punch size 
For quantitative analysis of DBS samples, a disk must be punched from the centre of 
the dried drop of blood. The size of the punch used for cutting the fixed sized disk prior 
to solvent extraction was investigated using 3mm, 6mm and 8mm diameter punch. A 
small spot size will produce a small sample. This will affect the amount of analyte 
extracted from DBS card into solvent.  For the 6mm and 8mm punch sizes, the area of 
the various punch sizes was calculated.  The following equation (4.1) was used;             
Area (𝐴) = 𝜋𝑟2          Equation 4.1                                                                                    
Where A is the area, π is a constant and r is the radius of the disk. 
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It was observed that using a 6mm disk punch would result in wasting more than 50% of 
the deposited sample on the card. The diameter of a 30µl spot was 9.5mm, with a 
surface area of 70.88mm2. The areas of a 6mm and 8mm spot size were 28.27mm2 and 
50.26mm2 respectively. Owing to the fact that, the difference in surface area between 
the 6mm and 8mm disk was also more than 30%, the 8mm disk size was maintained 
for the assay since a bigger area will lead to more sample being taken, which will 
intend lead to larger detector response with better sensitivities for all analytes. The 
problem with extraction and low detection limits may be further affected by 
extraneous material (matrix effect) extracted from the substrate of the card. 
4.2 Preliminary method used for the identification of CVD drugs in 
solution 
The starting point for method development was the use of a previously developed 
bioanalytical method by Drs Tanna and Lawson at De Montfort University (Lawson et 
al., 2013). This method was used for the quantification of three drugs (bisoprolol, 
ramipril and simvastatin) in a DBS feasibility study with poor sensitivity reported for 
simvastatin. This method was used as the foundation for initial trials, improved, built 
upon and expanded for the analysis of the eleven cardiovascular drugs in small volume 
blood samples collected using microsampling methods. 
Preliminary method instrumental conditions 
The chromatographic system used consisted of an Agilent 1290 LC which was coupled 
to an Agilent G6530A QTOF mass spectrometer, used in the TOF mode. The eleven 
target drugs and internal standard were chromatographed on an Zorbax Eclipse C18 
rapid resolution HD column (Agilent Technologies, Cheshire, UK, 100 mm x 2.1 mm i.d., 
1.8µm particle size) which was preceded by a Security Guard Ultra guard column 
(Phenomenex, Macclesfield, UK). The column oven temperature was set to 40 ◦C. 
Sample injection volume was 2µl. The mobile phase consisted of water containing 0.2% 
(v/v) formic acid (eluent A) and acetonitrile containing 0.2% (v/v) formic acid (eluent B) 
and was delivered at 0.6 ml/min with gradient elution. The mobile phase was initiated 
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at 5% B and maintained for 0.5 min before increasing to 20% B and then to 95% B by 
1.5 min and held until 3.0 min before returning to 5% B. The gradient elution 
programme was then held for 1.5 min to re-equilibrate the column prior to the next 
injection.  
Operation of the mass spectrometer was in electrospray positive ion mode. The MS 
source and chamber conditions were as follows: fragmentor voltage: 165 V; skimmer: 
65 V; drying gas temperature: 350°C; dry gas flow: 10 l/min; nebuliser: 50.0 psig; 
sheath gas temperature: 400°C; sheath gas flow: 12 l/min. Mass range: 100–1000 m/z; 
recording rate: 1 Hz. HRMS lock reference masses: 121.0508 m/z and 922.00979 m/z. 
MassHunter Workstation Acquisition Software for TOF/Q-TOF version B.04.00 (Agilent 
Technologies) was used to operate the system and acquire all data and the data 
processed using Qualitative Analysis B.04.00 and Quantitative Analysis B.04.00 
software (Agilent Technologies). The mass extraction window used was 5ppm. 
Calibration of the TOF mass spectrometer was performed daily before starting the 
analysis. 
4.2.1 Experimental 
4.2.1.1 Chemicals and materials 
Acetonitrile, methanol and water of LC–MS grade were purchased from Fisher 
Scientific (Loughborough, UK). Amlodipine besylate salt, atenolol (R-(+), 99%), atenolol 
d7, atorvastatin calcium salt, bisoprolol hemifumarate salt, diltiazem hydrochloride, 
doxazosin mesylate salt, lisinopril, losartan potassium salt, ramipril, simvastatin and 
valsartan were purchased from Sigma–Aldrich (Poole, UK). Autosampler vials and vial 
caps were purchased from Agilent Technologies (Cheshire, UK). 
4.2.2 Analysis and detection of the selected CVD drugs in methanol 
using the preliminary method. 
Standard stock solutions of each target drug amlodipine, atenolol, atorvastatin, 
bisoprolol, diltiazem, doxazosin, lisinopril, losartan, ramipril, simvastatin, and valsartan 
were prepared in methanol at a concentration of 1 mg/ml. An intermediate stock 
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solution of 10,000ng/ml was prepared from each standard stock. A multicomponent 
working solution of 100ng/ml was prepared from the intermediate stock solutions by 
diluting with methanol: water (70:30, v/v) and used for LC-HRMS analysis. 
The mass to charge (m/z) ratios of the ionised species for all the target drugs which 
included ([M+H]+, [M+Na]+, [M+K]+) were calculated based on their molecular formula 
using the Qualitative Analysis software version 4.00 (Mass calculator) as well as in 
comparison with the m/z values of the drugs reported in the literature (Chapter 2, 
Table 2.5). The ionised species with the highest intensity signal was used for the 
detection of each of the target drugs. Results obtained indicated that the molecular 
(protonated) ion gave the highest intensity signal for atenolol, atenolol d7, 
atorvastatin, bisoprolol, diltiazem, doxazosin, lisinopril, losartan, ramipril and valsartan 
(Table 4.1). For amlodipine and simvastatin, the abundance was greater for the sodium 
adduct ion ([M+Na]+). The sodium adduct ion for amlodipine and simvastatin were 
stable and gave reproducible response and thus was used for identification and 
quantitation.  
Table 4.1 Target cardiovascular drugs, and the mass to charge (m/z) values of the most intense ion 
used for identification. 
Target drug Ion with highest 
response 
m/z value 
Amlodipine (M+Na)+ 431.1344 
Atenolol (M+H)+ 267.1703 
Atorvastatin (M+H)+ 559.2610 
Bisoprolol (M+H)+ 326.2326 
Diltiazem (M+H)+ 415.1686 
Doxazosin (M+H)+ 452.1928 
Lisinopril (M+H)+ 406.2336 
Losartan (M+H)+ 423.1695 
Ramipril (M+H)+ 417.2384 
Simvastatin (M+Na)+ 441.2611 
Valsartan (M+H)+ 436.2343 






Figure 4.1 Representative LC-HRMS total ion chromatogram (TIC) for a 100ng/ml multicomponent 
solution of the selected cardiovascular drugs. 
 
 
Figure 4.2 Representative LC-HRMS overlaid extracted ion chromatograms (EIC) of a 100ng/ml 
multicomponent solution standard containing the selected target drugs. 
 
The initial data obtained is the total ion chromatogram (TIC) which records all the ions 
collected by the TOF during the LC run, this data is shown in Figure 4.1. The presence 
of each drug is identified by extracting ions of the individual specific m/z value to 
produce the extracted ion chromatogram (EIC) shown in Figure 4.2. 
Though the preliminary method could identify all the cardiovascular drugs, the 
detector response for amlodipine, atenolol, atorvastatin, lisinopril, and valsartan 
(Figure 4.2) at the 100ng/ml concentration investigated were relatively low (<50,000 
counts) compared to bisoprolol, diltiazem, losartan, ramipril and simvastatin (>150,000 
counts). In addition, chromatographic peak shape for amlodipine and lisinopril were 
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not very sharp. Good peak shape is important for improved chromatographic 
resolution. As a result, liquid chromatography and mass spectrometry conditions of the 
preliminary method were optimised for the selected target analytes to improve 
sensitivity and chromatographic separation for all the target drugs. This was achieved 
by investigating the LC and MS method parameters such as the LC gradient, amount of 
mobile phase modifier used, effect of using different analytical columns, the 
chromatographic run time and post time (Jangala et al., 2014). MS source condition 
investigated was the fragmentor voltage. The best conditions for optimal responses 
observed for the selected target drugs were used to create an optimised method. 
4.2.3 Preliminary method instrumental optimisation chromatography 
The goal of method development was to develop a robust, sensitive, selective and high 
throughput assay to simultaneously determine the selected CVD drugs in a single run. 
Due to significant difference in calibration range, the dose strength used in combined 
therapy as well as physicochemical characteristics such as molecular weight, logP, pKa, 
polarity, stability and dissolution it was necessary to ensure that the method was 
suitable for quantitation of all the target drugs. For example, looking at the ionisation 
constants values of the target drugs: amlodipine (pKa, 8.7), atenolol (pKa, 9.67 and 
14.08), atorvastatin (pKa, 4.31), bisoprolol (pKa, 9.67 and 14.09), diltiazem (pKa, 8.18 
and 12.86), doxazosin (pKa, 7.24 and 12.67), lisinopril (pKa, 3.17 and 10.21) losartan 
(pKa, 3.85 and 5.85), ramipril (pKa, 3.75 and 5.20), simvastatin (pKa, 14.91) and 
valsartan (pKa, 3.9 and 4.7) (Chemicalize, 2017), it is evident that there are significant 
differences in the degree of ionisation of the compounds. This will affect their 
extraction from DBS into solvent as the polar compounds will show affinity for polar 
solvents and non-polar compounds into non-polar solvents. Hence the choice of 
extraction solvent as well as the extraction procedure is key to successful detection 
from DBS since no extraction means no detection. It was therefore imperative to 
suitably optimise the extraction procedure, the liquid chromatography and mass 
detection conditions, for the subsequent simultaneous determination of the target 
drugs from DBS. The purpose of optimisation was to ensure that the selected drugs 
were well resolved on the chromatographic column, with improved MS quantification 
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and also reduced analyses time. Hence liquid chromatography and mass spectrometry 
source conditions were investigated to select the best instrumental parameters for the 
quantification of the selected CVD drugs.  
4.2.3.1 Investigation of amount of mobile phase modifier 
The pH and ionic strength of the mobile phase can affect the ionisation of the target 
analytes at the ESI source as well as chromatographic separation. Based on the target 
analytes, ionic strength and pH can impact peak shape, selectivity and retention 
(Wagner et al., 2014). However, due to significant differences in the pKa of the 
selected analytes and since the use of buffer solutions are likely to clog the mass 
spectrometer, a non-buffered mobile phase was used for separation. Rather formic 
acid was added to the mobile phase. Ionic modifiers are normally added to the mobile 
phase to provide a source of protons in LC-MS analysis (Wagner et al., 2014). As a 
weak acid, formic acid was added to the mobile phase to allow the formation of the 
desired ions. The use of formic acid in ESI positive mode enhances the ionisation of the 
positive ions, maintain the ionisation state of analyte in the eluent, improve peak 
shape and adjust pH of mobile phase (Xu and Madden, 2012; Sargent, 2013). A low 
mobile phase pH is ideal for acidic analytes to prevent the analytes from being ionised. 
In addition, most basic (amine) analytes are also suitably retained at low pH due to 
protonation. 
However, the amount of formic acid added to the mobile phase is known to affect the 
number of ions reaching the detector. Hence the percentage of formic acid was 
optimised to maintain good peak shapes while being consistent with good ionisation in 
the mass spectrometer (Nirogi et al., 2006). Since no prior LC-MS work has been 
reported on most of the selected drugs in DBS, information on previous work from the 
literature involving simultaneous detection of cardiovascular drugs in plasma and 
serum was studied (Dias et al., 2013; Kailasam, 2011; Gonzalez et al., 2011; Magiera et 
al., 2011). In these work, 0.1% formic acid was used as the mobile phase modifier. 
Investigation was therefore performed with 0.1% formic acid and results compared 
with using 0.2% formic acid as documented in the preliminary method.  
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The separation and ionisation of the target drugs were affected by composition of 
mobile phase. Results indicated that 0.1% formic acid worked best for all the target 
drugs (Figure 4.3). Peak responses were greater with using 0.1% formic acid in contrast 
with 0.2% formic acid used as control. The use of 0.1% formic acid showed an increase 
in peak area response ranging from 8% - 45% for all the target drugs. The results agree 
with Dias et al (2013) and Gonzalez et al (2011) who used 0.1% formic acid as the 
amount of mobile phase modifier for the simultaneous quantification of cardiovascular 
drugs in plasma. This result also indicates that the composition of the mobile phase 
was a critical factor for achieving good ionisation (Shah et al., 2016). The composition 
of the mobile phase was therefore optimised as water containing 0.1% formic acid 
(eluent A) and acetonitrile containing 0.1% formic acid (eluent B).   
 
Figure 4.3 A representative plot of mean response for the selected CV drugs using 0.1% and 0.2% 
formic acid as mobile phase modifier (n = 3). 
 
4.2.3.2 Investigation of gradient time table 
In reverse phase chromatography, the separation of a sample with a wide variety of 
compounds using a single composition of mobile phase will not produce satisfactory 
retention. For example, when separating compounds that differ widely in polarity, the 























the column and never elute. Hence using gradient elution which is a process to 
increase the mobile phase strength as a function of time is always best for separation 
(Cape et al., 2017). This results in faster analyses, better peak shape and quantitation. 
LC gradient is therefore a very important parameter to investigate during method 
development (Snyder et al., 2012). Changing the gradient could impact positively or 
negatively on chromatographic peak resolution for the target analytes, shorten the run 
time as well as enhance the MS signal. 
Therefore, the gradient timetable under the chromatographic conditions was 
investigated. Information on the various gradients used in previous studies involving 
the simultaneous detection of cardiovascular drugs in plasma (Dias et al., 2013; 
Gonzalez et al., 2011) were obtained from the literature and investigated.  
Among the gradients studied, two gradients (B and C) Table 4.2 (Dias et al., 2013; 
Gonzalez et al., 2011) gave better analyte response compared to the gradient used by 
Lawson et al (2013) in the preliminary method which served as control.  
Table 4.2 Gradient timetable for preliminary method and the two best gradients obtained.  
Gradient A Control Gradient B Gradient C 
  (Lawson et al., 2013)    (Dias et al., 2013)    (Gonzalez et al. 2011)   
  Time/min B%   Time/min B%   Time/min B% 
1 0 5 1 0 4 1 0 4 
2 0.5 20 2 0.5 40 2 0.5 65 
3 1.5 95 3 1.5 98 3 1.5 95 
4 3 95 4 3 98 4 3 95 
5 3.01 5 5 3.01 4 5 3.01 4 
 
Among the various gradient tables investigated, gradient C (Table 4.2) gave the highest 
detector response for all the target drugs (Figure 4.4). It was also observed that the 
target analytes eluted faster with gradient C (Table 4.3), with no compromise to peak 
resolution allowing the run time to be shortened. This was because of increasing the 
slope of the gradient by starting the gradient at a higher percent organic. At 0.5 min, 
the amount of eluent B was 65% for gradient C, compared to 20% and 40% for gradient 
A and B (Table 4.2). The steepness of the slope caused the analytes to elute faster.  
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Table 4.3 Comparison of retention times between the three gradients investigated. 
  Gradient A_control Gradient B Gradient C 
Drug Retention Time (minutes) 
Amlodipine 1.529 1.522 1.005 
Atenolol 0.971 0.955 0.811 
Atorvastatin 1.866 1.844 1.400 
Bisoprolol 1.411 1.404 0.945 
Doxazosin 1.478 1.455 0.979 
Lisinopril 1.172 1.187 0.862 
Losartan 1.711 1.700 1.161 
Ramipril 1.512 1.505 1.004 
Simvastatin 2.297 2.198 2.000 
Valsartan 1.812 1.777 1.300 
 
 
Figure 4.4 Comparison of magnitude of response for each target drug using the three gradients 
investigated (n = 3).  
 
 
























Figure 4.6 Representative EIC for atorvastatin with the three gradients investigated 
 
 
Figure 4.7 Representative EIC for lisinopril with the three gradients investigated 
 
 
Figure 4.8 Representative EIC for simvastatin with the three gradients investigated 
 
No changes to peak shape were observed for gradients A, B and C. However, there was 
a significant increase in peak area for all the target analytes (Figure 4.4) when gradient 
C was compared with gradient A (control). Representative EIC’s are shown in (Figure 
4.5 - 4.8) for amlodipine, atorvastatin, lisinopril and simvastatin respectively. The 
increase in response was about 28% for amlodipine and atenolol and greater than 54% 
for atorvastatin, bisoprolol, diltiazem, doxazosin, lisinopril, losartan, ramipril and 
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simvastatin. Since gradient C gave the highest response for all the target drugs relative 
to gradient A and B, it was chosen as the new gradient for the optimised method.  
4.2.3.3 Investigation of Run Time 
Runtime is the time it takes for a complete chromatography cycle. Reducing the 
chromatographic run time has huge benefits for work efficiency, it increases 
throughput and saves on cost of expensive solvents used as mobile phases. It also 
reduces analyses time when the analytical assay is to be used in clinical settings where 
many samples may be analysed e.g. hospitals.  In the preliminary method, the system 
cycle time was 4.51 minutes consisting of a sample run time of 3.01 minutes and a post 
time of 1.5 minutes for column re-equilibration. Using the new gradient (gradient C), 
the chromatographic run time was investigated to look at its effect on magnitude of 
detector response, peak shape and resolution. Based on the retention time data of the 
selected target analytes obtained from using gradient C (Table 4.3), runtime was 
shortened to 2.51 minutes. The mobile phase was initiated at 4% B and held for 0.5 
minutes before increasing to 65% B for 1.0 minutes and then to 95% B by 1.5 minutes 
and maintained until 2.5 minutes before returning to 4% B. Column re-equilibration 
was achieved by holding the gradient elution programme for 1.5 minutes prior to the 
next injection. 
 
Figure 4.9 Differences in magnitude of response for each target drug using chromatographic run times 





















Shortening the run time from 3.01 minutes to 2.51 minutes impacted positively on the 
magnitude of response for all the target analytes except diltiazem (Figure 4.9). 
However, the drop in response for diltiazem was not significant when compared to the 
gain in response for the other target analytes. ≥ 15% increase in peak area (response) 
was observed for atenolol, atorvastatin, lisinopril, ramipril, simvastatin and valsartan. ≥ 
5% increase was observed for amlodipine, doxazosin and losartan. There were no 
changes in peak shape and resolution was not affected. Hence the run time was set to 
2.51 minutes for the optimised method. 
4.2.3.4 Investigation of Post Time 
Post time refers to the time it takes to return the analytical column to starting mobile 
phase conditions after a previous gradient has run. Sufficient column equilibration is 
necessary between injections so that retention times of the target analytes remain 
reproducible during method development (Snyder et al., 2012). Changing the post time 
in a gradient system can affect the time it takes for the back pressure to equilibrate. 
However, to increase analytical throughput, a method with a short post time is always 
ideal. Hence the chromatographic post time was changed and investigated by 
shortening it from 1.5 minutes to 1.0 minutes. Changing the post time should not have 
any effect on signal size, however the results indicated that, reducing the post time 
resulted in a drop of response of ≥ 12% for amlodipine, atenolol, atorvastatin, 
bisoprolol, diltiazem, doxazosin, losartan, simvastatin and valsartan (Figure 4.10).  This 
could be due to the fact that the 1.0 minute post time was not sufficient enough to 
equilibrate the column back pressure before the next injection. Hence the post time of 
1.5 minutes was maintained in the optimised method. The results also show good 
system reproducibility as there were no wide variations in between data collected 




Figure 4.10 Differences in magnitude of response for each target drug using post times 1.0 minutes 
and 1.5 minutes.  
4.2.3.5 New or alternative analytical column development 
Finer particle columns are known to give better separation efficiency. Two analytical 
columns (Zorbax Eclipse C18, 1.8µm, 100mm x 2.1 and Kinetex 1.7µ C18 100 x 2.1mm) 
were investigated to compare the sensitivity, magnitude of responses and retention 
times for the selected cardiovascular drugs. 
A) A standard stock solution with concentration 1mg/ml was prepared in methanol for 
each target drug.  B) Freshly prepared intermediate solution of concentration 
10,000ng/ml was prepared out of the standard stock for each drug.  C) 
Multicomponent working solutions for the concentration ranges 0.05, 0.1, 0.5, 1, 5, 10, 
25, 50, 100, 250ng/ml were prepared for all the target drugs and run on the LC-HRMS 
using atenolol d7 as the internal standard. The concentration of internal standard used 
was 20ng/ml. This concentration was selected on the basis that too high a 
concentration of the internal standard could suppress the ionisation of the target 
drugs and reduce sensitivity (Wagner et al., 2014). From previous experiments (section 
4.2.2), it was observed that the detector response of atenolol d7 at the 100ng/ml 
concentration investigated was about 900,000 counts. However, response for 

















Post time 1.0 min
Post time 1.5 min_control
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concentration of 20ng/ml for atenolol d7 producing detector response of 200,000 was 
ideal to prevent ion suppression of the target analytes with low detector response. The 
analyses were performed in triplicate at each concentration (n = 3). 
The calibration curves for the eleven target analytes were generated in replicate (n = 3) 
using a plot of target analyte/IS peak area ratio against nominal analyte concentration. 
The magnitude of response, retention times, and LOQ’s with a signal to noise ratio of 
≥10 for the selected CVD drugs were compared for both columns (Table 4.4). 
Table 4.4 Retention times and LOQ’s for the target drugs and internal standard on both columns. 
Drug Retention Times LOQ (ng/ml) 
  Kinetex 
column 
Zorbax column Kinetex column Zorbax column 
Amlodipine 0.969 1.005 0.1 0.05 
Atenolol 0.781 0.828 0.1 0.05 
Atorvastatin 1.272 1.400 0.1 0.1 
Bisoprolol 0.931 0.965 0.05 0.05 
Diltiazem 0.964 1.003 0.05 0.05 
Doxazosin 0.935 0.985 0.1 0.1 
Lisinopril 0.804 0.862 0.1 0.1 
Losartan 1.097 1.168 0.05 0.05 
Ramipril 0.981 1.007 0.1 0.1 
Simvastatin 1.728 2.005 0.1 0.1 
Valsartan 1.213 1.300 0.1 0.1 










Figure 4.12 Representative EIC of atenolol at the LOQ on the kinetex and zorbax analytical columns. 
 
 









Figure 4.15 Representative EIC of diltiazem at the LOQ on the kinetex and zorbax analytical columns. 
 
 
Figure 4.16 Representative EIC of doxazosin at the LOQ on the kinetex and zorbax analytical columns. 
 
 





Figure 4.18 Representative EIC of losartan at the LOQ on the kinetex and zorbax analytical columns. 
 
 
Figure 4.19 Representative EIC of ramipril at the LOQ on the kinetex and zorbax analytical columns. 
 
 






Figure 4.21 Representative EIC of valsartan at the LOQ on the kinetex and zorbax analytical columns. 
 
From Table 4.4, LOQ data are comparable on both columns, for all the target drugs 
except for amlodipine and atenolol where sensitivities were better on the zorbax 
column. By convention, smaller particle size columns generally give higher separation 
efficiencies hence better chromatographic performance (Magiera et al., 2011). Hence, 
the kinetex column with a particle size of 1.7µ, will be expected to show better 
sensitivities for the target analytes, but this was not the case. It was also observed that 
the target analytes eluted faster on the kinetex column (Table 4.4). This is because for 
small molecules, smaller particle sizes result in fast diffusion, which leads to faster 
chromatography. Response (peak area) data for both columns indicate that, response 
on the zorbax column are ≥ 15% high for all the selected CVD drugs, compared to the 
kinetex column. Representative EIC’s are shown for the candidate CVD drugs (Figure 
4.11 – 4.21). Hence, the zorbax C18, 2.1 x 100mm, 1.8µm was selected as the column 
of choice for the developed method.   
4.2.4 Method development of mass spectrometry conditions  
The MS source condition investigated was the fragmentor voltage for better sensitivity 
of the selected cardiovascular drugs. Other MS parameters used in the preliminary 
method were maintained. These include the skimmer: 65 V; drying gas temperature: 
350˚C; drying gas flow: 10 l/min; nebuliser: 45.0 psig; sheath gas temperature: 400˚C; 
sheath gas flow: 12 l/min. Mass range: 100 –1000 m/z; recording rate: 1 Hz.  
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4.2.4.1 Investigation of fragmentor voltage 
For better analyte signal in MS analyses, the MS source and chamber conditions must 
be optimised for the target analytes being studied. One parameter that significantly 
affects the ionisation efficiency of target analytes in the ESI chamber is the fragmentor 
voltage (Rogatsky and Stein, 2005). The fragmentor voltage is particularly important 
during method development, as it affects the transmission of the ions and also the 
dissociation of molecules into fragments (Alakhali et al., 2013). Dias et al (2013) 
reported different fragmentor voltages for different cardiovascular drugs investigated 
in human plasma. Whilst a significant improvement in detector response (peak area) 
has been observed for amlodipine, atorvastatin and lisinopril under the optimised LC 
conditions, peak area response for these drugs were still ≤ 200,000 counts compared 
to atenolol, bisoprolol, diltiazem, doxazosin, losartan, ramipril, simvastatin and 
valsartan with an average of ≥ 500,000 counts. Hence under the optimised LC 
conditions, fragmentor voltage was investigated to determine the best fragmentor 
voltage for optimised response for amlodipine, atorvastatin and lisinopril and to 
further improve sensitivity of these three target drugs. The optimum fragmentor 
voltage is known to be compound dependant and was therefore studied using a 
100ng/ml concentration of the CVD drugs at a 2µl injection volume (n=3), between 80 
V and 190 V in 5 V increments.  
Table 4.5 The target cardiovascular drugs, their mass to charge (m/z) values and the fragmentor 
voltages with highest analyte signal. 
Target drug Specie with 
highest response 
m/z value Fragmentor voltage with 
highest detector response 
Amlodipine (M+Na)+ 431.1344 150V/ 170V 
Atenolol (M+H)+ 267.1703 140V 
Atorvastatin (M+H)+ 559.2610 170V 
Bisoprolol (M+H)+ 326.2326 145V 
Diltiazem (M+H)+ 415.1686 175V 
Doxazosin (M+H)+ 452.1928 140V 
Lisinopril (M+H)+ 406.2336 85V/ 150V/ 175V 
Losartan (M+H)+ 423.1695 80V 
Ramipril (M+H)+ 417.2384 140V 
Simvastatin (M+Na)+ 441.2611 85V 
Valsartan (M+H)+ 436.2343 85V 





Figure 4.22 A representative plot of mean response against fragmentor voltage for amlodipine (n = 3). 
 
 
Figure 4.23 A representative plot of mean response against fragmentor voltage for atenolol (n = 3). 
 
 
























































































































































































































































































































































Figure 4.25 A representative plot of mean response against fragmentor voltage for bisoprolol (n = 3). 
 
 
Figure 4.26 A representative plot of mean response against fragmentor voltage for diltiazem (n = 3). 
 
 

























































































































































































































































































































































Figure 4.28 A representative plot of mean response against fragmentor voltage for lisinopril (n = 3). 
 
 
Figure 4.29 A representative plot of mean response against fragmentor voltage for losartan (n = 3). 
 
 



























































































































































































































































































































































Figure 4.31 A representative plot of mean response against fragmentor voltage for simvastatin (n = 3). 
 
 
Figure 4.32 A representative plot of mean response against fragmentor voltage for valsartan (n = 3) 
 
 

























































































































































































































































































































































Results of the experiment (Table 4.5), confirmed that optimum response for each of 
the selected targets drugs and internal standard is fragmentor voltage dependent. This 
result agrees with (Dias et al., 2013) who used different fragmentor voltage for a 
multianalyte LC-MS/MS analysis of cardiovascular drugs in human plasma. Data from 
their report indicates that for optimum signal of the targets, fragmentor voltages were 
different.  Since the relative response of amlodipine, atorvastatin and lisinopril 
compared to the remaining target drugs were ≤ 200,000 counts, the goal was to select 
a voltage that will boost the response for these drugs. From Figures 4.22, 4.24 and 
4.28, the highest responses for amlodipine, atorvastatin, and lisinopril, were obtained 
at fragmentor voltages 170V, 170V and 85V respectively. However, a fragmentor 
voltage of 150V was selected as the ideal voltage for the optimised method. This was 
on the basis that, at 150V, response for amlodipine, atorvastatin and lisinopril were 
comparable to responses at their optimum fragmentor voltages and response for 
atenolol, bisoprolol, diltiazem, doxazosin, losartan, ramipril, simvastatin, valsartan and 
internal standard (atenolol d7) were not significantly affected (Figure 4.22 – 4.33). 
Based on the LC and MS parameter investigations, the selected LC and MS conditions 
used for the optimised method are summarized in Table 4.6. 
Table 4.6 A summary of the preliminary and optimised method LC and MS conditions. 
  Preliminary method Optimised method 
LC 
conditions 
 Mobile phase contains 0.2% 
formic acid 
 Mobile phase contains 0.1% 
formic acid 
  
 Mobile phase initiated at 5% B, 
maintained for 0.5 min, 
increased to 20% B and then to 
95% B by 1.5 min, held until 3.0 
min before returning to 5% B. 
 Mobile phase initiated at 4% B, 
maintained for 0.5 min, 
increased to 65% B and then to 
95% B by 1.5 min, held until 2.5 
min before returning to 4% B. 
   Run time of 3.01 minutes  Run time of 2.51 minutes 
    
MS 





4.3 Application of optimised LC and MS conditions to the analysis 
of DBS samples 
The optimised LC and MS conditions were applied to the analyses of the selected CVD 
drugs in DBS samples. Target analyte spiked DBS calibration standards were prepared 
using the standard operating procedure (SOP) developed for the preparation of 
calibration and validation standards for the 11 target cardiovascular drugs and internal 
standard in whole blood (Appendix 1). The DBS standard containing the highest 
concentration of all the target drugs was used for analyses.  
4.3.1 Chemicals and materials 
Autosampler vials, (250µl) vial inserts and vial caps were purchased from Agilent 
Technologies (Cheshire, UK). Specimen collection paper type 903, microcentrifuge 
tubes (1.5 ml), volumetric pipettes, pipette tips and polyethylene bags were obtained 
from Fisher Scientific (Loughborough, UK). An 8 mm diameter punch was obtained 
from Maun Industries Ltd. (Nottingham, UK). Lithium heparin coated blood collection 
tubes were purchased from International Scientifique Supplies Ltd. (Bradford, UK). 
Fresh blank blood was donated by informed volunteers in line with De Montfort 
University ethics protocol. 
4.3.2 Preparation of calibration and validation DBS samples 
Amlodipine, atenolol, atorvastatin, bisoprolol, diltiazem, doxazosin, lisinopril, losartan, 
ramipril, simvastatin and valsartan standard and intermediate stock solutions were 
prepared as detailed in section 4.2.2. Multicomponent working solutions for each 
target drug were prepared freshly as detailed in the SOP for the preparation of blood 
calibration standards (Appendix 1). 
For the preparation of spiked blood standards, several samples of fresh blank blood 
(900 µl) were spiked with 100 µl of one of each multicomponent working solution to 
produce final blood target drug concentrations in Table 4.7. The hematocrit of the 
blood was 45%. 100 µl of methanol/water (70:30, v/v) was spiked into 900µl of fresh 
blank blood to produce a zero (blank) blood sample. Internal standard, atenolol d7 
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stock solution was prepared in methanol at a concentration of 10µg/ml and diluted 
further with methanol/water (70:30, v/v) to produce an extraction solvent containing 
20 ng/ml of IS. Whilst it is generally recommended to use 5% solvent when preparing 
DBS calibration and quality control (QC) standards, 10% solvent was used in this assay. 
Work in this laboratory (Patel, 2011; Lawson et al., 2012) has shown that the use of a 
10% solvent standard did not produce any changes to the blood spot spreading. 
The calibration ranges were chosen to cover the therapeutic ranges in (Table 2.4 of 
Chapter 2) for the selected drugs. A minimum of 7-point calibration curve was 
prepared based on composite data from Chapter 2, Table 2.5 by spotting 30µl of 
calibration standards including blanks directly onto the 903 sampling paper using a 
volumetric pipette.  The prepared samples were dried at room temperature for at least 
3h prior to processing. A 30 µl volume produced a spot of size of   9̴.5 mm in diameter 
on the sampling paper.  
Table 4.7 Calibration standards of the 11 target cardiovascular drugs in human whole blood. 
Drug Calibration standards (ng/ml) 
      LOW     MED   HIGH 
Amlodipine  0.5 1 5 10 25 50 100 
Atenolol 10 20 50 100 200 500 1000 1500 
Atorvastatin  0.5 1 5 10 25 50 100 
Bisoprolol 0.1 0.5 1 5 10 25 50 100 
Diltiazem   0.5 1 5 10 50 100 300 600 
Doxazosin   0.1 0.5 1 5 10 25 50 100 
Lisinopril 0.1 0.5 1 5 10 25 50 100 
Losartan 5 10 25 50 100 250 500 1000 
Ramipril 0.1 0.5 1 5 10 25 50 100 
Simvastatin 0.1 0.5 1 5 10 25 50 100 
Valsartan 50 100 250 500 1000 2000 3000 4000 
 
4.3.3 Extraction of DBS samples 
Using the extraction procedure documented in Lawson et al 2013, the analyte spiked 
DBS standard prepared using the highest concentration of each analyte was solvent 
extracted for analysis. An 8mm disc was punched from the centre of a 30µl DBS sample 
and transferred into a clean 1.5ml microcentrifuge tube. 150µl volume of extraction 
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solvent consisting of MeOH: H2O (70:30, v/v) was added. The tube was vortexed for 
1min, sonicated in an ultrasonic water bath for 30 minutes and centrifuge at 13200rpm 
for 10 minutes. The supernatant was transferred into an autosampler vial with 250µl 
insert for analysis.  
4.3.3.1 Extract analysis by liquid chromatography high resolution mass 
spectrometry 
Sample injection volume was 20µl. Analysis was performed using the optimised liquid 
chromatography and mass spectrometry conditions selected for the optimised method 
as documented in Table 4.6. 
 
Figure 4.34 Representative LC-HRMS overlaid extracted ion chromatogram of a spiked DBS standard 
containing the highest concentration of the target drugs and 20ng/ml of IS. 
The results obtained indicated that all the target analytes were detectable in spiked 
DBS standard, except amlodipine (Figure 4.34). Whilst amlodipine was detected and 
quantified in solvent, it was not detected in DBS when the extraction procedure 
documented in Lawson et al (2013) was used. In addition, relative detector response 
for bisoprolol, diltiazem, losartan and valsartan were high, but responses for atenolol, 
atorvastatin, doxazosin, lisinopril, ramipril and simvastatin in DBS had suffered 
significantly in DBS matrix (Figure 4.34). Taking doxazosin, ramipril and simvastatin into 
consideration, initial investigation with a 100ng/ml concentration in solvents did not 
present any challenges (Figure 4.2), as the compounds were well resolved with good 
detector response (counts of ≥500,000). However, Figure 4.34 shows that for a 
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100ng/ml concentration in DBS, the magnitude of responses for these compounds has 
significantly dropped with counts of (≤300,000).  
This was attributed to poor extraction of these target analytes from DBS. The reason 
was because the card material and blood matrix present challenges for extraction of 
the analytes. Biological matrices such as blood contain proteins, lipids, salts, cells and 
many other components likely to interfere with the extraction of the drugs from filter 
paper. In addition, the selected CVD drugs show significant differences in 
physicochemical characteristics (molecular weight, logP, logD, polarity, stability, 
dissolution and thermodynamic properties). Hence, optimising sample extraction was 
essential to remove most of the unwanted interferents from the DBS extract to make 
the sample compatible with chromatographic separation and MS analysis.  
4.3.4 Optimised extraction of DBS sample 
The procedure for analyte extraction from DBS was optimised through trials by 
investigating parameters such as the extraction solvent, vortexing time, sonication 
with and without controlled heat, centrifuging time, drying of the supernatant under 
nitrogen gas and subsequent reconstitution with solvent, addition of formic acid to the 
reconstitution solvent. 
4.3.4.1 Investigation of extraction solvents using (Acetonitrile or Methanol) 
Optimal extraction improves the recovery of target analytes from DBS. To optimise the 
extraction of amlodipine, atenolol, atorvastatin, doxazosin, lisinopril, ramipril and 
simvastatin in DBS, attention was paid to the extraction procedure documented in 
previous work, relating to the simultaneous quantification of cardiovascular analytes in 
plasma and urine (Diaz et al., 2013; Gonzalez et al., 2010; Gonzalez et al., 2011; 
Tomazewski et al., 2014). It was observed that in these studies, following protein 
precipitation with organic solvents, the extracts were evaporated to dryness and the 
filtrate reconstituted in solvents. Hence this procedure was investigated through trials 
to improve the recovery of amlodipine, atenolol, atorvastatin, doxazosin, lisinopril, 
ramipril and simvastatin in DBS. 
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Different volumes (500µl and 300µl) of acetonitrile, methanol and (ACN: MeOH (50:50, 
v/v)) were investigated for protein precipitation and subsequent extraction of analytes 
from the DBS sampling paper. The extraction solvent composition documented in 
Lawson et al (2013) (MeOH: H2O (70:30, v/v)) was used as control. Following protein 
precipitation with either acetonitrile, methanol or a mixture of acetonitrile and 
methanol, the resultant supernatant was removed and dried under a gentle stream of 
nitrogen gas and the dried residue reconstituted with solvent, vortex mixed for 1 
minute and transferred into vials with 250µl inserts for analyses.  
 
Figure 4.35 Comparison of response in DBS using 300µl of extraction solvents (ACN, MeOH & ACN: 
MeOH, 50:50, v/v), with 70% MeOH as control (n = 4). 
 
 
Figure 4.36 Representative comparison of response in DBS using 300µl of extraction solvents (ACN, 























































It was observed that the use of an extraction solvent volume of 500µl was not feasible 
because it took a long time to evaporate the supernatant to dryness. In view of this the 
extraction solvent volume used was 300µl. Results obtained indicated that evaporating 
the supernatant to dryness and reconstitution of the filtrate with solvent significantly 
improved the recovery of atenolol, atorvastatin, bisoprolol, doxazosin, lisinopril, 
losartan, ramipril, simvastatin and valsartan. The gain in detector response ranged 
from 8% to 72% (Figure 4.35) for the target drugs when compared with the extraction 
protocol documented in Lawson et al (2013) used as control. For example, 
atorvastatin, lisinopril and simvastatin which were poorly recovered with the control 
extraction procedure shows an increase of 54%, 36% and 66% respectively (Figure 
4.36). An important observation was that, amlodipine which was initially not 
detectable with the control extraction procedure, was now detectable using 
acetonitrile as the extraction solvent. It was however not possible to quantify the peak 
because the s/n ratio was less than 10.  
In contrast with acetonitrile and (MeOH: ACN (50:50, v/v)), it was observed that using 
methanol as the protein precipitant was the best for the extraction of all the target 
analytes from DBS except for amlodipine which was not detectable in methanol. Figure 
4.35 shows that when acetonitrile is used, there is a slight gain in response (<5%) for 
diltiazem and doxazosin when compared with methanol. However, lisinopril suffers as 
it is not quantifiable and there is also significant reduction in detector response for 
atenolol (33%), atorvastatin (84%), losartan (73%), Ramipril (91%), simvastatin (50%) 
and valsartan (96%). When a mixture of (MeOH: ACN (50:50, v/v)) was used as the 
extraction solvent, amlodipine could not be detected and lisinopril was also not 
quantifiable. Methanol was therefore used for the subsequent extraction of the 10 
target analytes in DBS. Since amlodipine could be detected only in acetonitrile, further 
investigations were performed with acetonitrile as the extraction solvent to optimise 
the recovery of amlodipine in DBS. 
The gains in response observed for atenolol, atorvastatin, bisoprolol, doxazosin, 
lisinopril, losartan, ramipril, simvastatin and valsartan could be attributed to the fact 
that the extracts produced after drying the supernatant and solvent reconstitution 
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were clean and colourless. Indicating that the filtrate had less matrix interferences 
when compared with the straw-coloured extract produced using just MeOH: H2O 
(70:30, v/v) as extraction solvent (control). This led to a significant reduction in ion 
suppression at the ESI source of the MS with increased sensitivity.  
Investigation of vortexing times, sonication and centrifuging speed and times did not 
produce any significant gains in recovery of any of the target analytes. The solvent 
composition used for reconstitution and the volume were also investigated to select 
the best composition for optimal recovery of the dried extract from the sides of the 
microcentrifuge tubes. 
4.3.4.2 Investigation of reconstitution solvents/volumes using (acetonitrile 
or methanol) and water 
To achieve optimal recovery of the target analytes from the dried extract prior to 
analysis, a combination of appropriate solvent strength is normally required due their 
possible differences in solubility (Gonzalez et al., 2010). Hence different ratios of 
diluent, methanol or acetonitrile with water (Table 4.8) were investigated, to optimise 
the recovery of analytes from the sides of the microcentrifuge tubes. In addition, the 
reconstitution solvent volume was also investigated. This was performed by comparing 
a solvent volume of 150µl and 300µl for dissolving the dried extracts. 
Table 4.8 Ratios of (methanol or acetonitrile) with water investigated for reconstitution. 
Solvent Composition Percentages (%) 
Methanol 0 20 40 60 80 100 
Water 100 80 60 40 20 0 
              
Acetonitrile 0 20 40 60 80 100 
Water 100 80 60 40 20 0 
 
As with the extraction step, acetonitrile worked best for amlodipine and methanol was 
appropriate for the atenolol, atorvastatin, bisoprolol, diltiazem, doxazosin, lisinopril, 
ramipril, simvastatin and valsartan. Further investigation indicated that MeOH: H2O 
(40:60, v/v) solvent composition was the best for the extraction of the ten target 
analytes from DBS. Whilst ACN: H2O (40:60, v/v) solvent composition was best for 
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amlodipine. Figure 4.37 shows representative data for atorvastatin, lisinopril and 
simvastatin. 
 
Figure 4.37 Representative plot of reconstitution solvent composition (n = 3) for atorvastatin, lisinopril 
and simvastatin. For 20%_MeOH, p-value is 0.017; 40%_MeOH, p-value is 0.004; 60%_MeOH, p-value 
is 0.022; 80% MeOH, p-value is 0.046 and 100%_MeOH p-value is 0.624. 
 
The solvent volume investigation showed that 150µl volume was ideal for 
reconstitution. Doubling the solvent volume led to a 50% drop in response for all the 
target analytes. Indicating that the strength of the analytes in solvent is inversely 
proportional to the volume of solvent used (Strength = 1/volume) and most 
importantly showing that all the analyte had dissolved in solvent.  
 
Figure 4.38 Representative plot of reconstitution solvent volume for atorvastatin, lisinopril and 












































































4.4 Specific analytical challenges encountered in the 
quantification of amlodipine, atorvastatin, lisinopril and 
simvastatin in DBS 
The simultaneous quantification of multiple analytes with different physicochemical 
properties (molecular weight, logP, logD, pKa, polarity, stability, dissolution, 
thermodynamic properties) and physiological behaviour in dried blood matrix presents 
challenges due to the following reasons;  
 Limited research on dried blood matrix sample pretreatment and extraction 
procedure for multiple drugs with different physicochemical properties. 
 The large differences in concentration ranges of the different analytes in 
biological fluids. For example, due to the differences in prescribed doses for the 
selected drugs, the selected ranges investigated were 1 – 100ng/ml for 
amlodipine, atorvastatin and simvastatin versus 10 – 1500ng/ml for atenolol 
and 50 – 4000ng/ml for valsartan. 
The approach to overcome such challenges was to attempt to develop a robust sample 
clean up and extraction procedure suitable for all the analytes, but sensitive and 
selective enough to reduce as much as possible the matrix effects likely to occur in the 
ESI source of the MS. Among the 11 candidate CVD drugs selected in Chapter 2, section 
2.3 for investigation, challenges were encountered with the quantitation of 
amlodipine, atorvastatin, lisinopril and simvastatin in DBS as reported in section 
4.3.3.1. Hence, the following sub section discusses the analytical challenges 
encountered with the quantification of these drugs in DBS. 
4.4.1 Amlodipine 
Amlodipine is a compound with polar and non-polar functional groups (Figure 4.39). It 
is highly soluble in water and has a pKa of 8.7, which means that at physiological pH, it 
exists primarily in its ionised form (Meredith, 1992). Following oral administration, its 





Figure 4.39 Chemical structure of amlodipine. 
Amlodipine is reported to have a high degree of protein binding (98%) (Nirogi et al 
2006). This explains the reason why amlodipine was not detected in extracts from 
spiked DBS when the extraction procedure reported in Lawson et al (2013) was used. 
Precipitation of high molecular weight proteins was performed with methanol: water 
(70:30, v/v), and since amlodipine is highly bound to plasma protein, it will be retained 
on the DBS card rather than in the supernatant. Hence hydrolysis of the drug – protein 
bond will be necessary to free amlodipine and retain it in the extraction solvent. In 
addition, the 30% ratio of water in the extraction solvent may lead to the dissolution of 
water soluble components in the blood matrix such as salts likely to cause ion 
suppression.  
Like most other calcium channel antagonist of the dihydropyridine class, a racemic 
mixture of amlodipine is used for therapeutic purposes (Abernerthy, 1992; Hotha et 
al., 2013). As a chiral molecule, there is evidence that the opposite enantiomer of a 
chiral drug often differs significantly in its pharmacological, toxicological, 
pharmacodynamic and pharmacokinetic properties. (Hotha et al., 2013; Zeng et al., 
2010; Mohan et al., 2009; Midha et al., 1998; Islam et al., 1997; Drayer, 1986). Hence 
the physicochemical properties of both the racemate and the enantiomer, such as 
polarity, solubility and stability may differ. This leads to differences in solubility and 
retention time presenting further challenges with detection. 
Different extraction techniques (solid phase extraction (SPE) and liquid liquid 
extraction (LLE)) using different solvents have been reported in the literature for the 
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extraction of amlodipine from plasma and serum. Shah et al (2017) extracted 
amlodipine from plasma by solid phase extraction (SPE). 1.0% formic acid was added to 
plasma samples, before loading unto the cartridge preconditioned with methanol 
followed by water. Elution of analyte was performed with methanol followed by 
evaporation of eluate to dryness and finally reconstituting residue in mobile phase 
solvent.  Bathula et al (2012) also extracted amlodipine from plasma using SPE. Plasma 
samples were loaded unto the cartridge preconditioned with methanol followed by 
water. Washing was done with water containing 0.1% ammonia and elution was 
performed with methanol containing 0.1% ammonia. 
Conversely, Danafar and Mehrdad (2016) and Chan Mei et al (2013) extracted 
amlodipine from plasma by liquid–liquid extraction technique using ethyl acetate. 
After vortexing and centrifuging the organic layer was transferred to another tube, 
evaporated to dryness and residue reconstituted with mobile phase solvent. Rezk and 
Badr (2014) used diethyl ether for the extraction of amlodipine from plasma. After 
vortexing and centrifuging the organic layer was transferred to another tube, 
evaporated to dryness and residue reconstituted with mobile phase solvent. In the 
extraction of amlodipine from plasma, Shentu et al (2012) used acetonitrile followed 
by the addition of water containing 0.1% formic acid. 
Massaroti et al (2005) also extracted amlodipine from plasma using 10µl of NaOH 
followed by the addition of a mixture of ethyl acetate/hexane (80:20, v/v). After 
vortexing and centrifuging, the organic layer was transferred to another tube, 
evaporated to dryness and residue reconstituted with mobile phase solvent. Pandya et 
al (1995) also extracted amlodipine from plasma samples by incubation for 2 h at 36°C 
with 2ml of pepsin (proteolytic enzyme) solution to break the drug protein bounds. 
Plasma protein was then precipitated by the addition of 2ml of 0.2 M borate buffer 
solution and finally amlodipine was extracted with 2ml of dichloromethane. 
The problem of extracting amlodipine from DBS was resolved by using acetonitrile 
containing 10µl of 0.5M sodium hydroxide (NaOH) and the internal standard as the 
extraction solvent. Following vortexing, sonication and centrifuging as describe in 
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Table 4.9, the supernatant was dried down and the dried extracts dissolved with a 
reconstitution solvent consisting of (acetonitrile: water, 40:60 v/v) with 0.1% formic 
acid (Chen et al., 2018). The NaOH was added to the extraction solvent (Massaroti et 
al., 2005; Shentu et al., 2012) to hydrolyse the drug – protein bond. This ensured that 
amlodipine was retained in solvent, rather than on the DBS card with the precipitated 
high molecular weight proteins leading to possible detection (Figure 4.40). This 
procedure resulted in the detection and quantification of the [M+Na]+ ion of 
amlodipine at m/z 431.1344 (Section 4.2.2, Table 4.1) with a retention time of 1.005 
minutes. Methanol could not be used as the extraction solvent for amlodipine because 
the addition of NaOH produced a supernatant that was dark in colour and could not be 
used for analyses.   
Conversely, all the published papers on the plasma extraction of amlodipine using MS 
methods for detection used the molecular [M+H]+ ion of amlodipine at m/z 409.2 for 
quantitation. However, the [M+H]+ ion of amlodipine at m/z 409.1525 with the 
developed LC-HRMS assay could not be detected in DBS extracts hence the [M+Na]+ 
ion was used for quantitation. 
Table 4.9 Summary of preliminary and optimised extraction procedure. 
Preliminary extraction procedure Optimised extraction procedure 
• 8mm disc punched into an 
eppendorf tube. 
• 150µl of (70:30v/v) MeOH:H20 
containing 20ng/ml atenolol d7 as 
(I.S) added.  
• Tubes are vortexed for 1 min, 
sonicated for 30 mins and 
centrifuged at 13200rpm for 
10mins.  
• 120µl of supernatant transferred 
into LC vials for analysis. 
 
• 8mm disc punched into an 
eppendorf tube.  
• 300µl of (ACN plus 10µl of NaOH) for 
amlodipine or MeOH containing 
20ng/ml atenolol d7 as (I.S) added 
for the 10 CVD drugs.  
• Tubes are vortexed for 1 min, 
sonicated at 40°C for 30 mins and 
centrifuged at 13200rpm for 10mins. 
• 270ul of supernatant are transferred 
into microcentrifuge tube and dried 
under a gentle stream of N2 gas.  
• Dried residue reconstituted with 
150µl of either 40:60v/v MeOH:H20 







Figure 4.40 Representative LC-HRMS overlaid [M+Na]+ ion EIC’s of amlodipine DBS standard using the 
preliminary and optimised extraction procedures. 
 
4.4.2 Lisinopril 
Lisinopril is a hydrophilic molecule containing amino and carboxyl groups (Figure 4.41).  
After oral administration, the bioavailability of lisinopril is about 25%, but varies widely 
between individuals (6 to 60%) (Vlase et al., 2010). As a polyfunctional amphoteric 
compound lisinopril has two basic and two acidic moieties (pKa 10.75, 7.13, 3.13 and 
1.63). Thus, lisinopril can produce both negative and positive ions. Previous studies by 
Qin et al (2007) and Shah et al (2016) have reported that sensitivity for lisinopril was 
higher in the positive ionisation mode. Being an amphoteric compound, lisinopril is 
ionised in aqueous solution whatever the pH, thus giving a poor chromatographic peak 
shape (tailing) on reversed-phase chromatography. 
 




In addition, lisinopril has been shown to exist as a two (cis and trans) isomer at room 
temperature (Tsakalof et al., 2002). The rate of isomerization is known to influence 
peak shape because cis-trans isomers differ in their hydrophobicity. Therefore, 
lisinopril can produce two separate chromatographic peaks or a good and bad shaped 
peak depending on column chemistry and mobile phase composition. 
Using trifluoroacetic acid (TFA) as additive to the aqueous phase is known to impact 
positively on the retention of lisinopril and its peak shape on C18 chromatographic 
column (Vlase et al., 2010). However, the use of TFA in mass spectrometry has a major 
drawback. The strong ion pair formed by TFA with analyte cannot ionised, thus it will 
not be detected by the mass spectrometer since ions are required for detection. The 
poor sensitivity due to TFA can be avoided by using a weaker acid such as formic acid 
(Vlase et al., 2010). The presence of formic acid in reconstitution solvent improved the 
peak shape and increased the ionisation of lisinopril (Qin et al., 2011). Using 0.1% 
formic acid, lisinopril is transformed into a neutral adduct hence the ionisation of 
carboxylic groups is suppressed by the low pH (Zhou et al., 2008). The formate anion 
forms a weaker ion-pair with ionised primary and secondary amino groups, 
neutralizing their charge (Shah et al., 2016). This way the lipophilicity of lisinopril is 
increased and the chromatographic peak becomes symmetric. Figure 4.42 shows the 
gains for lisinopril when 0.1% formic acid is added to the reconstitution solvent. 
 
Figure 4.42 Representative LC-HRMS overlaid EIC’s of lisinopril DBS standard using the preliminary and 
optimised extraction procedures. 
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4.4.3 Atorvastatin and simvastatin 
Atorvastatin and simvastatin belong to the group of cardiovascular drugs called statins 
(Figure 4.43). Statins are lipophilic compounds and their molecules exist in two forms, 
lactone and open-ring hydroxy acid form (Novakova et al., 2008; Kosek et al., 2017). In 
vivo, the hydroxy acid forms are the active drugs to lower plasma cholesterol while the 
lactone forms are inactive prodrug. Lactone form of statins can be absorbed from the 
gastrointestinal tract and transformed to the active drugs in the liver and non-hepatic 
tissues.  
Atorvastatin is administered in the open-ring hydroxy acid form, the active form and 
gets completely absorbed upon oral administration (Partini et al., 2013). It has an oral 
bioavailability of about 12–14% due to its rapid presystemic clearance in the gut wall 
as well as metabolism in the liver (Kosek et al., 2017). Atorvastatin is also highly bound 
to plasma protein (~96%) and has the elimination half-life of approximately 14h, which 
is considerably longer than that of most other statins (Androw, 1997). It is extensively 
metabolized to its 2- and 4-hydroxylated derivatives and various β-oxidation products 
(Partini et al., 2013). 
Simvastatin on the other hand is a prodrug, which is administered as an inactive 
lactone. The lactone is absorbed from gastrointestinal tract and hydrolyzed to the 
active-hydroxy acid form in the liver (Ahmed et al 2012). The bioavailability of 
simvastatin is very low and reported to be 5% (Patel and Kothari, 2017; Vetrova et al., 
2015). 
Statins are a typical example of drugs, where there is interconversion between lactone 
and open-ring hydroxy acid (Jemal and Xia, 2000; Yang et al., 2006). This 
interconversion can take place during sample preparation and the analyses stage 
leading to inaccuracies of results. Hence, it is essential to select conditions that will 
eliminate or minimise their in-vitro interconversion during method development. It’s 
been reported that adjusting pH to between pH 4 and pH 5, significantly reduce the 
interconversion between lactone and acid forms (Jemal et al., 2000; Ahmed et al., 
2012, Partini et al., 2013). Since statins are extreme hydrophobic compounds, they are 
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known to suffer significant matrix effects during analyses in matrices such as blood or 
plasma (Dias et al., 2013).  
 
Figure 4.43 Chemical structure of (a) atorvastatin and (b) simvastatin. 
To select conditions towards optimising the extraction of the statins, attention was 
paid to previous work, relating to the estimation of atorvastatin and simvastatin in 
plasma. Evaporating the supernatant to dryness and subsequent reconstitution 
significantly reduced the matrix effect and led to improved recovery of both statins 
due to the clear and colourless filtrates produced. In addition, acidifying the 
reconstitution solvent with 0.1% formic acid will lower the pH of the extract and hence 
minimised any possible interconversions of between the lactone and hydroxyl acid 
forms. Heat enhances solubility, hence application of moderate heat during sonication 
on a water bath, improved the recovery of atorvastatin and simvastatin. Heating of the 
water bath during sonication was experimented at 40˚C and 60˚C, with another 
extraction conducted with no heat serving as control. At 40˚C there were gain of about 
18% and 36% for atorvastatin and simvastatin respectively (Figure 4.44). Figure 4.45 





Figure 4.44 Effect of heat on the extraction of atorvastatin, lisinopril and simvastatin (n = 4). 
 
 
Figure 4.45 Representative LC-HRMS overlaid EIC’s of atorvastatin DBS standard using the preliminary 
and optimised extraction procedures. 
 
Figure 4.46 Representative LC-HRMS overlaid EIC’s of simvastatin DBS standard using the preliminary 


































4.5 Final DBS extraction protocols. 
4.5.1 Extraction protocol for atenolol, atorvastatin, bisoprolol, 
diltiazem, doxazosin, lisinopril, losartan, ramipril, simvastatin and 
valsartan  
An 8 mm disc (  2̴0 µl of blood) was punched from the centre of each DBS sample and 
transferred to a 1.5 ml micro-centrifuge tube. A 300 µl volume of methanol containing 
IS (20 ng/ml), atenolol D7, was used for the extraction of atenolol, atorvastatin, 
bisoprolol, diltiazem, doxazosin, lisinopril, losartan, ramipril, simvastatin and valsartan 
because of its optimum extraction efficiency and less interference. Tubes were 
vortexed for 1 min, sonicated for 30 mins in a temperature controlled ultrasonic bath 
at 40°C and centrifuged at 13200rpm for 10mins. 270 µl of each supernatant was 
transferred into a new microcentrifuge tube and dried under a gentle stream of N2 gas. 
Dried residue was reconstituted with 150 µl of methanol/water (40:60, v/v) containing 
0.1% formic acid. The final extracts were transferred into auto-sampler vials for LC-
HRMS analyses. Figure 4.47 shows an overlaid EIC from a spiked DBS standard 
containing the 10 analytes and internal standard extracted using the optimised 
extraction procedure. Table 4.9 shows a comparison of the preliminary and optimised 
extraction procedures for the selected target analytes and internal standard. 
 
Figure 4.47 Representative LC-HRMS overlaid EIC’s of a spiked DBS standard containing 20ng/ml of IS 




4.5.2 Final DBS extraction protocol for amlodipine 
An 8-mm disc was punched from the centre of a 30 µl DBS sample and transferred into 
a clean 1.5 ml microcentrifuge tube. 300 µl of acetonitrile containing 20 ng/ml atenolol 
d7 was added. 10µl of 0.5M sodium hydroxide was added to the extraction solvent. 
Tube was vortexed for 1 min, sonicated for 30 mins in a temperature controlled 
ultrasonic bath at 40°C and centrifuged at 13200 rpm for 10mins. 270 µl of 
supernatant was transferred into new microcentrifuge tubes and dried under a gentle 
stream of N2 gas. Dried residue was reconstituted with 150 µl of acetonitrile/water 
(40:60, v/v) containing 0.1% formic acid and transferred into an autosampler vial for 
analysis. Figure 4.48 shows the process of analyte extraction from a spiked DBS 
standard.   
 
Figure 4.48 Schematic for the process of extraction of analytes from DBS cards using the optimised 
extraction procedure. 
For volumetric absorptive microsampling (VAMS) samples, the whole substrate was 
used for extraction. Figure 4.49 shows the process of analyte extraction from a spiked 
VAMS standard. 
 




Chapter 5 Validation of optimised LC-HRMS method using 
903 sampling paper and volumetric absorptive 
microsampling (VAMS) device 
 
There are international guidelines that bioanalytical methods used for measurement of 
analyte concentrations in human samples are well characterised, fully validated and 
documented to a specified standard to ensure reliable results (FDA, Guidance for 
industry, bioanalytical method validation 2001; Araujo, 2009; EU, Guideline on 
bioanalytical method validation, 2011; Lynch, 2016). This chapter therefore discusses 
the validation of the developed microsampling based LC-HRMS assay for the 
quantification of amlodipine, atenolol, atorvastatin, bisoprolol, diltiazem, doxazosin, 
lisinopril, losartan, ramipril, simvastatin and valsartan on 903 sampling paper and 
volumetric absorptive microsampling (VAMS) device. A discussion of the various 
validation parameters investigated and a comparison of validation results for the two 
methods of microsampling is presented. 
5.1 Introduction 
Measurement of concentrations of analytes and their metabolites in biological samples 
(such as blood, plasma and serum) is a significant part of therapeutic drug monitoring 
(TDM). Derived data may be used to define or adjust the dose of the medication for 
the purposes of personalising the treatment for the patient by observing several 
factors that affect the efficacy and adverse effects of the drug. For example, the results 
of bioequivalence studies and TDM are required to make essential decisions 
supporting the safety and efficacy of a drug. Unreliable results could lead to the 
prescribing of wrong dose of the treatment to the patient with catastrophic 
consequence (Selinger et al., 2014). Thus, it is paramount that developed bioanalytical 
assays are fit for their intended purposes.  
There are currently no official guidelines present for the validation of dried blood spot 
(DBS) assays (Enderle et al., 2016). Hence, the validation of the developed dried 
microsampling based LC-HRMS assay was conducted based upon FDA and EU 
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guidelines (FDA, Guidance for Industry: bioanalytical method validation 2001; EU, 
Guideline on bioanalytical method validation, 2011). Further considerations on the 
matrix and sampling specific validation parameters were based on the European 
Bioanalysis Forum (EBF) recommendation on the validation of bioanalytical methods 
for dried blood spots (Timmerman et al., 2011). The main characteristics of the 
developed assay that are crucial to ensure that performance are acceptable and 
analytical results are reliable were investigated. As per the FDA and EU guidelines, the 
essential parameters that need to be defined to ensure the acceptability of a 
bioanalytical method are precision, accuracy, sensitivity, selectivity, linearity, recovery, 
stability and matrix effects. Parameters based on EBF recommendations investigated 
include blood spot volume and the hematocrit (Hct) effect known to affect (drying 
time, homogeneity, diffusion and assay reproducibility) in DBS quantitative assays.  
Different methods of blood microsampling have been developed recently to overcome 
the drawbacks of conventional DBS sampling (Spooner et al., 2015; Ye and Gao, 2017). 
Examples of these drawbacks include the difficulties with self-use, precise volume 
sampling and the effect of variability in individual hematocrit levels and their impact 
on the spot size and formation. One of such novel devices is volumetric absorptive 
microsampling (VAMS), which is discussed in Chapter 3, section 3.3.2. VAMS is 
designed to sample a fixed 10µl or 20µl volume of blood by sorption regardless of the 
blood hematocrit. The developed LC-HRMS assay was therefore validated using the 
conventional 903 sampling paper as a means of taking a microvolume of blood and the 
10µl version of VAMS using spiked fresh human blood. Following successful validation, 
they were used for volunteer blood sample collection and subsequent analyses of the 
collected samples.  
5.2 Method validation 
For the purposes of validation studies, three concentrations were chosen for the 
independent preparation of quality control samples (QCs) at the low, medium and high 
concentration levels for each target drug and run alongside calibration standards as 
detailed in Table 4.7. To demonstrate that the developed bioanalytical method was fit 
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for purpose, validation was conducted based upon FDA and EU guidelines (FDA, 2001; 
EU, 2011). The selectivity, linearity, sensitivity, intra and inter-assay accuracy and 
precision, limit of quantification (LOQ), matrix effects, hematocrit effects and stability 
were determined for amlodipine, atenolol, atorvastatin, bisoprolol, diltiazem, 
doxazosin, lisinopril, losartan, ramipril, simvastatin and valsartan on the 903 sampling 
paper and the VAMS device. Since amlodipine required a different extraction 
procedure from spiked blood samples, validation on the two methods of 
microsampling were performed separately for amlodipine. 
5.2.1 Selectivity 
Selectivity was evaluated to demonstrate that the developed LC-HRMS assay could 
differentiate the target analytes and internal standard (IS) from endogenous 
components in the 903 sampling card and VAMS device as well as the blood matrix. 
Selectivity was determined using three (3) individual sources of blank human whole 
blood. Possible interference from the matrix was investigated by the analyses of blank 
blood samples and target analyte spiked blood samples collected on 903 sampling 
paper and VAMS device.  
Using the accurate masses for the 11 cardiovascular drugs and internal standard, 
determined by means of the qualitative analysis software version 4.00 (Mass 
calculator, Agilent Technologies) in Chapter 4, section 4.2.2, selectivity was evaluated 
by comparing extracted ion chromatograms (EICs) derived at the limit of quantification 
(LOQ) from a 903 sampling paper and VAMS calibration standard for each target 
analyte and the internal standard with those obtained from blank blood samples 
prepared on 903 sampling paper and VAMS device. A narrow mass extraction window 
of 5ppm was used to demonstrate enhanced selectivity. A representative proof of 
enhanced selectivity for atenolol on VAMS using mass tolerance filters of (a) ±200 






Figure 5.1 Demonstration of enhanced selectivity at the LOQ of atenolol with m/z 267.1703 using 
mass tolerance filters of (a)±200 ppm, (b)±100 ppm and (c)±5 ppm. 
A side by side comparison of representative EICs at the LOQ for each analyte and 
internal standard on 903 sampling paper and VAMS is shown in Figures 5.2(a) – (l). One 
internal standard was used in the developed LC-HRMS assay because the introduction 
of several compounds as IS could lead to ionisation competition with the analytes of 
interest at the ESI source of the mass spectrometer resulting in additional matrix 
effects. The protonated molecule [M+H]+ gave a high response for atenolol at m/z 
267.1703, atorvastatin at m/z 559.2610, bisoprolol at m/z 326.2326, diltiazem at m/z 
415.1686, doxazosin at m/z 452.1928, lisinopril at m/z 406.2336, losartan at m/z 
423.1695, ramipril at m/z 417.2384, valsartan at m/z 436.2343 and atenolol d7 
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(internal standard) at m/z 274.2143. The sodium adduct ion [M+Na]+ showed the 
highest signal intensity for amlodipine at m/z 431.1344 and simvastatin at m/z 
441.2611. The sodium adduct ion for amlodipine and simvastatin were stable and gave 
reproducible response and thus was used for quantification. The LC-HRMS method 
showed good selectivity because the EICs revealed that no interfering peaks were 
observed at the retention times for each of the eleven drugs and IS investigated using 








































Figure 5.2 (a) – (l). A side by side representative LC-HRMS extracted (5ppm) ion chromatogram (EIC) of 
an extracted blank blood sample (red) and a calibration standard at the LOQ spiked with the eleven 
target drugs (black) on 903 sampling paper and VAMS. (a) amlodipine (b) atenolol (c) atorvastatin (d) 
bisoprolol (e) diltiazem (f) doxazosin (g) lisinopril (h) losartan (i) ramipril (j) simvastatin (k) valsartan 
and (l) atenolol d7 (internal standard).   
5.2.2 Linearity and sensitivity 
Replicate (n = 6) analyses of calibration standards prepared on 903 sampling paper and 
VAMS were separately run per day over the three days. A calibration plot for each 
target analyte/IS peak area ratio against nominal analyte concentration was produced 
and an equally-weighted linear regression was applied. The limit of quantification of 
amlodipine, atenolol, atorvastatin, bisoprolol, diltiazem, doxazosin, lisinopril, losartan, 
ramipril, simvastatin and valsartan in the 903 sampling paper and VAMS extracts was 
defined by the lowest concentration that gave a signal-to-noise (S/N) ratio greater than 
or equal to 10. Back calculations gave relative errors less than 15% (typically between 2 
and 10% for VAMS and between 2 and 14% for 903 sampling paper over the 
appropriate calibration range for each drug. The data (slope, intercept and the mean 
correlation coefficient R2 and LOQ) for each drug is presented in Table 5.1a and 5.1b 








for 903 sampling paper and VAMS respectively. The LOQ data shows comparable 
results for 903 sampling paper and VAMS. These results demonstrate that the 
sensitivity of VAMS is good taking into consideration the fact that amount of blood 
sample extracted was 10µl compared to ~20µl on 903 sampling paper. The results also 
demonstrate that the assay is sensitive enough for the determination of very low levels 
of the drugs in volunteer samples. The capability of the assay to quantify at such low 
concentrations will prevent the generation of false negative results. The high 
sensitivity reported for the target drugs also demonstrate the robustness of the 
extraction procedure. For example, in the quantification of bisoprolol, ramipril and 
simvastatin from DBS, Lawson et al (2013) reported sensitivities of 0.5ng/ml, 1ng/ml 
and 5ng/ml respectively, compared to 0.1ng/ml for all three drugs with this multi-drug 
LC-HRMS assay. 
Table 5.1 (a) Linearity and sensitivity data for the eleven cardiovascular drugs in 903 sampling paper. 
Drug Range (ng/ml) y = ax + b R2 LOQ (ng/ml) 
Amlodipine 0.5 - 100 y = 0.004x + 0.043 0.993 ± 0.004 0.5 
Atenolol 10 - 1500 y = 0.0044x - 0.047 0.997 ± 0.001 10 
Atorvastatin 0.5 - 100 y = 0.0014x + 0.0244 0.986 ± 0.013 0.5 
Bisoprolol 0.1 - 100 y = 0.019x + 0.034 0.994 ± 0.003 0.1 
Diltiazem 0.5 - 600 y = 0.016x + 0.053 0.997 ± 0.002 0.5 
Doxazosin 0.1 - 100 y = 0.016x + 0.033 0.992 ± 0.005 0.1 
Lisinopril 0.1 - 100 y = 0.002x + 0.031 0.978 ± 0.007 0.1 
Losartan 5 - 1000 y = 0.004x + 0.0713 0.995 ± 0.002 5 
Ramipril 0.1 - 100 y = 0.025x + 0.018 0.997 ± 0.002 0.1 
Simvastatin 0.1 - 100 y = 0.013x + 0.081 0.996 ± 0.003 0.1 
Valsartan 50 - 4000 y = 0.002x - 0.139 0.994 ± 0.003 50 
 
The following equation was used;   𝑦 = 𝑎𝑥 + 𝑏                      Equation 5.1                                                                                     
Where (y) is the ratio of analyte to I.S response, (a) is the slope, (x) represents the 






Table 5.1 (b) Linearity and sensitivity data for the eleven cardiovascular drugs in VAMS. 
Drug Range (ng/ml) y = ax + b R2 LOQ (ng/ml) 
Amlodipine 0.5 - 100 y = 0.007x + 0.086 0.990 ± 0.002 0.5 
Atenolol 10 - 1500 y = 0.0074x - 0.136 0.992 ± 0.001 10 
Atorvastatin 0.5 - 100 y = 0.0033x + 0.023 0.997 ± 0.001 0.5 
Bisoprolol 0.1 - 100 y = 0.0097x + 0.096 0.996 ± 0.002 0.1 
Diltiazem 0.5 - 600 y = 0.008x + 0.224 0.995 ± 0.003 0.5 
Doxazosin 0.1 - 100 y = 0.0067x + 0.067 0.992 ± 0.001 0.1 
Lisinopril 0.1 - 100 y = 0.0013x + 0.021 0.985 ± 0.004 0.1 
Losartan 5 - 1000 y = 0.0024x + 0.110  0.993 ± 0.007 5 
Ramipril 0.1 - 100 y = 0.017x + 0.271 0.986 ± 0.001 0.1 
Simvastatin 0.1 - 100 y = 0.016x + 0.215 0.988 ± 0.003 0.1 
Valsartan 50 - 4000 y = 0.006x + 0.125 0.992 ± 0.001 50 
 
5.2.3 Accuracy and precision 
The accuracy and precision of the developed microsampling based LC-HRMS method 
were determined by intra and inter-day replicate analyses of six spiked 903 sampling 
paper and VAMS quality control (QC) samples containing the selected target analytes 
at the low, medium and high concentration levels on three separate days. Accuracy 
was expressed as the mean relative error (RE %) and precision was expressed as the 
coefficient of variation (CV %) and data obtained for both were within the predefined 
15% limit for all concentrations in each run for all the target drugs with reference to 
FDA and EU guidelines. The overall variation in data between runs was also ≤15% for 
all target drugs on 903 sampling paper and VAMS and thus met international guideline 









Table 5. 2 (a) Intra and inter-day accuracy and precision data for the eleven target cardiovascular 
drugs in 903 sampling paper extracts (n = 6 at all concentration levels). 
        Coefficient of variation (%) 






Intra day Inter day 
Amlodipine 1 0.94 -5.53 8.91 6.94 
 
25 23.48 -6.07 13.55 7.83 
 
100 103.24 3.24 8.99 1.54 
Atenolol 50 51.87 3.73 4.00 1.37 
 
500 498.02 -0.40 4.14 1.36 
 
1500 1517.51 1.17 2.22 1.24 
Atorvastatin 1 1.05 5.43 4.06 5.93 
 
25 25.23 0.91 7.54 2.45 
 
100 100.69 0.69 7.19 2.41 
Bisoprolol 1 1.09 9.09 2.63 3.50 
 
25 25.54 2.15 6.10 4.14 
 
100 102.42 2.42 3.21 2.76 
Diltiazem 5 5.29 5.80 5.95 0.83 
 
100 98.64 -1.36 6.41 1.06 
 
600 611.85 1.97 2.03 1.49 
Doxazosin 1 1.07 7.38 9.23 1.03 
 
25 25.59 2.36 3.74 3.58 
 
100 99.24 -0.76 3.89 2.78 
Lisinopril 1 1.04 4.26 9.14 1.37 
 
25 24.91 -0.37 6.55 1.89 
 
100 100.31 0.31 6.61 2.19 
Losartan 25 25.25 1.02 3.08 0.54 
 
250 248.57 -0.57 5.03 0.59 
 
1000 1014.66 1.47 5.99 1.62 
Ramipril 1 1.01 1.23 4.29 2.60 
 
25 25.23 0.92 6.17 2.92 
 
100 101.76 1.76 4.60 3.28 
Simvastatin 1 1.06 5.71 10.01 6.81 
 
25 25.13 0.51 6.43 0.86 
 
100 99.85 -0.15 3.98 2.11 
Valsartan 250 242.75 -2.90 3.71 1.44 
 
2000 2078.29 3.91 3.32 3.44 






Table 5.2 (b) Intra and inter-day accuracy and precision data for the eleven target cardiovascular drugs 
in VAMS extracts (n = 6 at all concentration levels). 
        Coefficient of variation (%) 




Accuracy (RE)% Intra day Inter day 
Amlodipine 1 1.08 7.33 8.06 13.45 
 
25 27.47 3.02 9.90 3.68 
 
100 101.14 2.51 1.14 12.09 
Atenolol 50 51.58 3.16 1.71 2.07 
 500 499.02 -0.20 6.04 0.97 
 1500 1518.72 1.25 2.99 1.71 
Atorvastatin 1 1.05 5.41 7.16 3.56 
 25 25.18 0.70 4.31 1.99 
 100 101.27 1.27 5.96 0.27 
Bisoprolol 1 1.06 5.94 5.98 4.73 
 25 25.20 0.81 7.93 1.73 
 100 100.43 0.43 4.71 1.16 
Diltiazem 5 5.16 3.15 4.22 2.54 
 100 100.26 0.26 6.87 1.40 
 600 603.52 0.59 2.59 0.42 
Doxazosin 1 1.04 3.51 4.10 1.30 
 25 25.77 2.03 7.68 0.93 
 100 100.79 2.51 7.06 1.81 
Lisinopril 1 1.06 4.49 5.66 2.53 
 25 25.16 0.63 9.18 1.75 
 100 100.32 0.32 7.82 0.75 
Losartan 25 25.75 2.98 3.84 1.76 
 250 250.13 0.05 4.13 2.16 
 1000 1013.88 1.39 9.88 0.48 
Ramipril 1 1.04 4,44 8.18 3.03 
 25 25.37 1.47 6.38 4.46 
 100 99.35 -0.65 3.72 0.67 
Simvastatin 1 1.05 5.18 7.28 0.97 
 25 25.15 0.59 6.25 1.30 
 100 99.84 -0.16 5.16 0.22 
Valsartan 250 250.34 0.14 5.27 1.19 
 2000 1971.85 -1.41 3.05 1.55 






5.2.4 Matrix effects 
The effect of matrix due to constituents from the blood, as well as from within the 903 
sampling paper and VAMS material may cause ionisation competition between 
analytes of interest and co-eluents (Tang and Kebarle, 1993). This was evaluated to 
ensure that the sensitivity and precision of the developed LC-HRMS assay was not 
compromised on either 903 sampling paper or VAMS. To assess the effect of matrix, 
blood samples were collected from three different sources. Replicate (n = 6) samples 
of the selected target analytes spiked in blank blood spot extracts from 903 sampling 
paper and VAMS to represent the low, medium and high concentrations were 
prepared. The prepared samples were compared with standards of equal 
concentration spiked into methanol/water (40:60, v/v) containing 0.1% formic acid for 
atenolol, atorvastatin, bisoprolol, diltiazem, doxazosin, lisinopril, losartan, ramipril, 
simvastatin and valsartan. For amlodipine, the prepared samples were compared with 
standards of equal concentration spiked into acetonitrile/water (40:60, v/v) containing 
0.1% formic acid. The matrix effect was calculated using equation 5.2.  
Matrix Effects = ( 
𝐵
𝐴 
− 1)  𝑋 100            Equation 5.2 
Where A represents the ratio of the target analyte/IS response from analyte spiked 
into pure solvent and B represents the ratio of target analyte/IS response from analyte 
spiked into extracted blank whole blood. The matrix effect data obtained for each 
target analyte investigated at the low, medium and high concentration levels of the 
calibration curve is presented in Table 5.3a and 5.3b for 903 sampling paper and VAMS 
respectively. No significant (<10%) matrix effects on the analyte signal due to 
endogenous components of blood or the sampling material was observed at the three 
tested concentrations of each target drug. These results demonstrate the robustness 
of the extraction procedure and the ionisation mechanism for these target analytes. 
However, comparing the results for 903 sampling paper and VAMS, it is noteworthy 
that the mean matrix effect data for lisinopril and simvastatin were significantly low on 
VAMS compared to 903 sampling paper (Tables 5.3a and 5.3b). The observed 
difference may be attributed to the constituents within the 903 sampling paper 
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causing ionisation competition with lisinopril and simvastatin at the ESI source of the 
MS. 
Table 5.3 (a) Matrix effect results obtained for the eleven target drugs studied at the low, medium 
and high concentration levels on 903 sampling paper. n = 6 for each concentration. 
Drug Nominal conc. (ng/ml) Matrix effect % (mean) Precision (CV%) 
Amlodipine 1 -3.32 5.66 
 25 -3.25 6.13 
 100 -1.99 4.41 
Atenolol 50 -1.94 5.59 
 500 0.84 2.03 
 1500 -1.86 1.72 
Atorvastatin 1 2.41 1.65 
 25 1.25 1.93 
 100 1.95 1.29 
Bisoprolol 1 -1.39 2.17 
 25 0.41 2.73 
 100 0.67 0.98 
Diltiazem 5 1.43 2.75 
 100 0.06 3.03 
 600 1.49 1.33 
Doxazosin 1 0.60 2.76 
 25 0.73 1.69 
 100 -0.85 2.01 
Lisinopril 1 8.91 4.55 
 25 5.99 1.60 
 100 2.54 2.33 
Losartan 25 0.94 1.72 
 250 2.07 1.51 
 1000 0.51 0.93 
Ramipril 1 0.35 2.86 
 25 0.54 2.94 
 100 1.98 0.34 
Simvastatin 1 7.01 6.23 
 25 -3.62 5.43 
 100 -4.56 5.68 
Valsartan 250 -1.12 2.71 
 2000 -1.70 2.97 





Table 5.3 (b) Matrix effect results obtained for the eleven target drugs studied at the low, medium 
and high concentration levels on VAMS. n = 6 for each concentration. 
Drug Nominal conc. (ng/ml) Matrix effect % (mean) Precision (CV%) 


















































Valsartan 250 -1.17 5.87 
 2000 
1.01 0.02 






5.2.5 Recovery of the 11 target analytes from 903 sampling paper and 
VAMS 
Recovery (extraction efficiency) was determined using replicate (n = 6) samples 
prepared at the (low, medium and high) concentrations for the eleven target drugs 
from spiked 903 sampling paper and VAMS extracts. Recovery was assessed by 
comparing the ratios of analyte to IS response from 903 sampling paper and VAMS 
extracts with those obtained from blank blood spot extracts spiked with solution 
standards of equal concentration. Recovery was calculated using equation 5.3:  
Percentage Recovery =  (
𝐵
𝐴 
)  𝑋 100       Equation 5.3, where B is analyte to IS response 
of 903 card or VAMS extract and A is analyte to IS response of post extraction blank 
903 card or VAMS spiked extract. Recoveries for atenolol, atorvastatin, bisoprolol, 
diltiazem, doxazosin, lisinopril, losartan and ramipril on 903 sampling paper and VAMS 
were consistent, with values between 77 and 103%. The high recoveries observed 
indicate analyte stability under the extraction conditions applied and good extraction. 
The overall mean recovery for amlodipine was 68% and 62% on 903 sampling paper 
and VAMS respectively and simvastatin was 67% on both. In contrast with previously 
published results, Lawson et al (2013) reported mean recoveries of 43% for simvastatin 
in dried blood spot extracts. Thus, simvastatin shows a significant increase in recovery 
(~35%) with the developed LC-HRMS assay. The observed difference is attributed to 
the robust extraction procedure developed for the extraction of the target drugs from 
DBS and VAMS samples. Compared to the extraction protocol documented by Lawson 
et al (2013) which used an extraction solvent volume of 150µl (Chapter 4, Table 4.9), 
the current extraction procedure uses - (a) a larger volume of extraction solvent 
(300µl) which ensures optimum extraction of simvastatin from DBS, (b) – it also include 
a dry down step which involves the concentration of extracted supernatant and 
subsequent reconstitution. This procedure produces cleaner extracts with less 
interference which reduces matrix effects and improve recovery. Valsartan is the only 
analyte that did not give comparable recoveries on the two sampling methods. A high 
extraction recovery of 95% was observed on 903 sampling paper, but on VAMS overall 
mean recovery was 47%. Possible reason for the difference may be poor extraction of 
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valsartan from the VAMS substrate. Recovery data for each target analyte at the low, 
medium and high concentration levels on 903 sampling paper and VAMS are 
summarised in Tables 5.4a and 5.4b. 
Table 5.4 (a) Recovery data for the 11 target drugs extracted from 903 sampling paper at the low, 
medium and high concentration levels (n = 6). 
Drug Nominal conc. (ng/ml) Recovery (%) Standard Deviation (SD) Precision (CV) 
Amlodipine 1 65.94 8.21 12.44 
 25 74.71 5.48 7.34 
 500 65.35 3.85 5.89 
Atenolol 50 89.13 6.53 7.32 
 500 82.54 7.60 9.21 
 1500 93.16 3.69 3.96 
Atorvastatin 1 101.09 10.24 10.13 
 25 95.43 7.25 7.60 
 100 99.76 1.64 1.64 
Bisoprolol 1 101.65 11.34 11.16 
 25 99.19 5.68 5.73 
 100 89.53 5.52 6.16 
Diltiazem 5 98.08 12.42 12.67 
 100 88.92 4.24 4.77 
 600 85.05 1.80 2.11 
Doxazosin 1 97.86 7.07 7.23 
 25 97.37 5.00 5.14 
 100 94.89 6.19 6.52 
Lisinopril 1 87.43 9.08 9.32 
 25 90.51 7.88 8.71 
 100 85.39 4.65 6.17 
Losartan 25 97.34 4.03 4.14 
 250 94.27 10.25 10.88 
 1000 87.1 4.61 5.30 
Ramipril 1 97.08 7.15 7.37 
 25 89.94 5.38 5.98 
 100 92.96 3.36 3.62 
Simvastatin 1 67.88 4.26 6.28 
 25 64.74 5.97 9.22 
 100 70.81 3.96 5.59 
Valsartan 250 100.66 3.44 3.41 
 2000 97.35 2.29 2.35 
 4000 88.67 9.11 10.28 
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Table 5.4 (b) Recovery data for the 11 target drugs extracted from VAMS at the low, medium and high 
concentration levels (n = 6). 
Drug Nominal conc. (ng/ml) Recovery (%) Standard Deviation (SD) Precision (CV) 
Amlodipine 1 57.33 3.83 10.17 
 25 
62.18 1.88 6.87 
 100 
66.42 4.25 8.99 
Atenolol 50 103.31 6.36 5.61 
 500 
106.17 2.65 2.34 
 1500 
98.95 1.26 1.28 
Atorvastatin 1 101.01 12.79 9.27 
 25 
95.61 10.91 8.69 
 100 
91.64 4.85 5.29 
Bisoprolol 1 88.41 6.82 6.29 
 25 
86.58 4.92 7.17 
 100 
88.02 0.81 1.39 
Diltiazem 5 78.69 4.75 3.43 
 100 
82.50 7.30 13.90 
 600 
74.50 0.29 0.38 
Doxazosin 1 89.66 2.28 2.26 
 25 
92.37 4.03 4.36 
 100 
86.64 3.03 4.83 
Lisinopril 1 88.71 11.97 13.40 
 25 
84.16 11.33 9.92 
 100 
91.66 9.43 9.46 
Losartan 25 93.78 6.23 6.64 
 250 
101.06 6.21 6.14 
 1000 
96.63 2.18 2.85 
Ramipril 1 88.25 4.40 4.98 
 25 
90.25 7.74 7.50 
 100 
83.52 3.53 4.23 
Simvastatin 1 62.87 13.18 8.09 
 25 
71.95 6.06 8.42 
 100 
66.94 1.91 2.85 
Valsartan 250 39.89 5.80 3.82 
 2000 
53.02 3.68 1.47 






5.2.6 Blood spot size investigation on 903 sampling paper 
This investigation was conducted to demonstrate that after selection of a disc size for 
analyses, the quantitative results obtained were not affected by the volume of blood 
deposited or the size of the blood spot presuming there is uniformity in the spread of 
the spot on filter paper. This experiment was not applicable to the VAMS device since 
it samples a fixed 10µl volume of blood. To investigate the blood volume effect on the 
quantification of the eleven target analytes, replicate analyses (n = 6) were performed 
at medium and high concentrations for the target drugs using prepared 20, 30 and 40 
µl blood spots. These spots had different diameters of approximately 7.2mm, 9.5mm 
and 12.0mm respectively, directly proportional to sample volume deposited. 8mm 
discs (approximately 20 µl of blood) were punched from the centre of the already 
prepared 20, 30 and 40 µl volume DBS standards. Extraction of the target drugs was 
performed using the procedure described in Chapter 4, section 4.5 prior to LC-HRMS 
analyses. Using a linear regression equation obtained from a calibration generated 
with 30 µl volume DBS, the analyte concentration of the extracts was determined.  
Method precision and accuracy were assessed using extraction data from an 8 mm 
discs, sampled from the centre of the 20, 30 and 40 µl volume DBS prepared at the 
medium and high concentration levels for the eleven target analytes. Table 5.5 shows 
the intra-day precision and accuracy of the method evaluated using 6 determinations 
for each concentration level. Results obtained for accuracy and precision were less 
than 15% and therefore met international guideline criteria. These experiments were 
performed to demonstrate that results obtained were not dependent on the size of 
the blood spot collected. Analysing a fixed sample size disc should produce extract 
data which is directly proportional to the concentration of the target analyte in the 
original blood sample. The results in Table 5.5 affirm that within experimental error for 





Table 5.5 Impact of dried blood spot size on accuracy and precision of assay at the medium and high 
concentrations for each target drug (n = 6). 
Amlodpine concentration in 
whole blood (ng/ml) 
DBS volume 
(µl) 
Mean concentration found 





25 40 24.87 ± 1.38 0.53 5.56 
 30 25.59 ± 1.61 2.35 6.29 
 20 25.99 ± 0.72 3.97 2.77 
     
100 40 103.59 ± 5.76 3.59 5.56 
 30 100.50 ± 4.59 0.50 4.57 
 20 103.04 ± 3.00 3.04 9.71 
     
Atenolol concentration in 
whole blood (ng/ml) 
DBS volume 
(µl) 
Mean concentration found 





500 40 523.84 ± 9.03 4.77 1.72 
 30 489.10 ± 19.27 2.18 3.94 
 20 494.26 ± 17.82 1.15 3.61 
     
1500 40 1492.36 ± 29.02 0.51 8.65 
 30 1456.05 ± 12.75 2.93 0.88 
 20 1590.79 ± 16.73 6.05 1.05 
     
Atorvastatin concentration in 
whole blood (ng/ml) 
DBS volume 
(µl) 
Mean concentration found 





25 40 24.33 ± 2.25 2.26 9.24 
 30 24.55 ± 2.06 1.81 8.39 
 20 24.80 ± 3.11 0.79 12.54 
     
100 40 100.94 ± 3.90 0.94 3.86 
 30 98.32 ± 2.83 1.68 2.88 
 20 100.35 ± 2.75 0.35 2.74 
     
Bisoprolol concentration in 
whole blood (ng/ml) 
DBS volume 
(µl) 
Mean concentration found 





25 40 25.41 ± 2.62 1.65 10.33 
 30 22.96 ± 0.71 8.17 3.07 
 20 25.25 ± 1.07 0.99 4.22 
     
100 40 99.93 ± 1.41 0.07 1.42 
 30 101.52 ± 7.10 1.52 6.99 
 20 105.27 ± 2.95 5.27 2.8 
     
Diltiazem concentration in 
whole blood (ng/ml) 
DBS volume 
(µl) 
Mean concentration found 





100 40 92.51 ± 5.40 7.49 5.84 
 30 93.18 ± 6.23 6.82 6.69 
 20 91.70 ± 5.59 8.3 6.1 
     
600 40 595.19 ± 14.09 0.8 5.73 
 30 590.04 ± 10.84 1.66 1.84 




Table 5.5 continued 
Doxazosin concentration in 
whole blood (ng/ml) 
DBS volume 
(µl) 
Mean concentration found 





25 40 25.37 ± 1.19 1.46 4.68 
 30 26.26 ± 0.96 5.03 3.64 
 20 25.71 ± 1.04 2.83 4.05 
     
100 40 100.77 ± 5.74 0.77 5.69 
 30 98.96 ± 2.17 1.04 2.2 
 20 103.19 ± 1.69 3.19 1.63 
     
Lisinopril concentration in 
whole blood (ng/ml) 
DBS volume 
(µl) 
Mean concentration found 





25 40 24.01 ± 1.02 3.96 4.27 
 30 26.47 ± 2.39 5.87 9.04 
 20 25.81 ± 2.18 3.25 8.44 
     
100 40 102.00 ± 7.91 2.00 7.75 
 30 100.21 ± 5.04 0.21 5.03 
 20 107.93 ± 3.41 7.93 3.16 
     




Mean concentration found 





250 40 251.40 ± 3.90 0.56 1.55 
 30 251.87 ± 2.51 0.75 1.00 
 20 250.16 ± 6.41 0.07 2.56 
     
1000 40 1012.38 ± 43.75 1.24 4.32 
 30 987.23 ± 20.32 1.28 2.06 
 20 1017.71 ± 14.84 1.77 1.46 
     




Mean concentration found 





25 40 24.80 ± 1.06 0.81 4.26 
 30 25.84 ± 0.95 3.36 3.69 
 20 24.67 ± 0.82 1.33 3.31 
     
100 40 101.18 ± 4.86 1.18 4.81 
 30 99.59 ± 1.09 0.41 1.10 
 20 102.95 ± 2.18 2.95 2.12 
     
Simvastatin concentration in 
whole blood (ng/ml) 
DBS volume 
(µl) 
Mean concentration found 





25 40 25.46 ± 1.77 1.82 6.95 
 30 25.57 ± 0.88 2.27 3.44 
 20 25.14 ± 0.54 0.58 2.16 
     
100 40 105.55 ± 6.18 5.55 5.86 
 30 100.84 ± 3.11 0.84 3.08 




Table 5.5 continued 
Valsartan concentration in 
whole blood (ng/ml) 
DBS volume 
(µl) 
Mean concentration found 





2000 40 1942.50 ± 17.02 2.87 0.88 
 30 1943.26 ± 11.80 2.84 0.61 
 20 1988.18 ± 33.18 0.59 4.18 
     
4000 40 4038.38 ± 77.57 0.96 1.92 
 30 4075.53 ± 83.71 1.89 2.05 
 20 4149.79 ± 26.93 3.74 0.65 
 
5.2.7 Evaluation of the effects of different hematocrit levels on data 
from 903 sampling paper and VAMS 
The hematocrit (Hct) level represents the relative volume of red blood cells (RBC) in 
blood. It has a direct effect on the viscosity of blood, which in turn affects the spread 
of blood on cellulose based paper and the level of drug absorbed into the red blood 
cells (Denniff and Spooner, 2010, De Vries et al., 2013). Blood with high Hct (due to the 
high cellular composition) is more viscous and leads to the formation of small spots on 
DBS cards. The Hct range varies according to age for healthy adult males and females. 
It is 40 – 54% and 36 – 48% respectively (Walker et al., 1990). Hct values may however 
deviate from these ranges in certain disease states e.g. anaemia and polycythaemia. 
An Hct value of 45% was chosen to represent the average value expected in the target 
population planned for this study. The bias caused by the hematocrit variability of the 
DBS sample has been considered a critical parameter affecting quantitative DBS 
analyses (O’mara et al 2011; Fan et al 2012). This has led to the development of novel 
devices like VAMS, which is reported to be independent of the hematocrit effect 
(Spooner et al 2015; De Kesel et al 2015; Mano et al 2015). Hence the influence of 
hematocrit on assay performance was evaluated at the low, medium and high 
concentrations of each target drug (n = 6) using 30µl spots on 903 sampling paper and 
10µl volume for VAMS device with an adjusted Hct of 35, 45 and 55% to cover the 
range for the target population.  
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5.2.7.1 Comparison of the effects of different Hct levels on the results 
obtained from spiked blood samples extracted from 903 paper and VAMS 
Blank human whole blood was centrifuged at 10,000g for 12 minutes (Koster et al., 
2015; Hettich Laboratory Limited, determination of the hematocrit value by 
centrifugation, 2016). The plasma generated was transferred into a clean 
microcentrifuge tube. The RBC suspension and plasma were mixed in proportions 
(35:65, v/v), (45:55, v/v) and (55:45, v/v) to give whole blood with an adjusted Hct of 
35, 45 and 55% respectively. These were used to prepare calibration samples on 903 
sampling paper and VAMS device for the eleven target analytes at the blank, low, 
medium and high concentration ranges. 30µl of each prepared standard were spotted 
on 903 sampling paper and allowed to dry for 3 hours. 8mm disc were punched from 
the centre of each spot and extracted using the procedure described in Chapter 4, 
section 4.5. In the case of VAMS, 10µl of each prepared standard were sampled on the 
polymeric tip of the device, dried and extracted using the procedure as described in 
Chapter 4, section 4.5.  
Concentrations of extracts were determined using a linear regression equation 
generated from calibration data produced from standards prepared with the 45% Hct 
on 903 sampling paper and VAMS. For the samples prepared on 903 sampling paper, a 
decrease in size of spots formed was observed with increasing Hct value across the 
range of 35% to 55% investigated. The results from the hematocrit investigation are 
shown in Tables 5.6a and 5.6b. Results from the VAMS device, gave accuracy (RE%) 
and precision (CV%) values within the pre-defined limit of ≤ 15% (De Vries et al., 2013) 
at all hematocrit levels for each tested analyte concentration. Results for 903 sampling 
paper shows only one marginal increase over the 15% limit at 15.3% for atorvastatin at 
the 35% Hct level. Possibly, because a punched sample on 903 sampling paper was 
used.  For 903 sampling paper, data from the 35% and 55% Hct levels show significant 
differences, that is negative values at the 35% Hct level and positive values for the 55% 
Hct levels as expected. For VAMS the differences are much reduced as expected. This 
demonstrates that quantitative analytical data collected on the VAMS device will not 
be affected by interindividual variability in hematocrit values for the hematocrit range 
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investigated for the 11 target drugs. In contrast with VAMS, results from the 903 
sampling paper indicates that at extreme hematocrit values, hematocrit effects may be 
significant on 903 sampling paper for the target drugs investigated, when a punched 
sample is used due to interindividual variation which may affect the quantitative 
results. However, taking into consideration the patient population used for this 
research, there is no evidence that heart disease affects a patient’s blood hematocrit 
level. Thus, the overall results demonstrate the acceptability of the developed 
microsampling based LC-HRMS method for quantitative analyses of CVD drugs. The 
results also demonstrate the robustness of the extraction procedure, as different 


















Table 5.6 (a) Influence of Hematocrit on the accuracy (RE %) of analyte quantification for 903 sampling 
paper presented as the difference from the analyte/internal standard peak area ratio at the 45% Hct 
level. Precision (CV %) values for each tested concentration are shown in brackets (n = 6). 
    Hematocrit 
Drug 
Nominal conc. 
(ng/ml) 35% 45% 55% 
Amlodipine 1 -3.8% (9.4%) Normalised (6.2%) 4.1% (8.9%) 
 25 3.6% (5.1%) Normalised (8.8%) 2.2% (4.9%) 
 100 -9.5% (4.3%) Normalised (3.0%) 11.8% (10.6%) 
Atenolol 50 -7.4% (4.1%) Normalized (5.9%) 8.8% (3.5%) 
 500 -7.6% (1.5%) Normalized (2.6%) 14.5% (5.0%) 
 1500 -8.4% (3.6%) Normalized (1.9%) 6.4% (2.1%) 
Atorvastatin 1 -4.1% (6.04) Normalised (10.1%) 4.0% (12.8%) 
 25 -15.3% (2.67) Normalised (6.6%) 12.5% (7.7%) 
 100 -14.6% (3.65) Normalised (3.0%) 2.2% (2.6%) 
Bisoprolol 1 -10.2% (9.2%) Normalised (5.1%) 11.2% (10.5%) 
 25 -12.4% (4.6%) Normalised (15.1%) 13.8% (5.5%) 
 100 -14.4% (7.3%) Normalised (7.0%) 7.9% (4.7%) 
Diltiazem 5 -9.4% (6.3%) Normalised (10.1%) 13.1% (5.5%) 
 100 -7.1% (10.6%) Normalised (6.6%) 13.9% (2.8%) 
 600 -12.3% (2.4%) Normalised (3.0%) 10.5% (1.5%) 
Doxazosin 1 -14.1% (5.2) Normalised (10.3%) 3.1% (7.8%) 
 25 -3.02% (4.6%) Normalised (3.9%) 2.8% (2.1%) 
 100 -7.9% (4.2) Normalised (5.5%) 5.7% (3.3%) 
Lisinopril 1 -10.7% (10.3%) Normalised (10.1%) 8.5% (6.1%) 
 25 -12.8% (4.7%) Normalised (6.6%) 3.4% (8.7%) 
 100 -6.6% (10.5%) Normalised (3.0%) 10.3% (10.1%) 
Losartan 25 -14.3% (7.02%) Normalised (5.0%) 7.14% (6.6%) 
 250 -9.8% (2.2%) Normalised (7.9%) 10.9% (6.0%) 
 1000 -9.34% (5.6%) Normalised (6.1%) 2.7% (1.9%) 
Ramipril 1 -10.6% (14.2%) Normalised (6.1%) 12.8% (7.8%) 
 25 -10.1% (4.1%) Normalised (5.9%) 7.2% (6.2%) 
 100 -9.1% (1.7%) Normalised (6.2%) 1.4% (1.37%) 
Simvastatin 1 1.5% (12.3%) Normalised (10.1%) 8.4% (3.8%) 
 25 -13.3% (6.0) Normalised (6.6%) 11.5% (7.4%) 
 100 -3.1% (2.9%) Normalised (3.0%) 9.5% (8.9%) 
Valsartan 250 -11.5% (5.5%) Normalised (1.6%) 5.4% (8.21%) 
 2000 -7.6% (7.2%) Normalised (8.2%) 13.6% (11.53%) 






Table 5.6 (b) Influence of Hematocrit on the accuracy (RE %) of analyte quantification for VAMS 
presented as the difference from the analyte/internal standard peak area ratio at the 45% Hct level. 
Precision (CV %) values for each tested concentration are shown in brackets (n = 6). 
    Hematocrit 
Drug Nominal conc. (ng/ml) 35% 45% 55% 
Amlodipine 1 -3.47% (9.77%) Normalised (7.27%) 3.21% (9.59%) 
 25 -5.29% (5.65%) Normalised (12.24%) -2.48% (4.53%) 
 100 2.41% (7.36%) Normalised (4.83%) 2.89% (5.42%) 
Atenolol 50 -6.52% (4.03) Normalized (7.15%) -5.80 (4.13) 
 500 5.19% (4.27) Normalized (4.38%) 5.10 (3.15) 
 1500 -1.13 (8.45) Normalized (4.72%) -2.19 (4.74) 
Atorvastatin 1 -0.72% (12.22%) Normalised (12.04%) 5.82% (9.17%) 
 25 0.08% (5.99%) Normalised (6.35%) 0.74% (4.83%) 
 100 -3.66% (7.58%) Normalised (7.66%) -4.83% (6.46%) 
Bisoprolol 1 -5.26% (6.4%) Normalised (12.44%) 2.01% (4.3%) 
 25 0.32% (5.2%) Normalised (3.12%) -0.68% (2.2%) 
 100 -1.14% (2.8%) Normalised (3.28%) -0.40% (2.7%) 
Diltiazem 5 2.43% (0.17%) Normalised (0.05%) -0.06% (4.85%) 
 100 -1.06% (0.01%) Normalised (0.01%) 0.87% (0.62%) 
 600 0.16% (0.03%) Normalised (0.02%) -0.16% (2.62%) 
Doxazosin 1 -3.08% (6.3%) Normalised (12.44%) -3.81% (4.40%) 
 25 2.43% (7.53%) Normalised (3.12%) -4.69% (4.84%) 
 100 -0.23% (1.14%) Normalised (3.28%) -0.20% (3.15%) 
Lisinopril 1 -0.93% (10.03%) Normalised (13.44%) 2.93% (13.60%) 
 25 4.35% (10.17%) Normalised (3.37%) 3.65% (8.45%) 
 100 -5.90% (9.32%) Normalised (4.64%) -0.95% (3.89%) 
Losartan 25 -1.42% (0.09%) Normalised (5.69%) -0.43% (8.53%) 
 250 4.20% (0.05%) Normalised (6.11%) 2.91% (3.07%) 
 1000 -1.85% (0.02%) Normalised (0.97%) -1.63% (1.72%) 
Ramipril 1 1.84% (3.16%) Normalised (2.15%) -3.60% (4.82%) 
 25 3.22% (8.05%) Normalised (9.7%) 2.00% (6.2%) 
 100 0.21% (1.83%) Normalised (2.38%) -0.55% (1.82%) 
Simvastatin 1 1.13% (3.68%) Normalised (8.16%) -0.21% (9.89%) 
 25 5.03% (6.08) Normalised (3.7%) -2.70% (6.6%) 
 100 -2.42% (2.9%) Normalised (3.2%) -5.70% (4.6%) 
Valsartan 250 -1.45% (2.28%) Normalised (1.15%) -1.05% (2.07%) 
 2000 -0.52% (3.37%) Normalised (3.48%) -2.81% (3.08%) 





5.2.8 Stability of dried blood samples on 903 sampling paper and VAMS 
The stability of dried blood samples after 10 weeks of storage at room temperature in 
903 sampling paper and 8 weeks of storage in VAMS was assessed to demonstrate the 
possibility to collect 903 card and VAMS samples in batches. This was done by the 
replicate analyses (n = 6) of blood samples on 903 sampling paper and VAMS 
containing amlodipine, atenolol, atorvastatin, bisoprolol, diltiazem, doxazosin, 
lisinopril, losartan, ramipril, simvastatin and valsartan at the low, medium and high 
concentrations. Using the extraction procedure described in Chapter 4, (section 4.5.1 
and 4.5.2), 8mm diameter discs were punched from the 903 sampling paper calibration 
standards at the low, medium and high concentrations of the 11 target drugs and 
analysed. For VAMS the whole sample was used for extraction. No significant changes 
in concentrations were observed after 10 weeks of storage in 903 paper and 8 weeks 
of storage in VAMS at the low, medium and high concentration levels of target drugs 
as shown in Table 5.7a and 5.7b. These results demonstrate that for spiked samples 
the eleven target drugs are stable in 903 sampling paper for 10 weeks and in VAMS for 
8 weeks when stored at room temperature. Studies in this laboratory have shown 
similar stability for atenolol, bisoprolol, simvastatin and valsartan in ‘real’ DBS samples 
from volunteers (Lawson et al., 2013). It also affirms the feasibility of using dried 
microsampling methodology in resource limited areas. This is because samples may 
have to be collected in remote areas of the country and will take several days or even 










Table 5.7 (a) Accuracy, precision and quantification of 903 sampling paper assay at the low, medium 
and high concentrations for each target drug after 10 weeks of storage at room temperature (n = 6). 
Drug Concentration in whole 
blood (ng/ml) 
Mean concentration 




Amlodipine 1 0.99 ± 0.05 6.43 7.59  
25 25.21 ± 1.12 4.43 6.28  
100 99.01 ± 4.36 -2.10 3.76 
Atenolol 50 59.90 ± 2.58 12.06 1.11 
 500 464.47 ± 23.96 -2.52 2.58 
 1500 1572.70 ± 39.71 4.69 0.85 
Atorvastatin 1 1.10 ± 0.08 1.34 11.69 
 25 27.64 ± 1.70 0.17 8.34 
 100 91.51 ± 7.86 -1.58 2.10 
Bisoprolol 1 1.19 ± 0.13 4.77 9.57 
 25 24.21 ± 3.07 -2.13 2.68 
 100 101.01 ± 5.86 4.50 5.74 
Diltiazem 5 4.70 ± 0.70 4.51 4.68 
 100 109.97 ± 2.40 1.93 5.64 
 600 631.98 ± 40.77 -3.95 2.64 
Doxazosin 1 1.11 ± 0.07 10.74 6.68 
 25 27.93 ± 1.46 3.47 5.52 
 100 100.45 ± 2.86 0.50 0.61 
Lisinopril 1 1.13 ± 0.10 13.00 9.01 
 25 29.13 ± 2.38 3.46 6.71 
 100 106.95 ± 5.34 -2.06 4.21 
Losartan 25 23.90 ± 2.50 4.40 7.93 
 250 259.25 ± 21.64 -0.47 2.85 
 1000 1111.52 ± 33.24 1.66 0.91 
Ramipril 1 1.12 ± 0.12 12.41 3.66 
 25 21.33 ± 6.12 5.12 2.09 
 100 94.96 ± 8.62 2.28 3.13 
Simvastatin 1 1.20 ± 0.11 4.30 5.45 
 25 23.62 ± 1.69 -0.89 3.00 
 100 95.28 ± 9.53 -1.09 2.70 
Valsartan 250 242.62 ± 24.98 -0.85 6.47 
 2000 1972.39 ± 81.47 7.35 8.62 







Table 5.7 (b) Accuracy, precision and quantification of VAMS assay at the low, medium and high 
concentrations for each target drug after 8 weeks of storage at room temperature (n = 6). 
Drug Concentration in whole 
blood (ng/ml) 
Mean concentration 




Amlodipine 1 1.05 ± 0.09 4.89 8.17  
25 25.67 ± 2.85 2.69 11.09  
100 100.17 ± 11.29 0.17 11.27 
Atenolol 50 55.71 ± 2.34 11.42 4.21 
 500 523.31 ± 46.34 4.66 8.85 
 1500 1516.29 ± 82.00 1.09 5.41 
Atorvastatin 1 1.11 ± 0.06 11.13 5.35 
 25 25.71 ± 2.18 2.83 8.49 
 100 102.24 ± 13.62 2.24 13.32 
Bisoprolol 1 1.10 ± 0.14 10.25 12.78 
 25 25.55 ± 1.18 2.22 4.61 
 100 97.26 ± 5.07 -2.74 5.21 
Diltiazem 5 5.05 ± 0.52 1.03 10.32 
 100 100.76 ± 8.33 0.76 8.27 
 600 627.81 ± 49.60 4.63 7.90 
Doxazosin 1 1.11 ± 0.11 10.78 10.11 
 25 25.43 ± 3.49 1.73 13.72 
 100 98.63 ± 11.48 -1.37 11.64 
Lisinopril 1 0.99 ± 0.06 -1.01 6.41 
 25 27.05 ± 3.66 8.19 13.55 
 100 107.65 ± 10.07 7.65 9.36 
Losartan 25 26.37 ± 2.82 5.48 10.70 
 250 254.55 ± 22.11 1.82 8.69 
 1000 977.61 ± 49.09 -2.24 12.18 
Ramipril 1 1.08 ± 0.13 8.14 12.09 
 25 24.07 ± 2.27 -3.70 9.44 
 100 98.16 ± 10.37 -1.84 10.57 
Simvastatin 1 1.08 ± 0.10 7.96 9.35 
 25 25.35 ± 1.82 1.39 7.19 
 100 94.20 ± 7.30 -5.80 7.75 
Valsartan 250 253.57 ± 30.06 1.43 11.86 
 2000 1921.63 ± 19.91 -3.92 1.04 







5.2.9 Correlation studies between 903 sampling paper and VAMS 
extracts for the eleven target drugs 
These studies were performed to get a feel of the relationship between analyte 
concentration from calibration samples prepared on 903 sampling paper and VAMS 
device. In the correlation studies, the ratios of analyte to internal standard 
concentrations of calibration standards (n = 6) for each target analyte on 903 sampling 
paper and VAMS device run on three separate days were compared by simple linear 
regression (Figure 5.3 (a) – (k)). 
 
Figure 5.3 (a) Correlation plot of amlodipine calibration standards obtained by analysis of extracts 
from 903 sampling paper (x) and VAMS device (y).  
 







































Figure 5.3 (b) Correlation plot of atenolol calibration standards obtained by analysis of extracts from 
903 sampling paper (x) and VAMS device (y).  
 
 
Figure 5.3 (c) Correlation plot of atorvastatin calibration standards obtained by analysis of extracts 
from 903 sampling paper (x) and VAMS device (y).  
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Figure 5.3 (d) Correlation plot of bisoprolol calibration standards obtained by analysis of extracts from 
903 sampling paper (x) and VAMS device (y).  
 
 
Figure 5.3 (e) Correlation plot of diltiazem calibration standards obtained by analysis of extracts from 
903 sampling paper (x) and VAMS device (y).  
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Figure 5.3 (f) Correlation plot of doxazosin calibration standards obtained by analysis of extracts from 
903 sampling paper (x) and VAMS device (y).  
 
 
Figure 5.3 (g) Correlation plot of lisinopril calibration standards obtained by analysis of extracts from 
903 sampling paper (x) and VAMS device (y).  
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Figure 5.3 (h) Correlation plot of losartan calibration standards obtained by analysis of extracts from 
903 sampling paper (x) and VAMS device (y).  
 
 
Figure 5.3 (i) Correlation plot of ramipril calibration standards obtained by analysis of extracts from 
903 sampling paper (x) and VAMS device (y).  
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Figure 5.3 (j) Correlation plot of simvastatin calibration standards obtained by analysis of extracts 
from 903 sampling paper (x) and VAMS device (y).  
 
 
Figure 5.3 (k) Correlation plot of valsartan calibration standards obtained by analysis of extracts from 
903 sampling paper (x) and VAMS device (y).  
 
The linear regression equations from calibration standards (n = 6) run over three 
different days on 903 sampling paper and VAMS device showed good correlations 
between the ratios of analyte to internal standard response for all the CVD drugs 
(Figure 5.3 (a) – (k)).  The correlation coefficient for the target drugs are: amlodipine R2 
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= 0.998; atenolol R2 = 0.997; atorvastatin R2 = 0.993; bisoprolol R2 = 0.999; diltiazem R2 
= 0.995; doxazosin R2 = 0.998; lisinopril R2 = 0.997; losartan R2 = 0.998; ramipril R2 = 
0.994; simvastatin R2 = 0.996; valsartan R2 = 0.990. Correlations were assessed by 
calculating a linear regression line with 95% confidence intervals. The linear regression 
equations for 903 sampling paper extracts and VAMS extracts obtained in the 
correlation study (x = 903 sampling paper extracts, y = VAMS extracts) are shown in 
(Figure 5.3 (a) – (k)). 
The results demonstrate that there is less variability in the ratio of analyte to I.S 
response data obtained by the analyses of the target cardiovascular drugs on 903 
sampling paper and VAMS device. 
5.3 Conclusion 
Validation of the bioanalytical assay was successful on both the 903 sampling paper 
and VAMS device. Results for the various validation parameters demonstrated 
accuracy and precision values within acceptable range, except the hematocrit 
investigation. Results from the hematocrit investigation confirms that VAMS is 
independent of the Hct for all the investigated analytes. In contrast, results from 903 
sampling paper shows that at extreme Hct values outside the normal range of 40 – 
54% and 36 – 48% for healthy adult males and females, the volumetric hematocrit 
effect may be significant when a punch is used. Correlation analysis between 903 
sampling paper and VAMS calibration standard extracts show that there is less 
variability in ratio of analyte to internal standard concentrations obtained by the two 
microsampling methods for the CVD drugs investigated.  This indicates that both 
methods of microsampling can generate reliable quantitation data for the selected 
cardiovascular drugs studied in dried blood microsamples.  
The overall validation results indicate that the developed assay was suitable for trials 
with volunteers. Thus, the validated bioanalytical method was applied to the 
quantification of the selected cardiovascular drugs in volunteer and patient dried 
blood samples collected on 903 sampling paper and VAMS. 
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Chapter 6 Application of validated LC-HRMS method for 
the analyses of volunteer blood samples collected on 
Whatman 903 cards and VAMS for the assessment of 
adherence to CVD prescription medication 
 
This chapter discusses the application of the developed and validated 903 card and 
volumetric absorptive microsampling (VAMS) microsampling based LC-HRMS assay for 
the assessment of adherence to CVD prescription medication. 903 card and VAMS 
blood samples collected from two groups of participants (heart disease volunteers) in 
the UK and Iraq, prescribed with one or more of the CVD drugs: amlodipine, atenolol, 
atorvastatin, bisoprolol, diltiazem, doxazosin, lisinopril, losartan, ramipril, simvastatin 
and valsartan were analysed with the developed LC-HRMS assay. The results of the 
analyses are also presented.   
6.1 Introduction 
Following method validation, application of the bioanalytical assay to clinical samples 
is key to demonstrate that the method can determine cardiovascular drug levels in 
volunteer samples. The two methods of microsampling (903 cards and VAMS) used for 
the validation of the developed assay in Chapter 5 were used for volunteer blood 
sample collection. It is however noteworthy that validation samples are fixed 
permanent “invitro” samples, which do not change over time and will therefore show 
less variability in results from the two microsampling methods as demonstrated by the 
correlation between 903 card and VAMS extracts from calibration standards in Chapter 
5, section 5.2.9. However, this correlation may not remain constant for 903 card and 
VAMS extracts measured in volunteer samples. The reason being that volunteer 
samples are “invivo” samples, which is constantly changing due to metabolism of the 
drugs in the body. Hence sampling time delay between the collection of microvolume 
blood samples by a volunteer on 903 card and VAMs could influence this correlation. 
The volunteer samples were collected from two groups of participants (a) Heart 
disease volunteer samples from De Montfort University-UK referred to in this thesis as 
DMU samples and (b) Heart disease volunteer samples from the Al Sader Teaching 
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Hospital and the Misan Cardiac Centre, Iraq herein referred to as Iraq samples. The 
study has received ethical approval from the De Montfort University Research Ethics 
Committee. The inclusion criteria for volunteer selection was to include any volunteer 
prescribed with oral cardiovascular medication with or without other medications. As 
well as, volunteers who were not taking any medication at all to serve as control. The 
exclusion criteria was to exclude volunteers who were not on any prescribed 
cardiovascular medication. Using the power law for sample size calculation, with an 
85% confidence level, the minimum number of volunteers required was 40. 
6.2 Volunteer selection, DMU sample collection and storage on 
Whatman 903 cards and VAMS 
One group of healthy volunteers prescribed with one or more of the selected target 
drugs were recruited from within De Montfort University staff. A dedicated webpage 
(DMU, 2016) about the research and its impact was created on the University’s 
website to increase awareness of the study and to help recruit participants. Volunteers 
were issued with a participant information leaflet (PIL) (Appendix 2) to read prior to 
attending the sample collection in the laboratory. The PIL explained the purpose of the 
study, how participants will be involved and the contact details of the researchers in 
case of further questions. A consent form and mini questionnaire were then 
completed on arrival of the volunteer at laboratory (HB00.15) to confirm voluntary 
participation. The mini questionnaire was used to capture information on a 
participant’s prescribed medicines, dosage, frequency of intake and approximate time 
since taking last doses in hours.   
Self-collected volunteer blood samples were collected on the Whatman 903 cards and 
VAMS device by following the protocol documented in the participant information 
leaflet (Appendix 2). A series of blank control 903 card and VAMS samples were taken 
from some volunteers not prescribed any of the target drugs and used as control. 
Collected 903 card and VAMS samples were labelled in line with the ethics protocol 
and dried for at least 3 hours at room temperature before packing in sealed bags for 
secure storage in a locked cabinet. 
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6.3 Patient selection, Iraq sample collection and storage on 
Whatman 903 cards and VAMS 
Cardiovascular disease patients attending a routine clinical follow-up at Al Sader 
Teaching Hospital and the Misan Cardiac Centre, Iraq were recruited for participation 
in the study. The PIL, consent form and mini questionnaire were translated into Arabic 
(Appendix 3) to help the patients understand the purpose of the study since English 
was not a first language. Each patient completed a consent form to confirm they 
understood the reason for the study and voluntarily agreed to participate before 
samples were collected. A mini questionnaire was also completed to collect 
information on a participant’s prescribed medicines, dosage, frequency of intake and 
approximate time since taking last doses in hours. Since patients were attending 
routine follow up appointments, they had no prior knowledge of the research study 
until they attended the clinic. Both groups of study participants (volunteers in UK and 
patients in Iraq) were all prescribed with one or more of the target drugs amlodipine, 
atenolol, atorvastatin, bisoprolol, diltiazem, doxazosin, lisinopril, losartan, ramipril, 
simvastatin and valsartan.  
Patient blood samples were organised and collected from the Al Sader Teaching 
Hospital and the Misan Cardiac Centre, Iraq by another PhD student of the DBS 
Analysis research group in De Montfort University – UK by name Ahmed Alalaqi. A 
series of blank control 903 card and VAMS samples were taken from a second group of 
volunteers not prescribed any of the target drugs and used as control. The spot sizes 
were sufficient to allow the use of an 8mm punch on 903 sampling paper without 
compromising the DBS sample, samples of smaller spot sizes were rejected. For VAMS, 
the whole sample was used for extraction. The quality of the volunteer samples 
collected on 903 cards and VAMS were assessed. Eight spots on 903 cards were 
rejected for quantification because the blood sample was not sufficient to allow the 




6.3.1 Volunteer feedback on self-sample collection 
903 cards require sufficient blood to be deposited within marked circles on the card. 
This made sampling difficult for some volunteers, as they had to produce sufficient 
blood from the lanced finger and direct the blood drop unto the card. In contrast, 
VAMS device is designed to wick the blood drop from the finger until the substrate is 
full seemingly making it easier to sample. Feedback on the ease of use of the two 
microsampling methods (Whatman 903 cards and VAMS) for blood sample collection 
was collected from DMU volunteer participants. Volunteer feedback centred on their 
experience on self-sampling with the two microsampling methods. Particularly 
concerning the ease of use of both the (903 card and VAMS) for blood sample 
collection. The feedback shows that self-sampled DBS or VAMS are a good alternative 
to venepuncture to use for the TDM of CVD drugs. Table 6.1 summarises the feedback 
on device usage received from volunteers who participated in the study. 
Table 6.1 Summary of feedback provided by DMU volunteers on the ease of use of the two 
microsampling methods. 
903 sampling paper VAMS 
 Difficult to drop the blood on the 
marked circles. 
 Last spot was small in size as bleeding 
stopped after the third spot. 
 Could not see the marked circles 
when dropping the spot on the card 
because I had to use the other hand 
to assist. 
 Spot dropped on the card before, 
finger could be directed unto the 
circle. 
 Took more time to sample on card 
 Will require assistance with card 
sampling. 
 Will take several practices to get 
samples in the marked circles. 
 Had to direct my finger to the marked 
circles, which was quite difficult to do. 
 Had to prick another finger to sample 
on card because did not bleed well. 
 A bit complex compared to VAMS. 
 
 Sampling is easy as the device 
sucks the blood off the fingertip. 
 All four samplers were easily filled 
due to the small size of the tip 
 Prefer VAMS to card sampling, 
because it is so easy to use. 
 See VAMS as a very easy to use 
platform. 
 Was very quick self-sampling on 
VAMS. 
 Can easily do sampling on VAMS 
without assistance. 
 Will be willing to give sample 
again as it is easy. 
 Very easy to sample, no need to 
turn or direct finger after pricking. 
 Did not bleed well and could still 
fill the VAMS substrates. 




6.4 Analyses of DMU samples collected on 903 card and VAMS by 
LC-HRMS 
Acceptable samples on 903 card and VAMS were solvent extracted for analyses using 
the procedure described in section 4.5 of Chapter 4 to infer their adherence to 
prescription medication. The validated 903 sampling paper and VAMS based LC-HRMS 
method in Chapter 5 was successfully used for the identification and quantification of 
the target cardiovascular drugs in 240 Whatman 903 card and VAMS samples obtained 
from 41 volunteers. No false positive signals (Table 6.2) were detected from 903 card 
and VAMS samples from volunteers receiving no medication. The measured 903 card 
and VAMS drug concentrations obtained from DMU samples are presented in Table 
6.2. The eclectic Cmax data from the literature for the individual drugs has also been 
included in Table 6.2 to provide reference values against which volunteer data can be 
compared. Values similar to, but lower than, the Cmax concentration depending on 
the time the dose was taken would be anticipated from volunteers who are adherent 
to prescribed medication. Likewise, absence of the drug in the volunteer’s blood 
sample will indicate nonadherence. On this basis, the data in Table 6.2 would suggest 
that concern might be raised over the results from: 
 volunteer 18 - where atenolol was detected but there was no detectable 
simvastatin  
 volunteer 19 – no detectable ramipril signal 










Table 6.2 903 sampling paper and VAMS concentrations of the studied cardiovascular drugs in DMU  
samples from volunteers prescribed with one or more of the CVD drugs investigated. 
Sampling 
Device 






903 1 M Bisoprolol 2mg 4 41.78 ± 1.99 37 - 87 
VAMS 
  
Bisoprolol 2mg 4 38.36 ± 2.55   
903 
  
Doxazosin 4mg 4 32.74 ± 1.04 18 - 48 
VAMS 
  
Doxazosin 4mg 4 37.12 ± 4.38   
903 
  
Valsartan 160mg 4 493.72 ± 8.78 879 - 3874 
VAMS 
  
Valsartan 160mg 4 503.11 ± 5.12   
  
     
  
903 2 M Atorvastatin 10mg 11 8.88 ± 0.99 3.2 -10.5 
VAMS 
  
Atorvastatin 10mg 11 9.22 ± 1.49   
903 
  
Losartan 50mg 11 28.95 ± 1.93 89 - 306 
VAMS 
  
Losartan 50mg 11 26.34 ± 2.08   
  
     
  
903 3 F Losartan 75mg 22 20.60 ± 5.65 263 - 783 
VAMS 
  
Losartan 75mg 22 16.84 ± 3.92   
  
     
  
903 4 F Simvastatin 20mg 13 2.90 ± 0.77 5.1 - 40.1 
VAMS 
  
Simvastatin 20mg 13 2.81 ± 0.30   
  
     
  
903 5 F Ramipril 1.25mg 5 3.11 ± 0.37 11.1 - 31.1 
VAMS 
  
Ramipril 1.25mg 5 2.77 ± 0.24   
  
     
  
903 6 F Losartan 100mg 5.5 11.60 ± 1.51 469 - 1131 
  
     
  
903 7 M Losartan 5mg  7 6.25 ± 3.41 89 -306 
  
     
  
903 8 M Atorvastatin (lowest) 16 6.11 ± 2.21 3.2 -10.5 
VAMS 
  
Atorvastatin (lowest) 16 4.98 ± 2.61   
  
     
  
903 9 F Atorvastatin 20mg 17 6.77 ± 3.84 5.0 -20.5 
VAMS 
  
Atorvastatin 20mg 17 5.14 ± 2.20   
  
     
  
903 10 M Ramipril 5mg 15 5.22 ± 0.31 11.1 - 31.1 
VAMS 
  
Ramipril 5mg 15 7.41±1.20   
903 
  
Simvastatin 20mg 15 1.79±0.74 5.1 - 40.1 
VAMS 
  
Simvastatin 20mg 15 1.44±1.19   
  
     
  
903 11 M Atorvastatin 10mg 14 5.21±1.99 3.2 -10.5 
  
     
  
903 12 M Bisoprolol 2mg 4 34.32±12.87 37 - 87 
VAMS 
  
Bisoprolol 2mg 4 32.93±1.96   
903 
  
Doxazosin 4mg 4 32.40±2.13 18 - 48 
VAMS 
  
Doxazosin 4mg 4 37.21±3.58   
903 
  
Valsartan 160 mg 4 407.16±14.73 879 - 3874 
VAMS     Valsartan 160 mg 4 412.31±11.68 
 




Table 6.2 continued 
Sampling 
Device 
N Sex CVD Drug Time after 




903 13 M Simvastatin 11 0.85±0.55 5.1 - 40.1 
VAMS 
  
Simvastatin 11 0.69±0.77   
903 
  
Ramipril 10mg 2.5 9.37±1.04 11.1 - 31.1 
VAMS 
  
Ramipril 10mg 2.5 8.09±0.99   
  
     
  
903 14 F Amlodipine 5mg 5 4.85±2.0 5.1 - 7.1 
VAMS 
  
Amlodipine 5mg 5 5.16±2.14   
  
     
  
903 15 M Amlodipine 5mg 7 4.61±0.58 5.1 - 7.1 
VAMS 
  
Amlodipine 5mg 7 4.37±1.98   
  
     
  
903 16 F Atorvastatin 10mg 17 2.86±1.72 3.2 -10.5 
VAMS 
  
Atorvastatin 10mg 17 2.02±0.93   
903 
  
Losartan 100mg 7 65.48±3.72 469 - 1131 
VAMS 
  
Losartan 100mg 7 58.18±4.23   
  
     
  
903 17 F Amlodipine 5mg 6 3.33±2.19 5.1 - 7.1 
VAMS 
  
Amlodipine 5mg 6 3.86±1.74   
903 
  
Losartan 100mg 6 74.76±8.03 469 - 1131 
VAMS 
  
Losartan 100mg 6 81.55±5.13   
  
     
  
903 18 M Atenolol 50mg 6 456.01±23.20 240 - 1370 
VAMS 
  
Atenolol 50mg 6 498.15±15.94   
903 
  
Simvastatin 40mg 6 ˂LOQ 5.1 - 40.1 
VAMS 
  
Simvastatin 40mg 6 ˂LOQ   
  
     
  
903 19 F Ramipril 10mg 18 ˂LOQ 11.1 - 31.1 
VAMS 
  
Ramipril 10mg 18 ˂LOQ   
  
     
  
903 20 M Amlodipine 5mg 2 4.09±3.19 5.1 - 7.1 
VAMS 
  
Amlodipine 5mg 2 3.86±1.78   
  
     
  
903 21 F Atorvastatin 20mg 14 14.01±2.39 5.0 -20.5 
VAMS 
  
Atorvastatin 20mg 14 10.88±2.37   
903 
  
Bisoprolol 5mg 3 23.58±1.94 37 - 87 
VAMS 
  
Bisoprolol 5mg 3 21.88±7.27   
  
     
  





29.59±5.31   
  
     
  
903 23 M Amlodipine 10mg 4 8.24±2.00 11.7 - 14.1 
VAMS 
  
Amlodipine 10mg 4 7.99±3.18   
903 
  
Ramipril 10mg 4 5.29±0.84 11.1 - 31.1 
VAMS 
  
Ramipril 10mg 4 4.26±0.69   
903 
  
Simvastatin 20mg 10 1.32±0.42 5.1 - 40.1 




Table 6.2 continued 
Sampling 
Device 





903 24 F Amlodipine 5mg 2.5 5.11±1.34 5.1 - 7.1 
VAMS 
  
Amlodipine 5mg 2.5 4.49±2.33   
903 
  
Ramipril 5mg 2.5 5.63±0.54 11.1 - 31.1 
VAMS 
  
Ramipril 5mg 2.5 4.82±0.39   
  
     
  





˂LOQ   
903 
  
Lisinopril 2.5mg 3.5 8.02±3.68 50 - 88 
VAMS 
  
Lisinopril 2.5mg 3.5 7.94±1.35   
  
     
  
903 26 F Amlodipine 10mg 12 5.49±1.56 11.7 - 14.1 
903 
  
Losartan 12.5mg 12 37.57±2.54 43.6 - 125.4 
  
     
  
903 27 M Amlodipine 5mg 4 6.85±1.77 5.1 - 7.1 
  
     
  
903 28 F Bisoprolol 1.25mg 0.3 9.28±0.55 17 - 87 
  
     
  
903 29 F Ramipril 10mg 4 hrs 7.03±0.39 11.1 - 31.1 
VAMS 
  
Ramipril 10mg 4 hrs 7.68±2.47   
  
     
  
903 30 F Ramipril 2.5 mg 3 hrs 6.49±0.96 <11.1 - 31.1 
VAMS 
 
F Ramipril 2.5 mg 3 hrs 6.99±0.46   
  
     
  
903 31 F Atorvastatin 40mg 15 18.36±7.20 >5.0 -20.5 
VAMS 
 
F Atorvastatin 40mg 15 13.62±4.75   
903 
 
F Bisoprolol 5mg 8 24.46±5.70 37 - 87 
VAMS 
 
F Bisoprolol 5mg 8 28.26±3.05   
  
     
  
903 32-36 F None - Control N/A ˂LOQ   
VAMS 32-36 
 
None - Control 
 
˂LOQ   
903 37-41 M None - Control N/A ˂LOQ   
VAMS 37-41   None - Control   ˂LOQ   
 
Data from volunteer 18 raised concern initially because, information from the 
completed mini questionnaire by the volunteer revealed, both drugs were stated to 
have been taken at the same time whereas simvastatin should be taken in the evening. 
It may be that the patient was distracted and took two atenolol tablets rather than one 
of each tablet. This would lead to a measured atenolol levels corresponding to a 
100mg dose as actually observed by the correlation between the measured 
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concentrations in DBS and VAMS and the Cmax data for a 100mg dose (Wu et al., 
2003). Non-detectable simvastatin suggests that the patient was nonadherent bearing 
in mind that volunteers 4, 10 and 23 took simvastatin at a lower dose of 20mg and was 
still detected after 10 hours. Data from volunteer 19 showed no detectable level of 
ramipril, the prescribed drug but, according to the information provided on the mini 
questionnaire, the sample was collected 18 hours after the dose was taken. Since the 
LC-HRMS system operates in the full scan mode, the data was revisited to look for the 
metabolite of the drug (ramiprilat) at m/z 389.2071, but ramiprilat was also not 
detected. In this case the dose was 10mg and as can be seen for volunteer 10, 
prescribed a 5mg dose, levels of ramipril were detected 15 hours after taking a dose. 
This would suggest that volunteer 19 was not adherent to the treatment. It should be 
noted that pharmacogenetics effects may impact individual rate of drug metabolism 
leading to unexpected changes in drug levels in the blood (Joseph et al., 2014). 
Cambien et al (1994) demonstrated a significant link between angiotensin converting 
enzyme (ACE) gene insertion/deletion (I/D) polymorphism and cardiovascular 
outcomes. However, the impact of this genetic polymorphism on ACE inhibitor 
response is not well understood. When asked about the data obtained volunteer 25 
freely admitted not taking atorvastatin tablets for several days and was clearly 
nonadherent to the prescribed medication. The reason cited was adverse effects due 
to muscle pain and joint swelling. These results clearly indicate areas where a clinician 
would be unaware of an adverse clinical condition which they would be able to rectify 
to improve the individual’s healthcare. This also demonstrates the robustness of the 
developed microsampling based LC-HRMS method.  
The validated assay in Chapter 5 was also successfully used for the identification and 
quantification of the selected cardiovascular drugs in 552 VAMS and 903 card Iraq 
samples collected from 100 patients (Table 6.3). The expected drug(s) were detected 
for adherent patient samples after analysis. In cases where patient was prescribed 
with more than one class of medication, the assay correctly identified if the patient 
was not adherent to any of the medication. The assay also identified all medications 
for adherent patients taking more than one drug.  
159 
 
Table 6.3 903 card and VAMS concentrations of the studied cardiovascular drugs in Iraq samples from 
patients prescribed with one or more of the CVD drugs investigated. 
Sampling 
device 
N CVD Drug Time after Oral 
intake (h) 
Concentration   
(ng/ml) (±sd)  
Cmax (ng/ml) 
903 1 Lisinopril 20mg 3 32.87±5.80 86.4 - 139 
        
903 2 Simvastatin 20mg 10 <LOQ 5.0 - 40.0 
        
903 3 Atenolol 50mg 36 <LOQ 240 - 1370 
VAMS  Atenolol 50mg 36 <LOQ   
        
903 4 Bisoprolol 10mg 48 <LOQ 29 - 87 
        
903 5 Valsartan 80mg 240 <LOQ 1010 - 2270 
VAMS  Valsartan 80mg 240 <LOQ   
        
903 6 Valsartan 160mg 5 200.57±13.66 1930 - 4000 
        
903 7 Atenolol 100mg 5 204.87±2.09 590 - 1370 
VAMS  Atenolol 100mg 5 188.22±5.29   
        
903 8 Bisoprolol 5mg 10 11.28±0.69 29 - 87 
VAMS  Bisoprolol 5mg 10 12.87±0.75   
        
903 9 Valsartan 160mg 12 135.80±3.35 1930 - 4000 
        
903 10 Atorvastatin 20mg 48 <LOQ 3.2 - 10.6 
VAMS  Atorvastatin 20mg 48 <LOQ   
903  Valsartan 40mg 12 147.34±2.42 535 - 1151 
VAMS  Valsartan 40mg 12 160.21±5.11   
        
903 11 Bisoprolol 2.5mg 22 0.45±0.27 17.3 - 43.0 
VAMS  Bisoprolol 2.5mg 22 0.34±0.14   
        
903 12 Simvastatin 20mg 12 <LOQ 5.0 - 40.0 
        
903 13 Diltiazem 90mg 72 <LOQ 105.7 - 150.9 
VAMS  Diltiazem 90mg 72 <LOQ   
        
903 14 Atenolol 50mg 9 200.11±7.75 240 - 1370 
        
903 15 Valsartan 80mg 4 131.49±0.88 1010 - 2270 
VAMS 15 Valsartan 80mg 4 126.45±2.62   
        
903 16 Losartan 25mg 10.5 19.04±3.66 43.6 - 125.4 




 Table 6.3 continued 
Sampling 
device 
N CVD Drug Time after Oral 
intake (h) 
Concentration   
(ng/ml) (±sd)  
Cmax (ng/ml) 
903 17 Losartan 100mg 13 112.30±1.60 469 - 1131 
VAMS 17 Losartan 100mg 13 103.38±9.08   
903 17 Bisoprolol 5mg 13 75.96±3.12 29 - 87 
VAMS 17 Bisoprolol 5mg 13 77.05±0.98   
        
903 18 Bisoprolol 2.5mg 3 42.60±4.82 17.3 - 43.0 
  18 Valsartan 80mg 3 277.13±22.27 1010 - 2270 
        
903 19 Valsartan 80mg 20 92.58±0.32 1010 - 2270 
VAMS 19 Valsartan 80mg 20 86.09±0.88   
  
    
  
903 20 Lisinopril 10mg 8 54.65±5.92 41.8 - 80.5 
VAMS 20 Lisinopril 10mg 8 48.69±3.30   
        
903 21 Losartan 50mg 48 <LOQ 89 - 306 
VAMS 21 Losartan 50mg 48 <LOQ   
        
903 22 Atenolol 50mg 26 211.04±21.64 240 - 1370 
        
903 23 Bisoprolol 5mg 3 5.74±0.70 29 - 87 
VAMS 23 Bisoprolol 5mg 3 6.03±0.25   
903 23 Valsartan 160mg 32 <LOQ 1930 - 4000 
VAMS 23 Valsartan 160mg 32 <LOQ   
        
903 24 Atenolol 50mg 27 86.11±2.05 240 - 1370 
VAMS 24 Atenolol 50mg 27 79.18±4.61   
        
903 25 Bisoprolol 5mg 15 11.90±0.67 29.0 - 87.0 
  25 Losartan 50mg 15 <LOQ 89 - 306 
        
903 26 Atenolol 50mg 20 142.91±5.77 240 - 1370 
VAMS 26 Atenolol 50mg 20 137.53±2.21   
        
903 27 Losartan 50mg 51 <LOQ 89.0 - 306.0 
        
903 28 Atenolol 50mg 3.5 149.25±18.26 240 - 1370 
VAMS 28 Atenolol 50mg 3.5 163.38±6.10   
        
903 29 Bisoprolol 5mg 21 5.13±0.20 29 - 87 
VAMS 29 Bisoprolol 5mg 21 4.14±1.40   
903 29 Valsartan 80mg 36 <LOQ 1010 - 2270 
VAMS 29 Valsartan 80mg 36 <LOQ   
        





 Table 6.3 continued 
Sampling 
device 
N CVD Drug Time after Oral 
intake (h) 
Concentration   
(ng/ml) (±sd)  
Cmax (ng/ml) 
903 31 Atenolol 100mg 10 706.98±20.46 590 -1370 
        
903 32 Atenolol 50mg 8 81.89±0.69 240 - 1370 
VAMS 32 Atenolol 50mg 8 68.62±1.66   
        
903 33 Atenolol 100mg 13 248.30±9.12 590 - 1370 
VAMS 33 Atenolol 100mg 13 254.16±5.37   
        
903 34 Atorvastatin 20mg 12 <LOQ 3.2 - 10.6 
  34 Losartan 100mg 2 47.80±4.98 269 - 783 
        
903 35 Atorvastatin 40mg 12.5 <LOQ 5.0 - 20.5 
  35 Lisinopril 20mg 23.5 <LOQ 86.4 - 139 
        
903 36 Bisoprolol 5mg 2.5 14.86±1.30 29 - 87 
  36 Lisinopril 5mg 2.5 33.33±6.55 <41.8 - 80.5 
  
    
  
903 37 Atenolol 25mg 15 94.17±8.36 <159 - 377 
  37 Atorvastatin 20mg 15 <LLOQ 3.2 - 10.6 
  37 Ramipril 5mg 15 3.75±0.22 9.3 - 20.8 
  
    
  
903 38 Atorvastatin 20mg 76 <LOQ 3.2 - 10.6 
VAMS 38 Atorvastatin 20mg 76 <LOQ   
903 38 Bisoprolol 5mg 76 <LOQ 29 - 87 
VAMS 38 Bisoprolol 5mg 76 <LOQ   
        
903 39 Diltiazem 90mg 38 <LOQ 105.7 - 150.9 
        
903 40 Diltiazem 60mg 1 25.17±0.57 21.9 - 86.7 
VAMS 40 Diltiazem 60mg 1 29.51±2.20   
903 40 Losartan 50mg 13 <LOQ 89.1 - 306.1 
VAMS 40 Losartan 50mg 13 <LOQ   
903 40 Valsartan 160mg 72 <LOQ 1930 - 4000 
VAMS 40 Valsartan 160mg 72 <LOQ   
        
903 41 Atorvastatin 80mg 48 <LOQ 5.0 - 20.5 
VAMS 41 Atorvastatin 80mg 48 <LOQ   
        
903 42 Atorvastatin 20mg 20.5 <LOQ 3.2 - 10.6 
  42 Lisinopril 5mg 11 30.93±10.79 <41.8 - 80.5 
        
903 43 Diltiazem 60mg 7.5 38.22±2.58 21.9 - 86.7 
        
903 44 Lisinopril 10mg 13 38.61±6.16 41.8 - 80.5 





 Table 6.3 continued 
Sampling 
device 
N CVD Drug Time after Oral 
intake (h) 
Concentration   
(ng/ml) (±sd)  
Cmax (ng/ml) 
903 45 Atenolol 100mg 10 346.61±13.05 590 - 1370 
VAMS 45 Atenolol 100mg 10 327.42±31.64  
        
903 46 Valsartan 80mg 11 115.93±2.12 1010 - 2270 
VAMS 46 Valsartan 80mg 11 121.04±2.46   
        
903 47 Losartan 50mg 8 37.66±5.23 89.1 - 306.1 
VAMS 47 Losartan 50mg 8 43.22±4.62   
        
903 48 Atorvastatin 40mg 12 14.04±1.28 5.0 - 20.5 
VAMS 48 Atorvastatin 40mg 12 15.33±0.59   
903 48 Bisoprolol 5mg 2 42.72±3.15 29 - 87 
VAMS 48 Bisoprolol 5mg 2 37.20±1.90   
        
903 49 Atorvastatin 20mg 32 <LOQ 3.2 - 10.6 
903 49 Diltiazem 60mg 8.5 51.1±1.94 21.9 - 86.7 
903 49 Valsartan 160mg 22.5 <LOQ 1930 - 4000 
        
903 50 Valsartan 80mg 7.5 81.81±2.54 1010 - 2270 
VAMS 50 Valsartan 80mg 7.5 90.16±3.27  
        
903 51 Valsartan 80mg 11 82.85±6.15 1010 - 2270 
VAMS 51 Valsartan 80mg 11 78.24±4.48   
  
    
  
903 52 Atorvastatin 20mg 21.5 <LOQ 3.2 - 10.6 
VAMS 52 Atorvastatin 20mg 21.5 <LOQ   
  
    
  
903 53 Diltiazem 90mg 11 87.26±6.9 105.7 - 150.9 
VAMS 53 Diltiazem 90mg 11 79.1±11.5   
  
    
  
903 54 Lisinopril 10mg 10 33.30±6.57 41.8 - 80.5 
VAMS 54 Lisinopril 10mg 10 36.90±3.51   
        
903 55 Valsartan 160mg 6 225.22±8.74 1930 - 4000 
VAMS 55 Valsartan 160mg 6 206.57±6.53   
        
903 56 Valsartan 160mg 26 <LOQ 1930 - 4000 
VAMS 56 Valsartan 160mg 26 <LOQ   
        
903 57 Atorvastatin 20mg 13 8.78±0.64 3.2 - 10.6 
        
903 58 Valsartan 160mg 3.5 224.80±10.49 1930 - 4000 
VAMS 58 Valsartan 160mg 3.5 231.15±6.36   
        
903 59 Diltiazem 60mg 18 8.86.7±0.34 21.9 - 86.7 




Table 6.3 continued 
Sampling 
device 
N CVD Drug Time after Oral 
intake (h) 
Concentration   
(ng/ml) (±sd)  
Cmax (ng/ml) 
903 60 Bisoprolol 5mg 13 3.82±0.38 29 - 87 
        
903 61 Atorvastatin 20mg 25.5 <LOQ 3.2 - 10.6 
        
903 62 Valsartan 160mg 15.5 117.41±2.89 1930 - 4000 
VAMS 62 Valsartan 160mg 15.5 120.74±3.85   
        
903 63 Bisoprolol 5mg 19 1.87±0.62 29 - 87 
        
903 64 Bisoprolol 5mg 1 2.13±0.09 29 - 87 
VAMS 64 Bisoprolol 5mg 1 2.46±0.18   
903 64 Lisinopril 10mg 1 24.97±2.05 41.75 - 80.47 
VAMS 64 Lisinopril 10mg 1 28.23±2.13   
        
903 65 Lisinopril 5mg 10 45.86±2.87 <41.8 - 80.5 
        
903 66 Bisoprolol 5mg 48 <LOQ 29 - 87 
        
903 67 Bisoprolol 2.5mg 18 3.38±0.70 17 - 43 
        
VAMS 68 Atenolol 100mg 2 781.05±48.83 590 - 1370 
        
903 69 Bisoprolol 5mg 4.5 11.39±1.06 29 - 87 
VAMS 69 Bisoprolol 5mg 4.5 10.33±3.88   
903 69 Valsartan 160mg 15 <LOQ 1930 - 4000 
VAMS 69 Valsartan 160mg 15 <LOQ   
        
903 70 - 89 Controls N/A <LOQ   
VAMS 90 - 100 Controls N/A <LOQ   
 
In contrast with the data from DMU samples collected within the university staff (Table 
6.2) where three volunteers representing 10% were suspected to be nonadherent, 
data from Iraq samples revealed 39% were suspected to be nonadherent (Table 6.3). 
The stated drug(s) were not detectable in twenty-seven (27) measured 903 card or 
VAMS samples (Volunteers 2, 3, 4, 5, 10, 12, 13, 21, 23, 25, 27, 29, 33, 34, 35, 37, 38, 
39, 40, 41, 42, 49, 52, 56, 61, 66 and 69). Out of the patients who were suspected to be 
nonadherent, 63% had not taken their medication for more than 24 hours (Volunteers 
3, 4, 5, 10, 13, 21, 23, 27, 29, 38, 39, 40, 41, 49, 56, 61 and 66). The huge difference in 
nonadherence between the two groups of participants (DMU samples and Iraq 
samples) could be due to the fact that the Iraq patients had no prior knowledge that 
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microvolume blood samples will be taking on the day of clinic visit to assess 
cardiovascular drug levels. Whereas volunteers recruited within DMU university staff 
were made aware of blood sample collection prior to sampling. Hence there is less 
possibility for the situation where a dose is taken because a test is anticipated (white 
coat syndrome) within the Iraq group.  
Secondly, the cost of prescription treatment may be another factor likely to cause 
medication nonadherence in Iraq. Health care service in this part of the world is based 
on “cash and carry” where patients must pay for the service to see a doctor and 
afterwards pay for their treatment. Hence patients who cannot afford the medications 
will simply not buy them (Baroletti and Dell'Orfano, 2010; Baggarly et al., 2014). It is 
noteworthy that volunteers in the Iraq group had all seen a clinician on the day before 
giving a microvolume blood sample for analysis, yet some of them had still not taken 
either one or two of their medication. Figure 6.5 reveals that statins were the drugs 
with a high rate of nonadherence (83% for atorvastatin and 100% for simvastatin). 
Adverse effects may also be a factor for the high level of nonadherence in the Iraq 
group of volunteers. Cardiovascular disease patients are normally prescribed with 
medications from different therapeutic classes (complex regimen) (Anderson and 
Nawarskas, 2001). Combined therapy therefore increases the risk of adverse drug 
effects and drug interactions for cardiovascular disease patients. (Abolbashari et al., 
2017). This is because the drugs may belong to different therapeutic classes and may 
have different physicochemical properties. Thus, the use of such an objective method 
of indicating adherence could help stimulate dialog between patients and clinicians to 





Figure 6.1 Compares the rate of adherence to nonadherence among the Iraq volunteer group for each 
of the target drugs. 
 
The results obtained from the analyses of the two groups of volunteer samples show 
that monitoring of CVD drug concentrations in 903 card and VAMS samples is feasible 
and provides an objective means of inferring adherence to medication. The collected 
information will also be relevant to serve as the basis for clinical decision making. This 
will aid clinicians to personalise the treatment for each patient. This research has 
demonstrated the possible application of microsampling based LC-HRMS for TDM of 
CVD drugs in routine clinical settings. Such a convenient testing method will lead to 
improved adherence among CVD patients and allow for convenient self or at-home 
sampling so reducing required clinic visits. VAMS seems to be more promising than 
DBS in terms of ease of usage and most importantly overcomes issues like Hct bias and 
sample inhomogeneity. The only disadvantage of the VAMS microsampler is the 
relatively high cost compared to 903 cards. One VAMS sampler is about five times 
more expensive than a conventional DBS card which can collect five spots at a time. 
Hence cost may be a significant consideration for applicability in resource limited areas 
of the world (Kip et al., 2017). 
When the results of this investigation are compared with that of published work 
utilising LC-MS/MS to test for therapeutic adherence among cardiovascular patient’s in 
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2013; De Nicolo et al., 2016), the results obtained with the validated LC-HRMS assay 
demonstrates comparable sensitivity for the target drugs investigated. However, the 
novelty of applying blood microsampling methods over plasma/serum analysis in the 
TDM of cardiovascular drugs are: the uniqueness of self-use or “at home sampling” by 
the patient. This offers the convenience of assessment at any desired sampling time, 
which is otherwise not possible with plasma and serum sampling as the patient must 
travel to the clinic for blood sample to be taken.  Secondly, the minimally invasive 
sampling procedure by means of a finger prick offers high patient acceptability, 
compared to venepuncture, which is highly invasive when plasma or serum is used for 
analysis. Thirdly, the amount of blood sample (microvolume) needed for analyses 
(≤30µl) which makes it ideal for routine clinical testing, in contrast with (~5ml) of blood 
required at each sampling time for plasma and serum analyses. 
When the results of this investigation are compared with published work utilising urine 
analysis which only serve as a qualitative tool to assess medication adherence 
(Tomaszewski et al., 2014; Hamdidouche et al., 2015; Lawson et al., 2016; De Nicole et 
al., 2017, Hamdidouche et al., 2017), the results obtained with the validated LC-HRMS 
assay provides quantitative (confirmatory) data based on patient’s blood drug levels 
which will be more useful to a clinician from a treatment point of view. This is because 
blood drug concentration is related to the effectiveness of the treatment. Hence it will 
help the clinician to tailor the treatment to each patient based on their individual 
differences in drug metabolism. The novelty of applying blood microsampling methods 
over urine analyses in the TDM of cardiovascular drugs are: The ability to generate 
information on the drug levels in the patient’s blood, which is key to relate adherence 
to positive clinical outcomes. This is not possible when urine samples are used for 
analyses since the relationship between the time of ingestion, the dose taken, and the 
levels of drug in blood cannot be established. Secondly, quantitative blood 
concentration data provides vital information on drug levels for each patient enabling 
treatment to be tailored or personalised, which is not possible when urine samples are 
used. A major limitation of assessing medication adherence by direct methods is the 
white coat syndrome, where patients take the dose before clinic visits. This is reported 
167 
 
to be very common when urine samples are used for analysis (MacLaughlin et al., 
2005). However, the developed microsampling based LC-HRMS assay/approach to 
inferring adherence can identify the situation where a dose is taken because a test is 
anticipated. This is comparable to a single dose trial and the pharmacokinetics would 
lead to a rapid increase followed by a decrease in the drug concentration in the blood 
depending on the t1/2 of the drug, rather than a steady state situation (Chapter 1, 
Figure 1.1). Analyses of two 903 card or VAMS samples collected several hours apart, 
from the same volunteer, would clarify the situation. A drug concentration significantly 
less in the second sample would indicate that the dose was taken in anticipation of the 
test whereas a comparable level is indicative of a steady state because of adherence to 
prescription.  
Lastly, except for Hamdidouche et al (2017) who reported a total analysis time of 5 
minutes per sample, all the previously cited work on plasma and urine LC-MS/MS assay 
for the assessment of cardiovascular medication adherence reported, a total analysis 
time of between 10 to 48 minutes per sample. Such long analyses time makes these 
assays unfeasible to use in clinical and hospital settings since there may be numerous 
samples to run. In contrast, the microsampling based LC-HRMS assay has a run time of 
just 2.5 minutes making it feasible for high throughput robust screening in clinical and 
hospital settings. 
The main limitation of the developed microsampling based LC-HRMS assay in this 
study, is the requirement of a separate extraction procedure for amlodipine, which 
therefore means that four DBS or VAMS samples are required for the analyses of 
volunteer dried blood samples where volunteers are prescribed with amlodipine in 
addition to any of the other 10 (atenolol, atorvastatin, bisoprolol, diltiazem, doxazosin, 






Chapter 7 Innovations in microsampling methods  
 
This chapter gives an overview of the current new developments in blood 
microsampling methods introduced to resolve the problems of hematocrit (Hct) effect 
and volumetric inaccuracies observed when the traditional DBS card is used for blood 
sample collection followed by the analysis and quantification of therapeutic drugs in 
humans.  
7.1 Introduction 
Microsampling is the only sampling procedure with the possibility to make self-
sampling or “at home use” a reality in clinical diagnostics and other life science 
applications. However, the hurdles surrounding volumetric inaccuracies of blood 
sample from different individuals’ due to the Hct effect presented by using the 
conventional DBS card has hampered its acceptance in regulated bioanalysis. These 
hurdles have been overcome by the development of microsampling devices designed 
to resolve the challenges with conventional DBS card usage (Deniff and Spooner, 2014; 
Sturm et al., 2015; Verhaeghe et al., 2017). Examples of such devices are VAMS, 
Noviplex plasma preparation cards, Ahlstrom 167L cards, Hemaxis – DB blood 
collection device, Tomtec dry media spot slides and the HemaPen, which are discussed 
below. 
7.1.1 HemaSpot-HF device 
HemaSpot-HF device is an easy to use microsampler for blood sampling and robust 
storage/shipping of blood samples at ambient temperatures. HemaSpot-HF uses a 
finger stick to collect and dry blood within a secure cartridge. The sample can be safely 
and easily shipped to the laboratory for analysis. 
HemaSpot-HF device consists of a robust cartridge housing a fan shaped absorbent 
paper known as the HemaForm (Figure 7.1). The HemaForm consist of eight identical 
strips surrounded by a desiccant and covered with a rubber application surface that 
has a small opening to allow entry for blood. After lancing the finger, three drops of 
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blood are deposited onto the small opening, which allows the blood sample to be 
absorbed by the HemaForm. Collected samples on the HemaSpot-HF device is left for 
two minutes and then secured by the tamper resistant latches on the edge of the 
cartridge to prevent contamination. The device can be shipped immediately at 
ambient temperature to the laboratory because, the desiccant surrounding the 
HemaForm completes the drying of the sample making the secured cartridge moisture 
proof. This contrasts with a conventional DBS sampling where collected samples must 
be dried for at least two hours prior to shipping.  
The HemaSpot-HF device comes with a printed bar code on the cartridge which can be 
scanned or read by standard readers such as smart phones or laboratory scanners for 
sample identification and labelling. The secure cartridge is opened with a special tool 
at the laboratory and part of the HemaForm removed with tweezers for analysis. The 
remaining dried blood samples can be stored securely in the moisture-tight cartridge. 
Since the device does not sample accurate volumes, it is not known if the device is able 
to eliminate the analytical bias caused by the Hct (Henion et al., 2013). 
 





7.1.1.1 Comparison of ratios of analyte to internal standard response for the 
CVD drugs on the HemaSpot – HF device and 903 sampling paper 
The analytical performance of the HemaSpot – HF device was compared to the 
traditional 903 sampling paper by investigating the ratio of analyte to internal standard 
(IS) response for atenolol, atorvastatin, bisoprolol, diltiazem, doxazosin, lisinopril, 
losartan, ramipril, simvastatin and valsartan extracted from the HemaSpot – HF device 
and the 903 sampling paper as control. DBS calibration standards, were prepared at 
the low, medium and high concentration of each target drug using the protocol 
described in Chapter 4, section 4.3.2.  
7.1.1.2. Spotting of prepared blood standards on HemaSpot-HF device and 
903 sampling paper. 
3x30µl (90µl) volume of each of the prepared blood standards (blank, low, medium 
and high) were spotted through the sampling entrance in the clear transparent cover 
unto the applicator disk of the HemaSpot - HF Device. The blood was allowed to soak 
completely to the edges of the fan form. Blood standards were spotted on 903 
sampling paper as described by the protocol in Appendix 1. Samples were air dried for 
at least 3 hours at room temperature. The dried samples were stored in number or 
code labelled re-sealable polythene bags in a secure cabinet in Lab HB 00.15. 
7.1.1.3. Extraction of target analytes from the HemaSpot – HF device and 903 
sampling paper 
Two (2) fingers containing (~20µl) of blood sample were cut from the centre of the 
prepared HemaSpot-HF blood sample. For the prepared standards on 903 sampling 
paper, an 8mm disk (~20µl) was punched from the centre of the spot. Samples were 
transferred into a clean 1.5ml microcentrifuge tube and extracted using the procedure 
described in Chapter 4, section 4.5.1. Table 7.1 shows the ratio of analyte to internal 





Table 7.1 (a) – (j) The ratio of analyte to internal standard response for the HemaSpot-HF and 903 
sampling paper at the low, medium and high concentration levels of the 10 CVD drugs (n = 6). 
(a) Atenolol       
Nominal conc. (ng/ml) 50 500 1500 
Sampling method 903 paper HemaSpot 903 paper HemaSpot 903 paper HemaSpot 
Ratio of Analyte to I.S 0.42 0.38 3.18 2.75 6.99 6.27 
SD 0.02 0.02 0.23 0.18 0.43 1.24 
Precision (CV%) 3.94 5.16 4.40 3.10 2.39 6.46 
       
(b) Atorvastatin       
Nominal conc. (ng/ml) 1 25 100 
Sampling method 903 paper HemaSpot 903 paper HemaSpot 903 paper HemaSpot 
Ratio of Analyte to I.S 0.03 0.03 0.09 0.09 0.27 0.29 
SD 0.003 0.005 0.01 0.01 0.02 0.04 
Precision (CV%) 10.13 11.76 7.37 5.48 8.87 14.07 
 
(c) Bisoprolol       
Nominal conc. (ng/ml) 1 25 100 
Sampling method 903 paper HemaSpot 903 paper HemaSpot 903 paper HemaSpot 
Ratio of Analyte to I.S 0.05 0.08 0.54 0.66 2.46 2.66 
SD 0.01 0.01 0.03 0.08 0.16 0.27 
Precision (CV%) 13.89 9.14 5.47 11.93 6.32 7.50 
       
(d) Diltiazem       
Nominal conc. (ng/ml) 5 100 600 
Sampling method 903 paper HemaSpot 903 paper HemaSpot 903 paper HemaSpot 
Ratio of Analyte to I.S 0.38 0.43 1.55 1.34 9.31 9.05 
SD 0.01 0.02 0.15 0.17 0.28 0.40 
Precision (CV%) 3.77 4.49 8.04 6.01 1.29 4.03 
       
(e) Doxazosin       
Nominal conc. (ng/ml) 1 25 100 
Sampling method 903 paper HemaSpot 903 paper HemaSpot 903 paper HemaSpot 
Ratio of Analyte to I.S 0.13 0.15 0.33 0.34 0.84 0.87 
SD 0.02 0.01 0.01 0.01 0.03 0.05 
Precision (CV%) 13.53 10.23 2.75 3.89 3.62 5.52 
       
(f) Lisinopril       
Nominal conc. (ng/ml) 1 25 100 
Sampling method 903 paper HemaSpot 903 paper HemaSpot 903 paper HemaSpot 
Ratio of Analyte to I.S 0.03 0.03 0.06 0.07 0.13 0.15 
SD 0.008 0.002 0.00 0.01 0.01 0.01 
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Table 7.1 continued 
 
(g) Losartan       
Nominal conc. (ng/ml) 25 250 1000 
Sampling method 903 paper HemaSpot 903 paper HemaSpot 903 paper HemaSpot 
Ratio of Analyte to I.S 0.17 0.20 1.00 1.06 5.80 6.32 
SD 0.01 0.02 0.07 0.14 0.11 0.50 
Precision (CV%) 6.50 10.61 7.03 13.03 1.95 7.92 
       
(h) Ramipril       
Nominal conc. (ng/ml) 1 25 100 
Sampling method 903 paper HemaSpot 903 paper HemaSpot 903 paper HemaSpot 
Ratio of Analyte to I.S 0.08 0.06 0.44 0.43 1.46 1.32 
SD 0.04 0.06 0.11 0.04 0.06 0.23 
Precision (CV%) 9.46 8.40 9.27 3.59 2.57 8.91 
 
(i) Simvastatin       
Nominal conc. (ng/ml) 1 25 100 
Sampling method 903 paper HemaSpot 903 paper HemaSpot 903 paper HemaSpot 
Ratio of Analyte to I.S 0.09 0.08 0.42 0.61 3.45 2.74 
SD 0.01 0.02 0.05 0.06 0.11 0.38 
Precision (CV%) 10.30 9.25 13.41 9.86 7.59 13.78 
       
(j) Valsartan       
Nominal conc. (ng/ml) 250 2000 4000 
Sampling method 903 paper HemaSpot 903 paper HemaSpot 903 paper HemaSpot 
Ratio of Analyte to I.S 0.25 0.23 2.01 1.73 6.09 5.81 
SD 0.02 0.03 0.13 0.29 0.89 0.78 
Precision (CV%) 6.89 11.47 6.58 11.79 14.55 13.51 
 
Sampling of prepared blood calibration standards on the HemaSpot – HF device, took a 
longer time (~4 minutes) to complete compared to using the 903 sampling paper 
which was completed in one minute. This may be due to the diameter of the 
application surface (sample entrance) in the clear transparent cover being very small. 
Hence, the blood drop collects as a bulb at the entrance of the device and takes time 
to soak through the absorbent paper, especially with the second and third drops of 
blood.  Another observation was that, even though the application surface of the 
device is perforated, two additional perforations had to be made on the application 
surface with a clean needle to aid suction of the blood into the absorbent paper and to 
prevent bubble formation at the sampling entrance. 
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The ratio of analyte to IS concentration data for atenolol, atorvastatin, bisoprolol, 
diltiazem, doxazosin, lisinopril, losartan, ramipril, simvastatin and valsartan extracted 
from the HemaSpot – HF device and 903 sampling paper were comparable at the low, 
medium and high concentrations of the target drugs investigated (Table 7.1).  No 
marked difference was observed between data for the two microsampling methods. 
This effect could likely be due to the nature of the sampling materials. HemaSpot – HF 
device and 903 sampling paper are made of cellulose based paper and may therefore 
have similar physical and chemical properties (Koster et al., 2015). Hence the observed 
similarity in data acquired. An overlaid total ion chromatogram (TIC) profile for a 
medium calibration standard on the HemaSpot – HF device and 903 sampling paper 
(Figure 7.2), shows that there is no difference between the two sampling materials. 
 
Figure 7.2 Overlaid TIC of a medium blood calibration standard extract on HemaSpot – HF device and 
903 sampling paper. 
 
7.1.2 TOMTEC Dry Media Spot Slides 
The Tomtec dry media spot slides are pre-cut DBS cards that comes in various spot 
sizes of 6mm, 8mm and 10mm to enable integration into a 96 well, 48 well and 24 well 
formats depending on application. The sampling device is made of two media, either 
cellulose (PDMS 4) or polyester polymer (PDMS 7) material (Figure 7.3). Both devices 
are designed to work with automated systems developed by the manufacturer. 
Polyester does not allow blood to soak into the fibres, hence the blood sample is 
housed by the interstices between the fibres. The dry media spot slides utilise fixed 
174 
 
volume sampling by means of a capillary which is used to collect the blood sample and 
then deposited onto the card. The idea is to reduce or eliminate the Hct bias caused by 
using a fixed punch from a DBS sample. The dry media spot slides are pre-etched 
(Figure 7.3) to enable whole sample analysis rather than punch a fixed size after 
sampling. 
  
Figure 7.3 A picture of (a) Tomtec PDMS 4 and (b) the PDMS 7 dry media spot slides (Tomtec, 2015). 
 
7.1.2.1. Evaluation of extraction efficiency of the selected CVD drugs on 
Tomtec PDMS 4, PDMS 7 and 903 sampling paper 
The extraction efficiency of atenolol, atorvastatin, bisoprolol, diltiazem, doxazosin, 
lisinopril, losartan, ramipril, simvastatin and valsartan were evaluated on the Tomtec 
PDMS 4 and PDMS 7 using 903 sampling paper as the control. DBS calibration 
standards were prepared at the blank, low, medium and high concentrations for the 
target CVD drugs (Chapter 4, Table 4.7). 10µl volume of each prepared standard was 
spotted unto 903 sampling paper, Tomtec PDMS 4 and Tomtec PDMS 7 sampling cards. 
The whole spot was used for extraction following the procedure described in Chapter 
4, section 4.5.1. Extracts were analysed using the developed and validated LC-HRMS 
assay in Chapter 5. Extraction efficiency was determined using the procedure 
described in Chapter 5, section 5.2.5. Table 7.2 shows the extraction efficiency of the 
selected CVD drugs at the low, medium and high concentrations investigated for 903 
sampling paper, Tomtec PDMS 4 and Tomtec PDMS 7 sampling cards. 
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Table 7.2 Extraction efficiency data for 903 paper, Tomtec PDMS 4 and PDMS 7 sampling materials at 
the low, medium and high concentration ranges of the target CVD drugs. 
(a) Atenolol     
Sampling method  Nominal concentration (ng/ml) 50 500 1500 
903 paper Recovery (%) 89.51 85.26 89.21 
 SD 13.81 7.04 1.66 
  Precision (CV %) 12.61 7.39 1.68 
Tomtec PDMS 4 Recovery (%) 80.35 85.75 84.71 
 SD 6.38 5.64 2.38 
  Precision (CV %) 7.06 5.89 2.51 
Tomtec PDMS 7 Recovery (%) 37.94 50.18 51.40 
 SD 3.31 4.60 1.43 
 Precision (CV %) 8.72 9.18 2.01 
     
(b)Atorvastatin     
Sampling method  Nominal concentration (ng/ml) 1 25 100 
903 paper Recovery (%) 98.34 102.87 101.79 
 SD 9.92 7.83 7.13 
  Precision (CV %) 9.47 13.42 6.38 
Tomtec PDMS 4 Recovery (%) 98.86 94.33 97.10 
 SD 5.58 2.48 6.04 
  Precision (CV %) 14.67 12.46 6.22 
Tomtec PDMS 7 Recovery (%) 180.09 192.45 132.69 
 SD 39.22 45.72 8.94 
 Precision (CV %) 13.43 23.75 6.74 
     
(c) Bisoprolol     
Sampling method Nominal concentration (ng/ml) 1 25 100 
903 paper Recovery (%) 88.68 86.64 80.04 
 SD 9.48 3.17 5.27 
  Precision (CV %) 6.84 5.59 8.78 
Tomtec PDMS 4 Recovery (%) 77.65 75.98 62.26 
 SD 3.38 7.53 1.35 
  Precision (CV %) 3.14 13.45 2.59 
Tomtec PDMS 7 Recovery (%) 136.73 73.15 38.60 
 SD 30.42 26.59 3.29 
 Precision (CV %) 3.25 36.35 8.53 
     
(d)Diltiazem     
Sampling method  Nominal concentration (ng/ml) 5 100 600 
903 paper Recovery (%) 86.74 74.70 93.00 
 SD 15.61 3.97 1.28 
  Precision (CV %) 12.32 11.43 1.75 
Tomtec PDMS 4 Recovery (%) 75.89 75.01 89.92 
 SD 19.23 4.40 0.94 
  Precision (CV %) 14.15 9.78 1.35 
Tomtec PDMS 7 Recovery (%) 25.13 20.09 12.86 
 SD 7.84 5.58 0.91 
 Precision (CV %) 4.02 27.78 7.08 
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Table 7.2 continued 
 
 (e) Doxazosin 
Sampling method  Nominal concentration (ng/ml) 1 25 100 
903 paper Recovery (%) 94.43 87.99 83.62 
 SD 6.43 3.55 4.57 
  Precision (CV %) 5.47 4.04 6.89 
Tomtec PDMS 4 Recovery (%) 86.44 93.83 91.21 
 SD 6.74 3.79 4.73 
  Precision (CV %) 6.65 4.04 7.74 
Tomtec PDMS 7 Recovery (%) 30.18 22.36 14.73 
 SD 11.95 3.34 0.84 
 Precision (CV %) 7.46 14.93 5.71 
     
(f) Lisinopril     
Sampling method  Nominal concentration (ng/ml) 1 25 100 
903 paper Recovery (%) 102.11 96.30 98.01 
 SD 6.85 11.85 7.94 
  Precision (CV %) 5.51 10.18 7.35 
Tomtec PDMS 4 Recovery (%) 105.49 102.24 90.08 
 SD 18.14 14.14 7.27 
  Precision (CV %) 7.10 11.94 5.59 
Tomtec PDMS 7 Recovery (%) 162.98 197.68 127.78 
 SD 34.66 24.37 6.08 
 Precision (CV %) 13.18 12.33 4.76 
     
(g) Losartan     
Sampling method  Nominal concentration (ng/ml) 25 250 1000 
903 paper Recovery (%) 102.06 102.15 105.32 
 SD 2.78 12.58 4.75 
  Precision (CV %) 2.73 12.34 4.51 
Tomtec PDMS 4 Recovery (%) 102.13 101.41 91.97 
 SD 10.68 11.05 1.07 
  Precision (CV %) 10.45 10.90 1.16 
Tomtec PDMS 7 Recovery (%) 99.54 89.00 79.26 
 SD 5.30 11.08 5.17 
 Precision (CV %) 5.07 12.45 6.52 
     
(h) Ramipril     
Sampling method  Nominal concentration (ng/ml) 1 25 100 
903 paper Recovery (%) 104.49 100.65 100.69 
 SD 11.358 8.405 2.032 
  Precision (CV %) 10.871 8.351 2.018 
Tomtec PDMS 4 Recovery (%) 98.01 102.07 95.46 
 SD 10.93 9.07 3.24 
  Precision (CV %) 11.15 8.55 3.39 
Tomtec PDMS 7 Recovery (%) 64.87 60.39 51.74 
 SD 6.28 8.05 2.53 
 Precision (CV %) 8.39 13.33 4.89 
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Table 7.2 continued 
 
 (i) Simvastatin 
Sampling method  Nominal concentration (ng/ml) 1 25 100 
903 paper Recovery (%) 66.22 62.32 59.18 
 SD 15.99 6.01 3.53 
  Precision (CV %) 7.40 12.44 6.51 
Tomtec PDMS 4 Recovery (%) 67.18 73.53 51.85 
 SD 6.36 13.30 2.03 
  Precision (CV %) 4.05 14.22 4.24 
Tomtec PDMS 7 Recovery (%) 32.94 13.38 7.31 
 SD 6.08 0.94 0.41 
 Precision (CV %) 9.66 7.04 5.64 
     
(j) Valsartan     
Sampling method  Nominal concentration (ng/ml) 250 2000 4000 
903 paper Recovery (%) 91.83 89.17 94.37 
 SD 4.24 4.08 5.15 
  Precision (CV %) 4.61 6.89 10.14 
Tomtec PDMS 4 Recovery (%) 72.89 70.91 64.62 
 SD 2.21 10.50 0.84 
  Precision (CV %) 4.18 14.80 1.89 
Tomtec PDMS 7 Recovery (%) 98.06 94.94 75.11 
 SD 9.40 4.62 6.78 
 Precision (CV %) 6.35 5.93 9.03 
 
The results on extraction efficiency (recovery) show consistent, reproducible and 
comparable data for all target drugs on Tomtec PDMS 4 (cellulose based material) and 
903 sampling paper. This is expected because, Tomtec PDMS 4 and 903 sampling paper 
are made of cellulose and thus may not show any wide differences in physical and 
chemical properties. In contrast with extraction efficiency data on Tomtec PDMS 7 
(polyester sampling cards) drug recoveries of the target analytes were very poor for all 
target drugs (<50%), except for losartan and valsartan where mean recoveries were 
~89%.  
The results on Tomtec PDMS 7 suggest significant matrix effects because of co-eluting 
compounds from the polyester sampling material resulting in ion suppression for 
target drugs (atenolol, bisoprolol, diltiazem, doxazosin, ramipril and simvastatin) and 
signal enhancement for (atorvastatin and lisinopril). Polyester is a class of polymer 
consisting of several monomers linked by ester moieties. The consistent and 
comparable recovery data for losartan and valsartan on Tomtec PDMS 7 in contrast 
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with Tomtec PDMS 4 and 903 sampling paper shows that the two compounds are not 
susceptible to matrix effects by the polyester material. This may be because losartan 
and valsartan belong to the same therapeutic class (angiotensin 2 receptor antagonist) 
and may therefore have similar physicochemical properties. 
LC-HRMS analyses of a blank solution extract of the VAMS device, HemaSpot - HF, 
Tomtec cotton (PDMS 4), polyester (PDMS 7) cards and 903 card shows similar total 
ion chromatogram (TIC) profile, apart from the polyester (PDMS 7) card (Figure 7.4). 
The comparable TIC profile seen for the VAMS device, HemaSpot, tomtec cotton 
(PDMS 4) and 903 sampling paper is expected because these devices may all be made 
of cellulose or cotton fibres.  
 
Figure 7.4 An overlaid TIC of a blank device extract of a Tomtec dry media spot slide PDMS 7, PDMS 4, 
VAMS, HemaSpot and 903 card.  
 
The TIC trace for the polyester (PDMS 7) sampling card is different because the device 
is made from terephthalic acid and ethylene glycol (Figure 7.5) in a condensation 
reaction with the loss of water to produce an ester (ethylene terephthalate). This 
reaction occurs in a repeated fashion since the acid monomer and the alcohol unit 
each have two functional groups, at the opposite sides of each compound. A simple 
illustration is demonstrated with [A-B-A-B-A-B] (Figure 7.5). This leads to the formation 
of the polymerised units of the monomer ethylene terephthalate to a condensed 




Figure 7.5 Formation of polyethylene terephthalate (PET). 
A walk through the chromatogram using the qualitative analysis software version 4.00 
(Agilent Technologies), over the peaks labelled (a) at retention time 0.9 minutes and 
(b) at 1.0 minutes on Figure 7.4 show extracted ion chromatogram (EIC) traces (Figure 
7.6 and Figure 7.7) consistent with this polymer. This is because there is a constant 
addition of a mass of m/z 44.00 representing the ester functional group to the peaks 
labelled (A) to (I) in Figures 7.6 and 7.7.  
 
Figure 7.6 Representative EIC of ions appearing from the peak (a) at a retention time of 0.904 minutes 
on Tomtec PDMS 7. 
 
Figure 7.7 Representative EIC of ions appearing from the peak (b) at a retention time of 1.004 minutes 
on Tomtec PDMS 7. 
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7.1.3 Ahlstrom 167L cards 
The Ahlstrom 167L card is a novel microsampling card reported to eliminate the 
hematocrit effect. Ahlstrom 167L utilises a punch for analysis and is reported to yield 
reliable quantitative results irrespective of the blood hematocrit. 
In contrast to the conventional 903 sampling paper, qualitative investigations showed 
that a 30µl blank blood standard produced spots of about ~9.5mm on 903 sampling 
paper and ~7.5mm on Ahlstrom 167L cards (Figure 7.8a and 7.9a). The difference in 
spot sizes on the two sampling cards could be attributed to the difference in weight 
(Table 7.3) and the variability in thickness of the two sampling cards. The mean weight 
of a blank 8mm disk from 903 and Ahlstrom 167L cards were 9.13mg and 19.19 
respectively. In addition, 903 sampling paper has a thickness of ~0.4mm, whilst that of 
Ahlstrom 167L cards is about ~1.0mm thick. Hence the blood drop spread over a larger 
surface area on 903 sampling paper, compared to Ahlstrom 167L cards thus producing 
small size blood spots. Another observation was that, the thickness of the Ahlstrom 
167L cards, affected the spread of the blood spot on both sides of the sampling card. 
Figure 7.8 shows that the size of the blood spots on the (a) front of the card are bigger 
compared to the size of the blood spots at the (b) back of the same card. However, this 
effect was not seen with the 903 sampling paper (Figure 7.9), where the spot size was 
the same on the (a) front and (b) back of the sampling card.  
 
Figure 7.8 30µl spots of blank blood standard on the front (a) and back (b) of Ahlstrom 167L card after 




Figure 7.9 30µl spots of blank blood standard on the front (a) and back (b) of 903 sampling card after 3 
hours of drying. 
 
Table 7.3 Comparison of an 8mm blank disk of 903 and 167L sampling card. 
 
Weight of 8mm blank card (mg) 
Disc number 903 Sampling paper Ahlstrom 167L 
1 9.01 19.63 
2 9.22 18.70 
3 9.15 19.24 
Mean weight 9.13 19.19 
 
An LC-HRMS analyses of a blank card solution extract from 903 sampling paper and 
Ahlstrom 167L was performed using the procedure described in Chapter 4, section 
4.5.1. A total ion chromatogram (TIC) of the extracted blank 903 card and Ahlstrom 
167L card is shown in Figure 7.10. 
 
Figure 7.10 Overlaid TIC of a blank 903 paper and Ahlstrom 167L card solution extract. 
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The overlaid total ion chromatograms reveal obvious differences between the two 
sampling cards by the peaks marked (a) on 903 sampling paper at a retention time of 
1.22 minutes and (b) on Ahlstrom 167L card at a retention time of 1.71 minutes. A 
walk through the two chromatograms using the qualitative analysis software version 
4.00 (Agilent Technologies), was performed to reveal the ions in peaks (a) and (b). An 
extracted ion chromatogram (EIC) showing the ions in peak (a) and (b) are shown in 
Figure 7.11 and 7.12 respectively. The EIC of peak (a) on 903 sampling paper shows 
ions of m/z 148.5350, 219.0478, 318.5819 and 418.1143, which is different from the 
EIC of peak (b) on Ahlstrom 167L card which shows ions of m/z 147.0809, 371.1210 
and 719.2524. 
 
Figure 7.11 Representative EIC of ions appearing from the peak (a) at a retention time of 1.22 minutes 
on 903 sampling paper. 
 
 
Figure 7.12 Representative EIC of ions appearing from the peak (b) at a retention time of 1.71 minutes 
on Ahlstrom 167L card. 
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7.1.4 Volumetric absorptive microsampling 
Volumetric absorptive microsampling, as introduced in (Chapter 3, section 3.3.2) is a 
novel microsampling bead technology developed specifically to collect fixed volumes 
of blood to eliminate the Hct effect associated with DBS cards. The device consists of a 
polymeric tip attached to a moulded plastic handle (Chapter 3, Figure 3.2). The process 
of sample collection involves wicking of a liquid sample onto the porous substrate 
upon contact. VAMS is used for fixed volume collection of a 10µl or 20µl volume of 
blood directly from a finger prick eliminating the volumetric haematocrit effect 
associated with the DBS sampling when a punch is used. VAMS utilise whole sample 
for analysis and is reported to yield reliable quantitative data (Qu et al., 2017; Kita and 
Mano, 2017). An example of VAMS is currently marketed as MitraTM and is available on 
the market in a clam shell containing either two or four sampling devices (Neoteryx, 
2015). The validation and application of VAMS for the collection of volunteer blood 
samples for the assessment of adherence to CVD prescription medication is presented 
in Chapters 5 and 6 respectively.   
7.1.5. Hemaxis – DB collection device 
Hemaxis – DB blood collection device is a new microsampling device that utilises 
microfluidic technology to collect accurate volumes of 5µl or 10µl of whole blood from 
a finger or heel prick unto a filter paper. The device is available in two formats 
depending on spot volume, either a 4 x (5µl) or a 4 x (10µL) version. Hemaxis utilises 
the whole spot for analysis and thus eliminates the hematocrit bias. The device is 
made of three main parts (1) a microfluidic chip, (2) a sampling card and (3) a 
protective case (Figure 7.13). The microfluidic chip with its microsized channels 
ensures easy blood collection by the user and enables precise volumes to be deposited 
unto the sampling card housed by the protective case to secure the sample after 
collection. This makes it easy for blood sampling to be performed by anyone, 
anywhere and at any time. The sample is then dried at room temperature prior to 
shipping. The sampling card onto which blood is deposited takes the format of the 
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conventional 903 Protein Saver card to allow compatibility with automated handling 
processes in laboratories.  
A similar product is currently under development by name (Hemaxis – DP) for the 
collection of microvolumes of plasma or serum without the use of a centrifuge or 
filtration membrane (Hemaxis, 2017). 
 
Figure 7.13 A picture of the Hemaxis-DB dried blood collection device (Hemaxis, 2017). 
7.1.6 Hemapen 
Hemapen is a single use novel microsampling device currently under development. It is 
designed for precise volume blood collection and storage in DBS format. Sampling 
involves end-to-end capillary collection of accurate volumes of blood onto pre-cut DBS 
paper. The DBS paper is securely housed in the integrated compartment of the device 
to ensure protection of the collected blood sample and prevent contamination 
between patients. Hemapen is developed to overcome the analytical hurdles 
associated with conventional DBS sampling such as Hct effect, volumetric inaccuracy 
and sample integrity. Like all other dried blood microsampling formats, Hemapen 
enhances blood sampling at remote locations and resource limited areas of the world. 
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The device has a post-collection locking feature which restricts access to the collected 
sample to only laboratory staff reducing any biohazard risk to handlers. Some of its 
unique features include an ergonomic handheld pen design (Figure 7.14) for user 
convenience and a transparent front end that enables the user to visualise emptying of 
the capillaries which signifies sample collection completion. 
 
Figure 7.14 Shows a picture of the Hemapen microsampling device (Trajan Scientific & Medical, 2015). 
An overlaid total ion chromatogram (TIC) profile for a blank card solution extract from 
the Hemapen and 903 sampling paper (Figure 7.14), shows that there is no significant 
differences between the two sampling materials. This is expected because the card 
material for Hemapen and 903 sampling paper are made of cellulose. 
 
Figure 7.15 Overlaid TIC of a blank 903 paper and Hemapen device solution extract. 
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7.1.7 Noviplex plasma preparation cards 
Noviplex card is a new microsampling tool that has been developed for the rapid 
generation of fixed volume of plasma from whole blood in about 3 minutes. In contrast 
with DBS cards, plasma is collected hence there are no hematocrit effects. The device 
works by collecting a non-volumetric amount of whole blood from a finger or heel 
prick directly onto an overlay on the noviplex card (Figure 7.16).   
The collected blood sample dissipates by capillary action across a spreading layer in the 
device, where an in-built separator membrane, separates the blood cells from the 
plasma by means of adsorption and filtration without the need for any capillaries or 
centrifuging process (Figure 7.16). The generated plasma is then collected on a plasma 
collection reservoir or removable disk which can be exposed for removal by stripping 
off the upper layer of the device. The plasma sample is removed after three minutes 
and dried for about 15 minutes prior to shipment to the laboratory without the need 
for dry ice. 
 
Figure 7.16 A schematic of a Noviplex plasma preparation card (Novilytic limited, 2017). 
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The device comes in two formats, the Noviplex plasma prep cards and the Noviplex 
duo plasma prep cards. The former collects a fixed 2.5µl volume of plasma sample 
from a variable amount of blood (25µl – 75µl), whilst the latter (Noviplex duo card) 
generates two times (2x) 3.8µl volume of plasma samples from a single application of 
about (60µl – 100µl) of blood. The Noviplex cards are reported to offer quick sample 
preparation, whilst maintaining assay reproducibility and selectivity (Novilytic limited, 
2017). 
7.1.8 Conclusion 
Looking at the innovations in microsampling methods discussed in this Chapter, which 
are all reported to address the hurdles with conventional DBS such as difficulties with 
self-sampling, volumetric inaccuracies and hematocrit effects, the vision of self-
sampling at home, away from a hospital will soon be a reality for various clinical 
applications including routine therapeutic drug monitoring (TDM). Which is currently 
limited because of the highly invasive sampling (venepuncture), the need for a 
phlebotomist and clinical appointments. This will be a huge step not only in objectively 
assessing patient’s adherence to medication, but also in the provision of personalised 
healthcare. The “self-provided” microvolume sample by the patient may offer 
healthcare providers with a unique means of providing evidence based and tailor-
made pharmacotherapy suited to each patient. Tanna and Lawson (2016) argue that 
this will help shift the balance of healthcare provision from the hospitals to the 
community broadening access to healthcare. Thus, application of microsampling 
methods to TDM and other clinical applications will provide enhanced patient benefits 
in terms of time, cutting down journeys to phlebotomy appointments, cost of travel 
and the active involvement of the patient in their own healthcare, as they discuss 
results from their blood drug level measurements with their healthcare provider. This 
approached to personalised healthcare could become routine providing huge savings 
for healthcare providers through better patient outcomes, optimised medication 
usage, reduction on avoidable hospital readmissions and needless patient deaths. 
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Chapter 8 Overall conclusions and future work 
 
8.1 Overall conclusion 
In this research study, the goal was to develop, validate and apply a microsampling 
based LC - HRMS assay for multi compound drug determination for the inference of 
adherence to CVD medication in cardiovascular disease patients. Hence considering 
the questions raised at the beginning of the research study in Chapter 1, section 1.5, 
the following conclusions can be drawn: 
A. A reliable and cost-effective DBS and VAMS based LC-HRMS assay has been 
developed and validated for the TDM of eleven candidate cardiovascular drugs 
in heart disease patients. To date this is the first microanalytical assay 
developed for the simultaneous determination of multiple (≥10) cardiovascular 
drugs in volunteer microvolume blood samples and therefore demonstrates 
novelty. 
B. The developed LC-HRMS assay provides information on the levels of medication 
in the patients’ blood. Thus, in the event of poor patient progress to treatment, 
this information can aid clinicians if for example; the problem is because of 
poor adherence to treatment, incorrect diagnosis or poor choice of medication. 
C. The results from the analyses of volunteer samples have demonstrated that 
monitoring therapeutic drug levels by direct analyses of patient microvolume 
blood samples can be a useful tool for dose optimisation and monitoring of 
drug interactions for individual patients. 
D. The research study has also shown that, it is possible to simultaneously 
quantify a wide panel of commonly used cardiovascular drugs: atenolol, 
atorvastatin, bisoprolol, diltiazem, doxazosin, lisinopril, losartan, ramipril, 
simvastatin and valsartan in microvolume blood samples collected using 
microsampling methods coupled with LC-HRMS analyses. However, due to the 
small sample volume and the wide differences in physicochemical properties of 
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the analytes, challenges with analyte extraction from DBS sample should be 
addressed accordingly. 
E. The study has also demonstrated that application of microsampling methods 
for the collection of blood samples is a feasible alternative to traditional blood 
sampling (venepuncture) for the TDM of cardiovascular drugs. It has high 
patient acceptability in contrast with venepuncture and most importantly 
offers no restrictions to sample collection because of patient’s ability to self-
sample. Thus, it is foreseen that the current innovations in microsampling 
methods will soon make self-sampling for the purposes of routine therapeutic 
drug monitoring a reality. 
F. The study has also demonstrated that indication of adherence to medication 
based on the levels of CVD drug in the patients’ blood is the most reliable 
marker for cases of nonadherence to CVD drugs since it is evidence based. This 
is because clinicians may need evidence to quantify the effects of prescribed 
medication to aid the clinical decision-making process and the data generated 
from blood drug levels can provide the evidence. 
G. The developed microsampling based LC-HRMS assay can be adapted and 
extended to other medical conditions with known prevalence of nonadherence 
to medication such as diabetes, depression and cancer.  
H. The study also shows that microsampling based LC-HRMS assays has great 
potential to enable the implementation of routine TDM of cardiovascular 
medications in everyday clinical practice. Providing an evidence based 
approach to the assessment of cardiovascular medication adherence. 
I. The microsampling based LC-HRMS assay also shows that, high-resolution full 
scan mass spectrometry analyses offers benefits in the TDM in cases of poor 
progression. Because all mass spectral data from the analysed sample is 
collected which makes it possible for the data to be revisited at a later time 
which may provide additional clinical data. 
J. The results have also demonstrated that VAMS overcomes the limitations 
observed with using conventional DBS cards such as difficulty in self-sampling, 
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volumetric inaccuracies and the hematocrit effects.  For the selected CVD drugs 
investigated, analyses on VAMS showed no hematocrit effects over a 
hematocrit range of 35% - 55%, whereas results on DBS cards revealed that 
hematocrit bias was significant at extreme hematocrit values. 
8.2 Future work 
This research study has unveiled several opportunities for further work.  
A. Using the developed extraction procedure for atenolol, atorvastatin, bisoprolol, 
diltiazem, doxazosin, lisinopril, losartan, ramipril, simvastatin and valsartan in 
microvolume blood samples collected on VAMS and DBS card, it was not 
possible to extract amlodipine. Thus, a different extraction procedure had to be 
developed separately for amlodipine. This meant that four dried blood samples 
were required to analyse samples from volunteers where amlodipine was 
prescribed with any of the other CVD drugs. Therefore, an extraction method 
for all the compounds to enable a single run needs to be explored further.  
B. Furthermore, since plasma is the gold standard matrix for the quantification of 
therapeutic drugs, a study to determine the ratio between DBS and plasma 
derived concentrations for the selected cardiovascular drugs should have been 
performed. Hence a bridging study to determine the ratio between (DBS and 
VAMS) and plasma derived concentration for the selected drugs should be 
considered in the future so that comparison between matrices is possible. This 
will further confirm that microsampling methods maintain the integrity of the 
original sample and represents an accurate surrogate of the original sample. 
C. It was also not feasible to validate the developed assay for the selected 
cardiovascular drugs on all the new microsampling methods discussed in 
Chapter 7. Thus, further work to validate the assay on HemaSpot-HF device, 
Ahlstrom 167L cards, Hemaxis – DB, Tomtec PDMS 4 and the HemaPen sample 
collection device should be considered in the future to allow comparison of 
data using these microsampling methods.   
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D. The developed microsampling based LC-HRMS assay, has now gone outside the 
boundaries of the UK and is currently under investigation for implementation in 
clinical practice in Iraq. However, for the developed microsampling based LC-
HRMS assay to be successfully implemented in clinical practice, on-line 
extraction which involves the automation of sample preparation and the 
extraction process must be explored for faster analysis. Currently an offline 
sample extraction procedure is employed which involves manual punching of 
disk from the dried blood sample on 903 cards followed by addition of solvents 
to punched disk, vortexing, centrifuging, evaporation of supernatant and 
reconstitution of dried residue in solvent for analysis.  This process may take a 
longer time if hundreds of patient samples must be analysed at the clinic. 
Hence the time taken to prepare the microvolume dried blood sample for 
analysis must be significantly reduced to enhance sample processing time and 
increase analytical throughput.  
E. The analysis of hundreds of patient samples will lead to the generation of big 
data which will slow down data processing due to current limitations with 
software and data storage. Hence MS instruments need to be embedded with 
the capability for data processing power to generate the data for analyses 
within the shortest possible time. Since a long waiting period for results could 
mean patient may be dead before the results is out. Thus, a move towards 
cloud storage is foreseeable and should be explored by instrument 
manufacturers. 
F. The increase in life expectancy has led to an ageing elderly population. This 
presents with huge challenges for healthcare systems because the 
accumulation of chronic diseases rises with older ages. Cardiovascular disease 
for example affects mainly the elderly. This results in high rates of 
multimorbidity where cardiovascular disease patients suffer from other 
conditions such as diabetes and depression. Multimorbidity leads to 
polypharmacy prescribing where patients are prescribed not less than 5 
different medicines at a time. This shoots up the economic burden on health 
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systems since the government must foot the bill for the medications prescribed 
for the elderly population. Hence medicine optimisation becomes critical to 
ensure the cost effectiveness of treatment in the elderly population for 
agencies like the National Institute for Health and Care Excellence (NICE) that 
set guidelines for the NHS to regulate cost of treatment. Thus, for efficient 
service delivery in clinical practice, expansion of the developed microsampling 
based LC-HRMS assay to screen for other medications that cardiovascular 
disease patients may be taking, for example oral antidiabetic and 
antidepressant drugs will help with the implementation of precision medicine. 
This will lead to patient care improvement and a reduction in medication 
wastage in healthcare provision and must be explored in the future. 
G. Furthermore, though the mass spectrometer has undergone massive 
transformation over the last three decades to reduce its size, it is still a huge 
bench top instrument which will not fit into every ward at the clinic. Hence 
manufacturers will need to reduce the size of the instrument into a portable or 
mobile bedside piece of equipment which is affordable and can easily be 
installed into hospital wards and clinics. In addition, transformation of the mass 
spectrometer into an integrated user-friendly push button unit that can take a 
biological sample, prepare the sample, perform analyses and produce reports 
will make service delivery efficient in clinical practice. Hence more efforts are 
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Appendix 1 Standard operating procedure for the preparation of 
calibration and validation standards for the 11 target cardiovascular 
drugs and internal standard in whole blood 
1. Introduction 
The purpose of this document is to describe the protocol to use in the preparation of 
calibration and validation standards for amlodipine besylate salt, atenolol, atorvastatin 
calcium salt, bisoprolol hemifumarate salt, diltiazem hydrochloride, doxazosin 
mesylate salt, lisinopril, losartan potassium salt, ramipril, simvastatin, valsartan and 
atenolol D7 (Internal standard), in human whole blood.  
Table A1.1 Proposed calibration ranges of the 11 target cardiovascular drugs in human whole blood 
Drug Proposed calibration ranges (ng/ml) 
Amlodipine 0.5, 1, 5, 10, 25, 50, 100 
Atenolol 10, 20, 50, 100, 200, 500, 1000, 1500 
Atorvastatin 0.5, 1, 5, 10, 25, 50, 100 
Bisoprolol 0.1, 0.5, 1, 5, 10, 25, 50, 100 
Diltiazem   0.5, 1, 5, 10, 50, 100, 300, 600 
Doxazosin   0.1, 0.5, 1, 5, 10, 25, 50, 100 
Lisinopril 0.1, 0.5, 1, 5, 10, 25, 50, 100 
Losartan 5, 10, 25, 50, 100, 250, 500, 1000 
Ramipril 0.1, 0.5, 1, 5, 10, 25, 50, 100 
Simvastatin 0.1, 0.5, 1, 5, 10, 25, 50, 100 
Valsartan 50, 100, 250, 500, 1000, 2000, 3000, 4000 
 
 2. Safety 
For the preparation and handling of the cardiovascular drugs, Personal Protective 
Equipment (PPE) must be worn as per the appropriate risk assessment and completed 
COSHH forms of each target drug.   For the preparation of blood samples, a laboratory 
coat and disposable latex gloves should be worn. Hands should be washed and 
disinfected before and after handling blood samples. Care should be taken to cover 
any cuts on the hands using waterproof dressings or plasters. If spillage occurs the 
contaminated area should be cleaned immediately using a suitable disinfectant and 
disposable paper towels. Benches should be wiped clean with a suitable disinfectant 
after each work session.  
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3. Storage of blood samples 
Following collection of blood samples, the samples in specimen tubes should be stored 
in number or code labelled re-sealable polythene bags in the refrigerator in Lab HB 
00.15. 
4. Disposal 
Discarded blood spot sampling paper and any contaminated materials used to clean 
spillages should be put into the plastic yellow (clinical waste) bag. Discarded specimens 
in microcentrifuge tubes, specimen tubes and contaminated pipette tips and LC vials 
should also be put into the plastic yellow (clinical waste) bags.  All contaminated 
sharps e.g. needles should be placed in the rigid walled, yellow and red, sharps bin.  
5. Equipment 
Analytical balance, volumetric pipettes, eppendorf tubes, volumetric flasks, dried 
blood spot sampling paper (Specimen collection paper type 903), volumetric 
absorptive microsampling (VAMS) device.  
6. Materials 
Amlodipine besylate salt, atenolol, atorvastatin calcium salt, bisoprolol hemifumarate 
salt, diltiazem hydrochloride, doxazosin mesylate salt, lisinopril, losartan potassium 
salt, ramipril, simvastatin, valsartan, atenolol D7 (Internal Standard), methanol (HPLC 
grade), and HPLC grade water. 
7. Diluent preparation (70:30 MeOH: H2O v/v) 
Preparation of 500ml of diluent: Transfer 350ml of methanol in a 500ml measuring 
cylinder and add HPLC grade water to 500ml. Transfer into a 500ml plain glass bottle 





8. Standard Stock preparation for the 11 target cardiovascular drugs and internal 
standard 
8.1 Standard stock solution preparation for each target drug 
For Amlodipine besylate, atenolol, atorvastatin calcium, bisoprolol hemifumarate, 
diltiazem hydrochloride, doxazosin mesylate, lisinopril, losartan potassium, ramipril, 
simvastatin and valsartan prepare a stock solution with concentration 1mg/ml. 
Procedure 
Weigh 5mg of each target drug directly into a 5ml volumetric flask on an analytical 
balance. Dissolve with 100% Methanol and make up to the mark, shake well and keep 
solution refrigerated. 
8.1.1 Preparation of intermediate stock solution with concentration 10000ng/ml for 
each drug 
Pipette 100µl of the 1mg/ml standard stock solution of drug into a 10ml volumetric 
flask and make to the mark with 70:30 MeOH: H20, v/v. Shake well and keep solution 
refrigerated 
8.2 Preparation of Internal Standard stock solution (Atenolol d7 10000ng/ml) 
Procedure 
Weigh 0.5mg of Atenolol d7 directly into a 50ml volumetric flask on an analytical 
balance. Dissolve with 100% Methanol and make up to the mark, shake well and keep 
solution refrigerated.  
Dilute stock solution with diluent to produce an extraction solvent with 20ng/ml 






8.2.1 Preparation of extraction solvent with 20ng/ml concentration of internal 
standard (Atenolol d7) 
Pipette 20µl of the 10,000ng/ml stock solution of atenolol D7 into a 10ml volumetric 
flask and make to the mark with 70:30 MeOH: H20, v/v. Shake well and keep solution 
refrigerated. 
9. Preparation of multicomponent working solutions for amlodipine, atenolol, 
atorvastatin, bisoprolol, diltiazem, doxazosin, lisinopril, losartan, ramipril, 
simvastatin and valsartan in 5ml and 10ml volumetric flask using (70:30 MeOH: H2O 
v/v) from the Standard stock solutions 
Table A1.2 – A1.12 shows the API concentrations of each target drug, the volume of 
stock solution required and the total volume of solution to be prepared. 







Solution 1 1 1 10 
Solution 2 5 5 10 
Solution 3 10 10 10 
Solution 4 50 50 10 
Solution 5 100 50 5 
Solution 6 250 125 5 
Solution 7 500 250 5 
Solution 8 1000 500 5 
 
Table A1.3 Calibration concentrations for atenolol in solution 
 Atenolol 
Concentration(ng/ml) 
Volume of 1mg/ml 
stock required (µL) 
Total volume(mL) 
Solution 1 100 1 10 
Solution 2 200 2 10 
Solution 3 500 5 10 
Solution 4 1000 10 10 
Solution 5 2000 10 5 
Solution 6 5000 25 5 
Solution 7 10000 50 5 












Solution 1 1 1 10 
Solution 2 5 5 10 
Solution 3 10 10 10 
Solution 4 50 50 10 
Solution 5 100 50 5 
Solution 6 250 125 5 
Solution 7 500 250 5 
Solution 8 1000 500 5 
 







Solution 1 1 1 10 
Solution 2 5 5 10 
Solution 3 10 10 10 
Solution 4 50 50 10 
Solution 5 100 50 5 
Solution 6 250 125 5 
Solution 7 500 250 5 
Solution 8 1000 500 5 
 







Solution 1 5 5 10 
Solution 2 10 10 10 
Solution 3 50 50 10 
Solution 4 100 100 10 
Solution 5 500 250 5 
Solution 6 1000 500 5 
Solution 7 3000 1500 5 














Solution 1 1 1 10 
Solution 2 5 5 10 
Solution 3 10 10 10 
Solution 4 50 50 10 
Solution 5 100 50 5 
Solution 6 250 125 5 
Solution 7 500 250 5 
Solution 8 1000 500 5 
 







Solution 1 1 1 10 
Solution 2 5 5 10 
Solution 3 10 10 10 
Solution 4 50 50 10 
Solution 5 100 50 5 
Solution 6 250 125 5 
Solution 7 500 250 5 
Solution 8 1000 500 5 
 







Solution 1 50 50 10 
Solution 2 100 100 10 
Solution 3 250 250 10 
Solution 4 500 500 10 
Solution 5 1000 500 5 
Solution 6 2500 1250 5 
Solution 7 5000 2500 5 














Solution 1 1 1 10 
Solution 2 5 5 10 
Solution 3 10 10 10 
Solution 4 50 50 10 
Solution 5 100 50 5 
Solution 6 250 125 5 
Solution 7 500 250 5 
Solution 8 1000 500 5 
 
Table A1.11 Calibration concentrations for simvastatin in solution 






Solution 1 1 1 10 
Solution 2 5 5 10 
Solution 3 10 10 10 
Solution 4 50 50 10 
Solution 5 100 50 5 
Solution 6 250 125 5 
Solution 7 500 250 5 
Solution 8 1000 500 5 
 
Table A1.12 Calibration concentrations for valsartan in solution 
 Valsartan 
Concentration(ng/ml) 
Volume of 1mg/ml 
stock required (µL) 
Total volume(mL) 
Solution 1 500 5 10 
Solution 2 1000 10 10 
Solution 3 2500 25 10 
Solution 4 5000 50 10 
Solution 5 10000 50 5 
Solution 6 20000 100 5 
Solution 7 30000 150 5 
Solution 8 40000 200 5 
 




10. Preparation of calibration standards in whole blood 
For each multicomponent solution (1, 2, 3, 4, 5, 6, 7, and 8) from section 9, pipette 
100µL to an eppendorf tube and add 900µL of blood. Mix well by vortexing for 1 
minute. This will produce the final calibration concentrations in table 3a – 3k below for 
each target drug in whole blood. For the blank preparation, pipette 100µl of diluent 
(extraction solvent containing 10ng/ml internal standard) and add 900µl of blood. Mix 
well by vortexing for 1 minute. 
Table A1.13 – A1.23 show the final calibration concentrations of each target drug in 
whole blood. 
Table A1.13 Final concentrations of amlodipine in whole blood 
 Concentration of 
Amlodipine standard 
solution (ng/ml) 
Volume of standard 
to be added to 
whole blood (µl) 
Final Concentration 
of Amlodipine in 
whole blood (ng/ml) 
Standard A 1 100 0.1 
Standard B 5 100 0.5 
Standard C 10 100 1 
Standard D 50 100 5 
Standard E 100 100 10 
Standard F 250 100 25 
Standard G 500 100 50 
Standard H 1000 100 100 
 
Table A1.14 Final concentrations of atenolol in whole blood 
 Concentration of 
Atenolol standard 
solution (ng/ml) 
Volume of standard 
to be added to 
whole blood (µl) 
Final Concentration 
of Atenolol in whole 
blood (ng/ml) 
Standard A 100 100 10 
Standard B 200 100 20 
Standard C 500 100 50 
Standard D 1000 100 100 
Standard E 2000 100 200 
Standard F 5000 100 500 
Standard G 10000 100 1000 






Table A1.15 Final concentrations of atorvastatin in whole blood 
 Concentration of 
Atorvastatin standard 
solution (ng/ml) 
Volume of standard 
to be added to 
whole blood (µl) 
Final Concentration 
of Atorvastatin in 
whole blood (ng/ml) 
Standard A 1 100 0.1 
Standard B 5 100 0.5 
Standard C 10 100 1 
Standard D 50 100 5 
Standard E 100 100 10 
Standard F 250 100 25 
Standard G 500 100 50 
Standard H 1000 100 100 
 
Table A1.16 Final concentrations of bisoprolol in whole blood 
 Concentration of 
Bisoprolol standard 
solution (ng/ml) 
Volume of standard 
to be added to 
whole blood (µl) 
Final Concentration 
of Bisoprolol in whole 
blood (ng/ml) 
Standard A 1 100 0.1 
Standard B 5 100 0.5 
Standard C 10 100 1 
Standard D 50 100 5 
Standard E 100 100 10 
Standard F 250 100 25 
Standard G 500 100 50 
Standard H 1000 100 100 
 
Table A1.17 Final concentrations of diltiazem in whole blood 
 Concentration of 
Diltiazem standard 
solution (ng/ml) 
Volume of standard 
to be added to 
whole blood (µl) 
Final Concentration 
of Diltiazem in whole 
blood (ng/ml) 
Standard A 5 100 0.5 
Standard B 10 100 1 
Standard C 50 100 5 
Standard D 100 100 10 
Standard E 500 100 50 
Standard F 1000 100 100 
Standard G 3000 100 300 







Table A1.18 Final concentrations of doxazosin in whole blood 
 Concentration of 
Doxazosin standard 
solution (ng/ml) 
Volume of standard 
to be added to 
whole blood (µl) 
Final Concentration 
of Doxazosin in 
whole blood (ng/ml) 
Standard A 1 100 0.1 
Standard B 5 100 0.5 
Standard C 10 100 1 
Standard D 50 100 5 
Standard E 100 100 10 
Standard F 250 100 25 
Standard G 500 100 50 
Standard H 1000 100 100 
 
Table A1.19 Final concentrations of lisinopril in whole blood 
 Concentration of 
Lisinopril standard 
solution (ng/ml) 
Volume of standard 
to be added to 
whole blood (µl) 
Final Concentration 
of Lisinopril in whole 
blood (ng/ml) 
Standard A 1 100 0.1 
Standard B 5 100 0.5 
Standard C 10 100 1 
Standard D 50 100 5 
Standard E 100 100 10 
Standard F 250 100 25 
Standard G 500 100 50 
Standard H 1000 100 100 
 
Table A1.20 Final concentrations of losartan in whole blood 
 Concentration of 
Losartan standard 
solution (ng/ml) 
Volume of standard 
to be added to 
whole blood (µl) 
Final Concentration 
of Losartan in whole 
blood (ng/ml) 
Standard A 50 100 5 
Standard B 100 100 10 
Standard C 250 100 25 
Standard D 500 100 50 
Standard E 1000 100 100 
Standard F 2500 100 250 
Standard G 5000 100 500 







Table A1.21 Final concentrations of ramipril in whole blood 
 Concentration of 
Ramipril standard 
solution (ng/ml) 
Volume of standard 
to be added to 
whole blood (µl) 
Final Concentration 
of Ramipril in whole 
blood (ng/ml) 
Standard A 1 100 0.1 
Standard B 5 100 0.5 
Standard C 10 100 1 
Standard D 50 100 5 
Standard E 100 100 10 
Standard F 250 100 25 
Standard G 500 100 50 
Standard H 1000 100 100 
 
Table A1.22 Final concentrations of simvastatin in whole blood 
 Concentration of 
Simvastatin standard 
solution (ng/ml) 
Volume of standard 
to be added to 
whole blood (µl) 
Final Concentration 
of Simvastatin in 
whole blood (ng/ml) 
Standard A 1 100 0.1 
Standard B 5 100 0.5 
Standard C 10 100 1 
Standard D 50 100 5 
Standard E 100 100 10 
Standard F 250 100 25 
Standard G 500 100 50 
Standard H 1000 100 100 
 
Table A1.23 Final concentrations of valsartan in whole blood 
 Concentration of 
Valsartan standard 
solution (ng/ml) 
Volume of standard 
to be added to 
whole blood (µl) 
Final Concentration 
of Valsartan in whole 
blood (ng/ml) 
Standard A 500 100 50 
Standard B 1000 100 100 
Standard C 2500 100 250 
Standard D 5000 100 500 
Standard E 10000 100 1000 
Standard F 20000 100 2000 
Standard G 30000 100 3000 
Standard H 40000 100 4000 
 
From Tables A1.13 – A1.23, there will be 8 calibration standards in whole blood (A, B, 
C, D, E, F, G, H and the blank). 
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For the purpose of validation studies, Solution C, Solution F and Solution H will be 
chosen to represent low, medium and high concentrations respectively for the 
preparation of validation samples. 
11. Spotting of blood targets on DBS card 
Pipette 30µL of each blood standard (A, B, C, D, E, F, G and H) including blank sample, 
and spot directly onto the sampling paper using a volumetric pipette. About thirty (30) 
spots should be made for each blood standard. Allow samples to air dry for at least 2 
hours at room temperature. The dried samples should be stored in number or code 
labelled re-sealable polythene bags in the secure cabinet in Lab HB 00.15. Details of 
the prepared calibration and validation DBS samples should be logged into the DBS 
records notebook in the secure cabinet. 
12. Spotting of blood targets on VAMS tips 
Emmerse the blank VAMS tips at angle of about 45 degrees into each blood standard 
(A, B, C, D, E, F, G and H) including blank sample. Wait for the tip to go fully red and 
then count two (2) additional seconds. This ensures that the VAMS substrate 
accurately samples 10µL of blood. Slowly remove the sampler tip from the 
microcentrifuge tube and close the clamshell. Allow samples to air dry for at least 2 
hours at room temperature. The dried samples should be stored in number or code 
labelled re-sealable polythene bags in the secure cabinet in Lab HB 00.15. Details of 
the prepared calibration and validation VAMS samples should be logged into the DBS 
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Dried blood spot analysis to assess adherence to cardiovascular medications  
What is the study? 
This project is on the development of a simple non-invasive test to assess adherence to 
cardiovascular therapy in primary and secondary care. 
Cardiovascular disease is one of the biggest killers worldwide affecting 1 in 3 people in the UK. 
Current care of such patients and increasingly for patients over 50 years old is the prescription 
of a combination of cardiovascular therapy drugs including beta blockers (BB), ace inhibitors 
(AI) and statins (ST). There is evidence that up to 60% of patients prescribed cardiovascular 
drugs do not adhere to their prescribed regimen leading to increases in morbidity, mortality 
and higher costs of care. The estimated cost of unused prescription medicines in the UK is ~£4 
billion annually. A simple test to monitor prescription drug levels would therefore be highly 
valued. 
What will happen? 
The programme for this study will involve testing the developed and validated of a dried blood 
spot (DBS) based analytical method for the principal cardiovascular drugs identified. This 
analytical method will be used to test DBS samples obtained from participants who are 
currently taking cardiovascular medication(s) to confirm the successful detection of these 
drugs in their blood. 
How will you be involved? 
After reading this Participant Information Leaflet you will be asked to sign a consent form prior 
to giving a blood spot sample and you will also be asked to complete a small questionnaire. 
Information requested in this questionnaire will be: 
a. Cardiovascular drug(s) prescribed 
b. Time since the last dose of the prescribed CVD drug(s) was taken 
c. Dose prescribed 




How is a blood spot sample collected? 
The general approach for the collection and use of DBS is as follows: One or two drop(s) of 
blood are obtained minimally invasively by a simple finger prick or thumb prick procedure. This 
small volume of blood (~ 25µl) is applied to a sample collection card or other blood sampling 
device and dried at room temperature for at least 2-3 hours. The sampling can be done almost 
anywhere. For example, in a laboratory or at home by the participant; in a clinic by a nurse; or 
in a pharmacy by the community pharmacist. The dried blood spot sample will then be sent to 
our laboratory for analysis. 
How is the blood spot analysed? 
In the laboratory, a fixed area of the DBS is extracted, either directly or as a disk punched from 
the DBS, and the presence of the drug in question is identified by mass spectrometry. 
 
Directions for collection of dried blood sample (DBS) on a Whatman 903 sample collection 
card 
Kit contents: 
- DBS Sample collection card (1) 
- Alcohol Prep Pad (1) 
- Lancet (1) 
- Gauze Pad (1) 
- Plaster (1) 
- Plastic re-sealable bag (1) 
 
1. Fill out the participant reference number on the DBS sample collection card. 
2. Warm the skin on a finger or thumb by gentle rubbing. 
3. Clean sample site with the alcohol pad provided and allow site to AIR DRY. 
4. Lance the sample site and wipe away the first blood drop with sterile gauze. 
5. Gently apply intermittent pressure near the puncture site to obtain the blood sample on the 
finger. 
6. Allow blood to accumulate on the finger or thumb tip and drop onto the sampling card in the 
circled area. The blood drop(s) should fall freely to the sampling card. 
7. AVOID TOUCHING the sampling card and DO NOT spread/smear/smudge blood to cover the 
circled area as this will render the DBS sample invalid. 




9. Once a circled area is covered, start on the next one. At least 2 circles, on the DBS card, must 
be filled for each sample – this would be from the same finger prick. Over spotting or layering 
can give rise to erroneous results and will be rejected. 
10. Sample cards must then be dried for 2-3 hours at room temperature. Sample cards should be 
kept apart (i.e. not stacked with each other if there is more than one card) and away from 
heat. 
11. After drying the sample cards must be stored in individual plastic re-sealable bags and are 
ready for collection or postage to the laboratory with the accompanying completed consent 
form and adherence questionnaire. 
 
Directions for collection of dried blood sample (DBS) on a VAMS sample collection device 
Kit contents: 
- Mitra TM (1 clamshell pack containing 4 samplers)  
- Alcohol Prep Pad (1) 
- Lancet (1) 
- Gauze Pad (1) 
- Plaster (1) 
- Plastic re-sealable bag (1) 
- Desiccant (1) 
 
1. Open sealed packaging and remove clamshell package. 
2. Label samplers with participant reference number (see Quick Start Guide provided). 
3. Uncover the samplers by pulling apart the clamshell and pressing the sides together to create a 
handle (Quick Start Guide step 2). 
4. Clean sample site (side or tip of finger) with the alcohol pad provided and allow site to AIR 
DRY.  
5. Lance the sample site and wipe away the first blood drop with sterile gauze. 
6. Gently apply intermittent pressure near the puncture site to obtain the blood sample on the 
finger. 
7. Apply sampler tip to surface of blood sample at an angle as shown in Steps 3 and 4 on the 
Quick Start Guide.  
8. Wait for the tip to go fully red and then count 2 additional seconds. Slowly remove the sampler 
tip from the blood.  
9. Repeat 7 and 8 above with the remaining 3 samplers in the 4 – pack.  
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10. Unfold clamshell to cover sampler tips and press to close.  
11. Apply the gauze pad and plaster over the lanced finger. 
12. Samplers must then be dried for 2-3 hours at room temperature away from heat or. 
13. The covered sampler tips can be immediately placed in the bag with the desiccant.  
14. The sampler is now ready for collection or postage to the laboratory with the accompanying 
completed consent form and mini questionnaire. 
 
Who should I contact if I have further questions? 
 
Dr Sangeeta Tanna                                            Dr Graham Lawson 
Leicester School of Pharmacy                              Leicester School of Pharmacy 
De Montfort University                                             De Montfort University 
The Gateway                                                           The Gateway 
Leicester LE1 9BH                                             Leicester LE1 9BH 
T: 0116 2078274                                             T: 0116 2577129 
E: stanna@dmu.ac.uk                                             E: glawson@dmu.ac.uk 
 
Dennis Bernieh 
Leicester School of Pharmacy 
De Montfort University 
The Gateway 




















Participant Reference Number: 
(To be completed by research team) 
 
Name of Researchers: Dr S. Tanna, Dr G. Lawson & D. Bernieh 
 
Please initial this box 
 
I confirm that I have read and understand the information sheet for the above 
study. I have had the opportunity to consider the information, ask questions and 
have had these answered satisfactorily 
 
I understand that my participation is voluntary and that I am free to withdraw at 
any time without giving any reason, without my legal rights being affected. 
 
I understand that the data collected during the study, may be looked at by 
responsible individuals from the research team or from individuals from regulatory 
authorities. 
 











Name of person taking consent Signature Date 
 
 










Dried blood spot analysis to assess adherence to cardiovascular medications 
 
Participant Reference Number: 
 
 
Q1. Have you read the participation information sheet and signed the consent form? 
Y/N 
 
Q2. Gender: M or F 
 
Q3. Are you prescribed any cardiovascular (heart disease) medications? 
Y/N 
 
If Yes to Q3 please complete Table 1. 
 












Approximate time since last 
dose (hours) 
Amlodipine     
Atenolol     
Atorvastatin     
Bisoprolol     
Diltiazem     
Doxazosin     
Lisinopril     
Losartan     
Ramipril     
Simvastatin     
Valsartan     
(Not listed) *     
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Dried blood spot analysis to assess adherence to cardiovascular medications 
 تحليل بقعة الدم لتقييم االلتزام أدوية القلب واألوعية الدموية
 ما هي الدراسة؟
في مراكز تقديم  القلب واالوعيه الدمويه هذا المشروع يعتمد على اليه قليله االيذاء للمريض لتقييم التزام المريض بادويه
 الخدمه االوليه والثانويه
أشخاص في  3  من 1أمراض القلب واألوعية الدموية هي واحدة من أكبر أسباب الوفاة التي تؤثر في جميع أنحاء العالم في  
ا ويتضمن عام 50هم أكثر من المملكة المتحدة. لرعاية الحالية لهؤالء المرضى وعلى نحو متزايد للمرضى  الذين اعمار
وهناك ادله  واالدويه الخافظه للدهنيات في الدم. ACE(، مثبطات BBالعالج  مزيج من األدوية بما في ذلك حاصرات بيتا )
ما يودي م٪ من المرضى ال يلتزمون باخذ عقاقير القلب واالوعيه الدمويه كما منصوص عليه 60على ان هناك ما يصل إلى 
دويه  في المملكه ه االعتالل والوفيات وارتفاع تكاليف الرعايه الطبيه . التكاليف المتوقعه لعدم استخدام االالى زياده نسب
 ليه.بليون باوند سنويا . اختبار بسيط لمراقبه تركيز االدويه في الدم سيكون ذو قيمه عا 4المتحده هي تقريبا 
 ماذا سيحدث؟
فه تراكيز االدويه دق عليه معتمدا على مبدا التحليل لبقعه الدم الجافه للكشف ومعربرنامج الدراسه يتضمن اختبار متقدم ومصا
م والتي يتم وسوف تستخدم هذه الطريق التحليليه الختبار عينات الد المستخدمه في عالج امراض القلب واالوعيه الدمويه.
 الدويه في الدم.اه لتاكيد االكتشاف الناجح لهذه الحصول عليها من المشاركين الذين يتناولون ادويه القلب واالوعيه الدموي
 
 كيف لك أن تشارك؟
ستبيان صغير بعد قراءه المعلومات عن البحث سيطلب منك التوقيع على استماره المشاركه قبل اعطاء وكما يطلب منك مليء ا
 وستكون المعلومات في هذا االستبيان مايلي 
 .االدويه المستخدمه من قبلك1
 م اخذ اخر جرعه من ادويه القلب واالوعيه الدمويه. اخر وقت ت2
 . الجرعه الموصوفه3
 جميع المعلومات عن فيما يتعلق بالعينه واالستبيان ستكون محفوظه وتمتع بالخصوصيه 
 
 كيف يتم جمع عينة بقعة الدم؟
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النهج العام في هذا االختبار يتضمن الحصول على قطره او قطرتين من الدم  بواسطه اجراء بسيط يتضمن وخز االصبع وتوخذ 
مايكرومل وسيتم وضع هذه العينه على ورقه خاصه او عن طريق تقنيات اخرى وتترك العينات لتجف  25كميه صغيره تعادل 
االقل .اخذ العينات يمكن ان يكون في اي مكان على سبيل المثال في المنزل او ساعات على  3-2في درجه حراره الغرفه لمده 
 المختبر او في عياده التمريض او في الصيدليه وبعدها يتم ارسال العينات الى المختبر.
 كيف يتم تحليل بقعه الدم؟
لعينه الموجوده على الورقه في المختبر يتم اخراج منطقه معينه من العينه بشكل مباشر او عن طريق قص منطقه من ا
 الخاصه .
 سريه؟ البحث في مشاركتي ستبقى هل
 إزالة سيتم .تامة وسرية مرور بكلمة محمية بيانات قاعدة في البحث أثناء عنك جمعها يتم التي المعلومات جميع وستبقى
 .تعطي قد تعريفية معلومات وأية اسمك من بدال استخدامها سيتم التي إشارة رمز
 الدراسة؟ لنتائج سيحدث ماذا
 ليستر مونتفورت، دي جامعة في السريرية الصيدلة في الدكتوراه رسالة من أساسيا جزءا الدراسه نتائج تكون وسوف
البحث هذا يمول من   
 الصحة وزارة وتموله ليستر,  مونتفورت دي جامعة في الدكتوراة لدرجة لدراسه هو البحث هذا
صحة ميسان. دائره العراقية،     
الدراسه؟ على ويشرف يتابع من  
 وعلوم الصحة كلية مونتفورت، دي جامعة قبل من عليها والموافقة الدراسة هذه استعرضت وقد
ميسان. صحة دائره في أخالقيات البحث ولجنة الحياة  
 ارشادات جمع العينه 
 المحتويات :
 .بطاقات جمع العينات1
 . وساده كحول للتعقيم2
 . النسيت3
 . شاش 4
 .بالستر5
 . كيس من البالستك لحفظ العينات6
 . تعبئه الرقم المرجعي للمشارك على بطاقه جمع العينات1
 . تدفئه جلد االصبع بالدلك الخفيف2
 . تعقيم موقع اخذ النموذج بالكحول وتركه ليجف 3
 . وخز االصبع ومسح اول قطره بالشاش المعقم4
 من اجل الحصول على العينه. اضغط ضغطا خفيفا بالقرب من موقع الوخز 5
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 صبع للسقوط الحر على الورقه الخاصه في المنطقه المخصصه للعينهاال .السماح لقطره الدم6
 . تجنب لمس بطاقه اخذ العينات او نشر العينه حيث ان ذلك يودي الى جعل العينه غير صالحه7
 يتها بالكامل .السماح لقطرات متعدده من السقوط على منطقه العينه حتى يتم تغط8
.عند اكمال عينه معينه يتم االنتقال الى العينه االخرى وعلى االقل يتم مليء دائرتين من الورقه  وهذا يكون من نفس مكان 9
 الوخز.يتم رفض العينه في حاله تكون طبقات في العينه
 . يتم تزويد المشارك بالشاش والبالستر10
 يتم حفظ العينات اال بعد التاكد من جفافها وان تحفظ بعيدا عن الحرارهساعات وال  3-2.تترك العينات لتجف من 11
.بعد جفاف العينات يتم حفظ العينات في االكياس البالستيكيه وتكون مهياه للنقل عن طريق البريد العادي مع استماره 12
 الموافقه على المشاركه واالستبيان 





 .كيس من البالستك لحفظ العينات5
 .مجففات الرطوبه6
 . افتح مختومة التعبئة والتغليف1
 . عينات تسمية مع الرقم المرجعي للمشارك2
 . سحب العينات3
 .تنظيف موقع العينه وتركه ليجف4
 . وخز االصبع ومسح اول قطره بالشاش 5
 ضع اخذ العينه للحصول على الدم. الضغط الخفيف قرب مو6
  4و  3. تطبيق راس اخذ العينه بزاويه  وكما موضح في الخطوات 7
 . انتظر حتى يصبح راس اخذ العينه اخر ثم انتظر ثانيتين اخريتين  وبسرعه ارفع الراس من من الدم8
 مع العينات المتبقيه  8و7. كرر الخطوات 9
 .حفظ العينات المسحوبه10
 لمريض بالشاش والبالستر. يجهز ا11
 . راس اخذ العينات يتم وضعه في الكيس مع مانع الرطوبه 12





 ؟بمن يمكن االتصال للمزيد من المعلومات
 د. سانكيتا تانا
 مدرسه ليستر للصيدله 
 جامعه دي مونت فورت 
 كيت وي
 LE1 9BHليستر 
 2078274 0116هاتف 
 stanna@dmu.ac.ukالبريد االلكتروني  
 
                                                                                         د.كراهام الوسن
 مدرسه ليستر للصيدله 
 جامعه دي مونت فورت 
                                                                                                 كيت وي
 LE1 9BHليستر 
 2577129 0116هاتف 
















 احمد العالق 
 مدرسه ليستر للصيدله 
 جامعه دي مونت فورت 
 كيت وي
LE1 9BH ليستر  









 بادويه القلب واالوعيه الدمويهبقعه الدم الجافه لتقييم االلتزام 
 الرقم المرجعي للمشارك:
 يملىء من قبل فريق البحث 
 اسماء الباحثين    احمد العالق            د.سانكيتا تانا    د.كراهام الوسن            
 
أؤكد أنني قد قرأت وفهمت ورقة المعلومات للدراسة المذكورة أعاله. وقد أتيحت لي الفرصة للنظر في المعلومات، وطرح 
 األسئلة، وكان هذه اإلجابة مرضية.                                                                                          
 
 طوعية وأنا حر في االنسحاب في أي وقت دون إبداء أي سبب، دون  تاثر حقوقي القانونية             وأنا أفهم أن مشاركتي
 
وأنا أفهم أن البيانات التي تم جمعها خالل هذه الدراسة، يمكن النظر فيها من قبل األفراد المسؤولين عن فريق البحث أو من 
 األفراد من السلطات التنظيمية.
 
   أنا أوافق على المشاركة في هذه الدراسة                                                                                        
 
 
 خاسم المشارك                                                    التوقيع                                                 التاري
 اسم الشخص الذي اخذ الموافقه                                التوقيع                                                 التاريخ
 
 















 استبيان االلتزام 
 
 يه واالوعيه الدموبقعه الدم الجافه لتقييم االلتزام بادويه القلب 
 
 الرقم المرجعي للمشارك:
 .  هل قراءت معلومات المشاركه بالبحث ووقعت استماره الموافقه               نعم                      ال1س 
 .الجنس   ذكر او انثى2س 
 ال                       . هل تصرف لك ادويه القلب واالوعيه الدمويه                                       نعم3س 
 1في حاله االجابه بنعم  يرجى مليء الجدول  رقم 
 اسماء االدويه الموصوفه 1جدول رقم 
عدد الجرعات اليوميه  الجرعه ملغم موصوف  اسم الدواء 
 )يوميا(
الوقت التقريبي 
 بالساعات الخر جرعه 
Amlodipine       
  Atenolol  
 
    
Atorvastatin  
 
    
Bisoprolol  
 
    
Diltiazem  
 
    
Doxazosin  
 
    
Lisinopril  
 
    
Losartan  
 
    
Ramipril  
 
    
Simvastatin  
 
    
Valsartan  
 
    
     اخرى *
 
 
 اخرى يرجى ذكر اسم الدواء 
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